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MISSION STATEMENT 
 
The Irish Prison Service, in partnership with statutory and voluntary agencies, seeks to provide people in its 
custody with programmes to assist in the prevention, treatment, rehabilitation, and aftercare so as to minimise the 
harmful effects of substance misuse and prevent the spread of HIV, Hepatitis B & C, and other infections. 
 
These programmes should be managed in the context of multidisciplinary working.  In the prison context a 
multidisciplinary team consists of members of a number of professions (healthcare, prison management, probation, 
education, chaplaincy, etc.) who commit to using their complementary skills to a common purpose (the coordinated 
provision of services to prisoners with substance misuse problems).  The team members are committed to a 
common purpose, goals, and approach, for which they hold themselves mutually responsible. 
 
Treatment programmes are provided directly by a clinical interdisciplinary team led by the substance misuse 
clinician.  This team comprises medical, nursing, other healthcare staff, together with addiction counselling and 
related clinical staff bound by common professional structures and ethical guidelines regarding the organisation 
and provision of treatment, respecting the right of the patient to confidentiality and appropriate clinical care. 
 
The IPS seeks to provide clinical services for the assessment, treatment, and care of patients comparable to those 
available in the community, and which are appropriate to the prison setting. 
 
Treatment programmes provided within the prison environment should be patient focussed, with the objectives of 
harm reduction, stabilisation of the patient’s addiction, with a longer term aim of assisting the return of the patient to 
a drug free lifestyle. 
 
All methadone treatment delivered in prison will be based on IPS Methadone Guidelines and/or other substitution 
guidelines depending on the agent used. 
 
Advice in relation to the practical organisation of such treatment programmes is outlined in the IPS Healthcare 
Standards Manual (Standard 9). 
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2. ADDICTION TREATMENT CHARTER 
 
It is the aim of the IPS to provide a high quality service to prisoners receiving treatment for addiction delivered with 
respect and courtesy upholding the dignity of all those involved.  Each prisoner is central to his/her individual care 
plan.  Care and treatment is crafted in a close collaboration between prisoner and health care worker in a 
therapeutic alliance. 
 
A prisoner is entitled to: 
• Access services regardless of age, race, gender, sexual orientation, religion, disability, marital status, family 
status or membership of the Travelling Community  
• An assessment of individual need on presenting for treatment 
• Access to appropriate treatment within an appropriate timeframe 
• Information on all available prison treatment options  
• Informed involvement in making decisions concerning treatment 
• An individual care plan and participation in the development and review of the plan 
• A respect for privacy and dignity from staff and other prisoners 
• Confidentiality in relation to information given and an explanation of the circumstances in which information will 
be divulged to others 
• An effective complaints procedure. 
• Give or refuse consent to take part in clinical trials, research or the teaching of students 
• A copy of this charter 
 
A prisoner’s responsibilities to the Addiction Service include: 
 
• Respecting the privacy and dignity of other prisoners and of service staff 
• Honouring commitments made in relation to their care plan or treatment contract 
• Complying with organisational arrangements and any rules made by the IPS for the effective, efficient, and safe 
delivery of the service 
 
 
Copies of this charter will be publicly displayed in healthcare facilities. 
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3.  CLINICAL INTERDISCIPLINARY CARE PLANNING 
 
Introduction  
 
Treatment programmes are provided directly by a clinical interdisciplinary team led by the substance misuse 
clinician.  This team comprises medical, nursing, other healthcare staff, together with addiction counselling and 
related clinical staff bound by common professional structures and ethical guidelines regarding the organisation 
and provision of treatment, respecting the right of the patient to confidentiality and appropriate clinical care. 
 
Interdisciplinary care planning is seen as an opportunity to focus on coordination of patient care and to undertake 
regular reviews of professional practice.  Collaborative work breaks down barriers, raising the awareness of each 
professional for the other.  Interdisciplinary ownership of patient records improves the efficiency of recording 
information and communication between professionals.  It allows care to be monitored and omissions to be spotted.  
There is more scope for care to be individualised.  Patient satisfaction increases because of greater involvement in 
planned care.  Other benefits include:  
 
• Better communication within the team, allowing problems to be addressed more promptly  
• Staff become more aware of their ongoing commitment to prescribing and evaluating care  
• Professional satisfaction increases leading to higher staff morale  
• Standards are met, professional carers are named and there are clear explanations of proposed treatments.   
 
Policy  
 
1. The IPS aspire that a care plan be drawn up for each patient receiving treatment for drug dependency. 
2. Care plans should be realistic and patient-centred.  All aspects of patient – biological, sociological, 
psychological and spiritual, should be considered in order to ensure holistic care.   
3. The interdisciplinary team in consultation with the patient should draw up the care plan.  Where appropriate the 
patient’s family may be involved with the patient’s consent.   
4. Members of the interdisciplinary team, not familiar with care planning, should receive training.   
5. Care plans should be reviewed as appropriate and review dates set and adhered to with a maximum of 6 
months between reviews.  It is advised that care-teams meet regularly to review goals and interventions.   
6. The emphasis of the care plan and the main members of the core team may change as the patient progresses 
through treatment into rehabilitation.   
7. Interdisciplinary or generic care plans are not a replacement for the required documentation from each 
discipline.   
8. The interdisciplinary care plan is to be kept in the back of the medical chart and signed up at the care-team 
meetings by the person designated to make the required intervention.   
9. If the required interventions are not made as per plan, the reason for this should be provided on the care plan, 
dated and signed.   
 
Interventions should reflect the philosophy of care within the service.   
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4. METHADONE TREATMENT PROGRAMME GUIDELINES FOR THE IRISH PRISON SERVICE. 
 
Based on European Methadone Guidelines 
 
 
Summary 
 
 
In most good programmes psychosocial interventions are considered a central part of methadone treatment.  
Research from the USA has demonstrated that there are several programme characteristics associated with 
treatment success such as comprehensive services and the integration of medical, psychosocial, counselling and 
administrative services (Ball & Ross, 1991).  McLellan et al (1993) described that service users who receive 
counselling and other psychosocial services with their methadone had better outcomes than those who only 
received methadone. 
 
The importance of creating and maintaining a therapeutic context in which methadone treatment 
programmes are delivered as part of the treatment of opioid dependence is widely accepted.    As is the 
case with any other service user populations receiving any kind of treatment, individual methadone maintenance 
service users may vary in their needs and they may differ in their responses to components of treatment.  The need 
for counselling and other interventions should therefore be assessed for each service user individually.  Some 
service users need more assistance than others to get their lives in order.  On the other hand, there is no reason 
why stable service users without major life problems should require counselling at all. 
 
Service users with psychiatric disorders could benefit from psychotherapy.  However, there is no reason to believe 
that psychotherapy is a treatment for all opioid dependants. Individual assessment is the key to good service 
delivery. 
 
 
Assessment of addiction and the degree of dependence is essential before prescribing methadone.  
Induction, treatment plan and initial dosage should all be determined with care.  Service users need to be informed 
not only about the actual pharmacological effects of methadone and the dangers of using other substances when 
on methadone, but also about the potential risk of overdose. 
 
It is highly recommended that new entrants start receiving methadone in the morning and preferably early in the 
week, so that the peak blood methadone concentrations occur when the health care area is still open and staff are 
available for consultation and intervention. 
 
In general, the initial dose will be between 10 – 20mg.  In cases where tolerance to opioids is high, the normal dose 
will be between 25 – 40mg.  When tolerance is low or uncertain, a dose between 10-20mg is more appropriate.  If 
in doubt perhaps it is best to err on the side of caution and prescribe a lower dose.  While too much 
methadone can be fatal, insufficient methadone is unlikely to be effective.   
 
During the first week of induction scheme, service user should be seen daily where possible so that a stabilisation 
dose can be established.  Where doses need to be increased during this first week, the daily increase should be a 
maximum of 5 to 10mg and not exceeding 20mg within a week of the initial dose. 
 
Careful consideration should be given if a dose increase exceeds 20mg per week.  It can take up to six weeks or 
more to be properly stabilised on methadone treatment.   
 
The majority of individuals in maintenance treatment will require 60 – 120mg per day.  Although some individuals 
can be successfully maintained on lower doses, an average heroin dependent person will use less heroin and 
remain longer in treatment, if maintained on higher rather than lower doses of methadone. 
 
Some groups such as pregnant women, people with HIV disease, service users with young children etc (see 
emergency criteria for treatment), should be given priority to enter methadone treatment.  They may also need 
special attention.  Liaison should be co-ordinated with specific services as antenatal, infectious diseases, so that 
their immediate problems can be addressed. 
 
Methadone treatment should not be seen as an isolated intervention but as part of a comprehensive 
programme of care.  It is important to identify and address other problems such as medical, social, mental health 
or legal problems.  This can be done either by the staff within the methadone programme or through liaison with 
other services and institutions.  A multidisciplinary approach to methadone treatment is essential. 
 
Prescribing is the sole responsibility of the doctor who signs the prescription. This responsibility cannot 
be delegated. 
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Apart from methadone, a range of other substitution medication is prescribed in different countries with success, 
such as Buprenorphine, long acting morphine and heroin. 
 
People working in methadone treatment will require specific training which addresses the 
pharmacological, toxicological, medical and psychosocial aspects of treatment of opioid dependence.  The 
attitude of the staff needs to be non-judgemental.  Supervision and regular team meetings are important elements 
of good practice.  To ensure high quality of the services delivered, continuous training is highly recommended. 
 
Keeping records of prescribing and of any activity surrounding a service user is necessary as in any medical 
practice, this may be computerised, hand written and combination of both.  A central list of service users in 
methadone treatment may prevent double prescribing.  The information contained on this is confidential and access 
to the list is restricted to doctors and clinical team who provide the treatment. 
 
A methadone treatment programme should be a safe place.  It should be easily accessible centrally located and 
clean.  At all times, service users should be assured of the confidentiality of their information and that it will not be 
used for non-medical purposes (see policies regarding confidentiality).  A good rapport between the staff and the 
service user is vital for the success of the treatment. 
 
When planning and designing a new treatment service, it is important to involve users of this service in the process 
as well were possible. 
 
Monitoring activities and evaluation of outcomes should be undertaken on a regular basis. 
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Chapter 1: Introduction  
 
Of critical importance is the recognition that, as in every other area of medicine, treatment must be tailored to the 
needs of the individual service user. 
 
These guidelines are not intended to dictate, but rather provide guidance and recommendations for good clinical 
practice of methadone treatment programmes. 
 
Methadone Substitution Treatment in Europe 
 
The type of methadone programmes varies from low threshold programmes in some countries to high threshold 
ones in others.  Both high and low threshold are formed in the Irish Prison Service. 
 
Low threshold programmes: 
 
• Are easy to enter 
• Harm reduction oriented 
• Have as primary goal to relieve withdrawal symptoms and craving and improve the quality of life of 
service users 
• Offer a range of treatment options 
 
High threshold programme 
 
• Are more difficult to enter / may have selective intake criteria  
• Abstinence oriented (including methadone abstinence) 
• Have no flexible treatment options 
• Adopt regular (urine) controls 
• Inflexible discharge policy (illegal opioid use not consented) 
• Compulsory counselling and psychotherapy 
 
Most countries have seen a rapid expansion in the provision of substitution services, especially in Spain, France, 
and Greece and in some Central and Eastern European countries.  A rapid expansion is even more evident in 
countries like Luxembourg, Finland and Greece, which had lower baseline levels of provision.  The impetus for the 
expansion has largely been a response to the HIV disease epidemic among drug users.  Whilst most countries 
have experienced few problems during this growth period, concern has been expressed in some member states.  It 
concerned the lack of training and skills of some practitioners who are now involved in substitute prescribing.  This 
is particularly notable among specialist services, including general practitioners and pharmacists (Department of 
Health UK guidelines, 1999; Farrell et al., 1999).  There is also concern about controls on prescribing and the risk 
of possible diversion of methadone onto the black market (Farrell et al., 1999). 
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Chapter 2: The evidence for the effectiveness of methadone 
 
Pharmacology 
 
Methadone (methadone hydrochloride, or 6-dimethylamino-4, 4-dipheny1-3-hepatone hydrochloride) is a synthetic 
opioid agonist that has effect on humans similar to those observed with morphine.  Methadone is well absorbed 
from the gastro-intestinal tract, irrespective of formulation type (e.g. syrup vs. tablet).  It has very good 
bioavailability of 80 to 95%.  The elimination half-life of methadone has been estimated to be 24 to 36 hours, with 
considerable variation across individuals (10 to 80 hours). 
 
The rate of metabolism of methadone by the CYP3A4 enzyme affects the clearance of methadone from the body.  
The expression of the CYP enzyme is influenced by genetic and environmental factors and by certain medications.  
It is highly variable which can result in methadone toxicity and at the other extreme, in opioid withdrawal.  Certain 
medications interact with the blood level concentration of methadone and special attention has to be given to 
people using other medications such as HIV medications, antibiotics, some anti-epileptics and medications that 
treat tuberculosis.  For more information on the interaction of methadone and other medications we refer to 
appendix 14 of the UK Guidelines and to the Methadone Briefing by Andrew Preston, 1996.  The UK Guidelines 
can be consulted on the Internet: http://www.doh.gov.uk/drugdep. The Drug Misuse and Dependence-Guidelines 
on Clinical Management. 
 
Side effects of methadone occur in the neuro-vegetative and psychological area.  The most common side effects 
include: increased transpiration, constipation, and disturbances of sleep, sex drive and concentration.  Such 
undesirable side effects may persist over longer periods of treatment, but mostly remain without medical 
consequences.  In total, these side effects affect less than 20% of methadone service users (Swiss Methadone 
Report, 1996). 
 
Methadone treatment with full tolerance and stable doses does not usually impair the ability to drive or operate 
mechanical machinery.  All service users that are not stable are strongly advised not to drive or operate mechanical 
machinery, and should be informed that if deemed at risk to others, confidentiality may be broken.  Where service 
users are being prescribed further psychotropic medication, further consideration to their ability to drive or operate 
mechanical machinery should be questioned.  However, before issuing or reissuing a driver’s license, careful 
checking is advisable to determine whether the service user’s situation is stable; whether there are any chances of 
relapse, and whether there is consumption or misuse of other substances.  Especially the simultaneous use of 
alcohol and/or medications (e.g. benzodiazepines) should be taken into consideration (Swiss Methadone Report, 
1996). 
 
 
Research 
 
Most research on methadone has been done in the USA.  The National Institute on Drug Addiction (NIDA) has 
funded and co-ordinated several studies which have examined various treatment outcomes of methadone 
maintenance treatment in the United States.  Some of these research projects were: the Drug Abuse Reporting 
Programme (DARP) studies with a 12-year follow-up; The Treatment Outcome Perspective Study.  (TOPS) 
gathered data before, during and after treatment on a nation-wide scale and The Methadone Research Project 
(The Ball and Ross Studies) looked at the effectiveness and status of MMT in six programmes in three cities 
(International Forum, 1994). 
Opiate addiction is complicated and that has both metabolic and psychological components.  It is important to deal 
with both aspects of this condition.  Since it is a condition where a service user is prone to relapse, careful risk 
assessment of this possibility should preclude any decision to stop methadone prescribing. 
 
Another important study is the British follow-up study of the National Treatment Outcome Research Study 
(NTORS), which monitored the progress of 1075 service users in residential and/or community treatment services 
over five years (Gossip et al., 1998). 
 
In conclusion, research supports the conclusion that methadone maintenance is more effective than no treatment 
or placebo in retaining people in treatment, reducing use of Heroin and other illicit drugs, preventing HIV infection, 
improving the health –related quality of life, and reducing involvement in criminal activity and imprisonment rates.  
Detoxification alone is seldom effective in producing long-term change.  The benefits of methadone maintenance 
programmes can be maximised by retaining service users in treatment, prescribing higher rather than lower 
dosages of methadone, orientating programmes towards maintenance rather than abstinence, offering counselling, 
assessment and treatment of psychiatric co-morbidity and social treatments and the use of contracts and 
counselling to reduce the use of additional drugs (Preston, 1996; Farrell, 1994; Ward, 1998). 
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Chapter Three: Outline of Best Clinical Practice 
 
Criteria for Treatment 
 
There are two internationally accepted diagnostic criteria that cover drug dependence: the first criteria of ICD 10 
which defines Dependency syndrome as: “A cluster of physiological, behavioural and cognitive phenomena in 
which the use of a substance or a class of substances takes on a much higher priority for a given individual than 
other behaviours that once had a greater value………”(WHO Expert Committee on Drug Dependence, 1998). 
 
Substance dependency is diagnosed if at least three of the following criteria had been present in the previous year: 
 
Psychological: 
 
• Strong desire or compulsion to take the substances 
• Difficulty in controlling behaviour regarding the onset, termination or levels of use 
 
Physiological: 
 
• Characteristic withdrawing syndrome or the substance if not taken 
• Evidence of tolerance and need of increased dose to achieve effect 
 
Social: 
 
• Progressive neglect of alternative interests/pleasures and increased time necessary to obtain, take 
or recover from substance 
• Persisting with substance use despite the negative harmful consequences 
 
The criteria for entering methadone treatment differ widely between programmes. 
 
High threshold programmes adopt strict criteria, such as: 
  
• A minimum age of 18 ( under in some cases) 
• History of failed treatment attempts 
• Strong motivation to enter treatment  
• One of the international diagnostic criteria for opioid dependence 
 
Some methadone programmes only accept heroin addicts for treatment if they suffer from illnesses, such as HIV 
disease or tuberculosis. 
 
At the other end of the scale there are low-threshold programmes, which would welcome anybody with a proven 
addiction to opioid who wish to enter a treatment programme. 
 
The criteria differ according to the type of treatment (maintenance or detoxification) because of the length of time a 
service user is expected to be in treatment.  Other factors, such as the availability of places, may influence 
inclusion criteria.  In areas where there are no waiting lists, programmes can adopt looser criteria than in places 
where there is a larger demand than supply of treatment possibilities. 
 
 
Assessment  
 
It is recommended best practice that all service users receive an initial nursing, counselling and doctors 
assessment before starting treatment.  Before starting any type of methadone treatment it is necessary to 
determine whether the service user is taking opioids and to establish the presence and severity of opiate 
dependence.  The doctor should conduct a personal interview with the service user and carry out a physical 
and mental state examination and have available the results of recent urine toxicology.  The final decision for 
the type of treatment should be taken on the basis of the needs of the individual service user and the options open 
to the clinician.  To ensure a successful treatment programme, the clinician or assessor is required to give the 
service user information on the full range of treatment options.  It should be ensured that the service user is 
matched to the most appropriate treatment for their current needs.  Further, when starting methadone or 
psychoactive substances, the doctor should give to the client detailed information on the treatment, on the possible 
side effects of the medication and the potential social consequences (such as long-term dependency and 
increased tolerance). 
 
 11
Part of the assessment process for new committals must include a minimum of one urine with specific test for 
heroin metabolites (6 A. Morph).  The doctor before their initial assessment of the service user should review 
nursing and counselling assessments. 
 
Urinalysis can be helpful in confirming opioid use, however, this should be considered with care.  It may 
encourage the use of opioids prior to an assessment.  Furthermore, it can only confirm opioid use, but it does not 
provide any information about the extent of use or dependence.  Its main usefulness may be in determining the use 
of other substances presently being used by the applicant (Ward et al., 1998). The results of any urinalysis should 
be considered only with a thorough clinical examination. 
 
 
Treatment plan and treatment goal (duration and dosage) 
 
Although these guidelines cannot modify potential local restrictions in therapeutic options, it can be stressed that 
the international literature, as well as the experience overtime in different parts of the world, underline the 
importance of the availability of a room for individual treatment assessment.  Restrictions in availability of places, in 
dosages and duration or type of treatment are counter-productive in the effective treatment of opioid dependent 
service users.  Making decisions about the treatment of individual service users has to be based as much as 
possible on a thorough assessment of what will work for that person and on reliable information about what works 
(Preston, 1996).  The decision about what treatment to offer is based on what treatment is available locally, on the 
service user’s previous history, current situation, social support network and expressed wishes.  The decision is 
also based on the clinician’s judgement of the required degree of structure, monitoring and support of the service 
users needs. 
 
Opioid use and dependence is associated with a range of medical, legal and psychosocial problems.  Additional 
problems should be addressed from the very beginning, either by the methadone programme itself or through 
referral to an appropriate service. 
 
Induction 
 
The calculation of the right starting dose should take the following factors into account: 
 
• That the right dose varies according to the treatment aim; 
• That illicit heroin varies in purity from area to area and from time to time; 
• That methadone is a long acting opiate; 
• That too much methadone can be fatal but insufficient methadone is unlikely to be effective. 
 
Starting service users on a dose of methadone that is too high may result in toxicity and death.  However, 
there is some danger inherent in the administration of a dose of methadone that is too low, in that withdrawal may 
occur.  The experience of withdrawal symptoms may prompt service users to seek relief from other sources, such 
as illicit opiates and benzodiazepines.  The combination of methadone with other substances may result in toxicity 
and death.  Furthermore, some service users may metabolise methadone quite rapidly and may also be in danger 
of withdrawal and self- medication (Humeniuk et al., 2000).  There is evidence that people entering treatment have 
a higher risk of dying during the first month than before they entered treatment (Caplehorn, 1999). 
 
Once opioid dependence has been confirmed in a service user, tolerance and methadone dose need to be 
assessed.  The usual way to determine tolerance is by clinical assessment of the service user’s medical and drug 
use history upon presentation.  Accuracy of clinical assessment may be improved by using corroborating evidence 
such as examining veins for evidence of injecting opioid use or urine tests.  A good rapport with the service user is 
vital in obtaining the necessary information.  It is important that enough time is allocated for the clinical interview as 
well as communication with other practitioners whom service users may have seen. 
 
The absolute condition for an effective start of methadone treatment is to provide the service user with 
relevant information, which should include the following: 
 
• The delay of 2 to 4 hours before methadone has a peak effect; 
• The accumulation of methadone over time resulting in a greater effect over 3 to 5 days or more, 
even on a fixed dose; 
• The risk of poly-drug use while on methadone, particularly other opiates, cocaine, benzodiazepines 
and alcohol; 
• The effect of medications that induce or inhibit activity on subsequent methadone concentrations.  
(for more information we refer to appendix 2). 
 
 
 
 12
One more of the following criteria can identify service users with a higher risk of methadone toxicity: 
 
• It is their first presentation to that practitioner and their medical and drug use history is unclear; 
• They are at high risk of poly-drug use of dependence 
• Their degree of neuro-adaptation is uncertain 
• There is risk of overdose on methadone or any other drug 
• They have a clinically significant respiratory disease 
• They have clinical evidence of the end stage of liver disease 
• They are currently being administered drugs that inhibit the CYP3A4 enzyme (*). 
 
Clinical titration of dosage needs to keep in mind the possibility of liver disease. 
 
It is highly recommended that methadone is commenced in the morning and preferably early in the week, so that 
the peak blood methadone concentrations occur when health care area is open and fully staffed enabling staff to 
intervene.  It is not recommended to start a new service user immediately before a holiday period. 
The aim of induction is to eliminate withdrawal.  
 
In general, the initial dose will be between 10 – 20mg.  In cases where tolerance to opioids is high, the normal dose 
will be between 25 – 40mg.  When tolerance is low or uncertain, a dose between 10-20mg is more appropriate.  If 
in doubt perhaps it is best to err on the side of caution and prescribe a lower dose.  While too much 
methadone can be fatal, insufficient methadone is unlikely to be effective.   
 
During the first week of induction scheme, service user should be seen daily where possible so that a stabilisation 
dose can be established.  Where doses need to be increased during this first week, the daily increase should be a 
maximum of 5 to 10mg and not exceeding 20mg within a week of the initial dose. 
 
Careful consideration should be given if a dose increase exceeds 20mg per week.  It can take up to six weeks or 
more to be properly stabilised on methadone treatment.  Compliance will only be maintained if both service user 
and doctor agree that a reduction scheme is desirable. 
 
The majority of individuals in maintenance treatment will treatment will require 60 – 120mg per day.  Although some 
individuals can be successfully maintained on lower doses, an average heroin dependent person will use less 
heroin and remain longer in treatment, if maintained on higher rather than lower doses of methadone. 
 
Detox regime suggestions 
 
The present policy in the IPS is to detox clients with a proven drug history unless they fall into the following 
categories. 
• Currently on methadone maintenance. 
• HIV positive. 
• Pregnancy. 
 
 
 
Assessment Process 
 
On committal to the institution the individual must be assessed by the nurse, if there is a history drug use, 
particularly if the person has not been treated with methadone before. 
 
A urine must be taken for toxicology specifically testing for heroin metabolites (6 Acetyl- Morph), the results of 
which must be available to the doctor examining the person prior to prescribing methadone. 
 
• The day of committal the person will not receive methadone (Day 1). 
• Day 2. -  The individual will be seen by the doctor with the results of the test. 
A maximum of 20 mgs Methadone to be dispensed. 
• Day 3.  – Reassessed by the doctor and dose titrated based on clinical findings.  
   
Extreme caution to be used in concurrent prescribing of benzodiazepines and other psychotropic drugs. 
Caution should also be exercised when assessing the 16 – 19 y.o.  
 
During this induction period the person should be kept under regular nursing and medical observation. 
 
Many service users, despite requesting detoxification, are more suitable for maintenance treatment.  Options 
should be sensitively explored with the service user, and the overall goal should be to maximise the service users 
potential health gain. 
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Undertaking a regular clinical review will ensure that the potential goal of abstinence can always be reconsidered.  
Yearly case plan review is strongly recommended for all service users. 
 
 
TREATMENT  
 
Maintenance programme suggestions 
 
Research suggests that the majority of individuals require 60-120mg per day.  Although some individuals can be 
successfully maintained on lower doses, an average heroin dependant person will use less heroin and stay in 
treatment longer, if maintained on higher rather than lower doses of methadone.  In situations where high daily 
doses fail to prevent withdrawal during the full 24 dosing cycle, it should be determined if the individual is taking 
enzyme-inducing drugs concurrently, or if the individual metabolises methadone at a faster rate than average and 
higher methadone doses will be needed (Humenuik et al, 2000; Preston, 1996; Ward et al, 1998).  Methadone 
levels should be performed on any service user receiving more that 100mgs. 
 
Although the majority of service users can be adequately treated with a daily dosage of between 60-120mg there 
are no objective data (include methadone plasma concentration) to suggest an adequate daily dose for an 
individual service user.  Asking the service user’s opinion about methadone dosage can have a positive effect on 
the treatment. 
 
Caution needs to be observed about high doses if there is associated alcohol/ Benzodiazepine dependence that 
could be the result of an under-medication with methadone.  In this case the stabilisation dosage needs to be 
reconsidered (Maremmani & Shinderman, 2000) 
 
In the prison setting when an established methadone maintenance patient is committed the following procedure 
should be followed. 
 
o Verify with the Central Treatment List (CTL) where the patient is registered as receiving his/her 
methadone. 
o Having verified where the patient is attending, contact should be established to ascertain the 
current dose of methadone, when it was last administered and any other relevant medical 
information.  
o This information should be furnished to the doctor and continuation of his/her prescription should 
ensue as appropriate. 
o Urine should be screened for methadone and other illicit drugs. 
 
Initially, service users may need to be seen by the doctor weekly and if stable fortnightly and then monthly.  A more 
thorough review may be useful every three months to consider what has been achieved and to set new goals.  
Twice weekly urines are recommended in the initial stages and thereafter weekly.  Co-existing physical, 
social, psychiatric and legal problems should be addressed as much as possible. 
 
 
Detoxification from Methadone Maintenance Treatment 
 
The available research suggests that the slower the course of diminishing doses, the better.  However, like all other 
decisions regarding the treatment plan, this can best be set individually in consultation with the service user.  
Supportive counselling is also considered an important part of withdrawing for maintenance and this should be 
continued after service users have finished the reduction regime because of the post-methadone syndrome.  This 
syndrome is associated with mild symptoms of the protracted withdrawal phase as well as with issues related to 
leading an opioid-free life.  The development of aftercare services in some places is an answer to these problems 
and involve a mix of education, skills training and features derived from self-help groups like Narcotics Anonymous 
(Ward etal; 1998). 
 
Systematic Detoxification on Committal  
 
At present any person giving a history of opiate use and testing positive for opioids on committal will be offered a 
medically assisted symptomatic detoxification for operational reasons.  A patient can present to healthcare staff for 
further assessment of other treatment option which may include methadone maintenance subject to the availability 
of a community place. 
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Populations requiring special consideration 
 
Pregnant Women 
 
Attracting and maintaining pregnant women in treatment services is vital.  Where possible the partner should be 
taken on as well.  It is advisable to give pregnant women priority to enter Methadone treatment because of the 
health risks for both the mother and the foetus associated with substance abuse, such as premature labour.  
Multiple drug use, poor nutrition and unsafe injecting can damage the foetus.  The long term outcome of women 
who enter methadone treatment programmes during pregnancy is better in terms of their pregnancy, childbirth and 
infant development, irrespective of continuing illicit drug use.  Women attending treatment services usually have 
better antenatal care and better general health than drug-using women not in treatment, even if they are still using 
illicit drugs (Finnegan, 2000) 
 
Once a stable treatment programme has been established, liaison with other medical services, particularly for 
antenatal care, can be initiated. This can be facilitated particularly through the Drug Liaison Midwife. 
 
Although many women would wish to detox, long-term methadone maintenance treatment is considered the best 
option for most opioid dependant pregnant women.  In the third trimester, many women will need higher doses 
because of weight gain and other physiological changes.  
 
If a woman wants to detoxify, it is recommended not to do this in the period prior to week 12 or after week 32 of 
pregnancy (Council of Europe, 2000).  Withdrawal symptoms should be avoided but particularly during the first 
trimester of pregnancy because of the risk of premature labour in this period.  The normal maximum reduction in 
the daily dose is between 1 –5mg weekly, fortnightly or monthly, depending on the woman’s response.  Women 
should not be encouraged to detox in the final trimester of pregnancy. 
 
If detoxification is unsuccessful and the service users drug use becomes uncontrolled, methadone dosage should 
be re-assessed until stability is regained. 
 
 
Neonates of Opioid Dependant Women 
 
Over 60% of neonates born to opioid dependant mothers have symptoms of neonatal abstinence syndrome (NAS) 
that tend to occur 24-74 hours after delivery and include the following: high-pitched cry, rapid breathing, hungry but 
ineffective sucking and excessive wakefulness.  Hypertonicity and convulsions can also occur.  The intensity of the 
NAS does not directly correlate with the dose of the methadone or other opioids used by pregnant women.  The 
use of Benzodiazepines by the mother in the anti-natal period and diarrhoea in the neo-nate can considerably 
prolong the period of withdrawal and may result in respiratory depression. 
 
They can usually be cared for in a normal maternity environment on condition that in case of emergency, they could 
be transferred to special care units.  
 
If medication is required, a range of opioid and non-opioid drugs can be used.  An oral morphine concentrate is the 
drug of choice and phenobarbitone may be used if the mother had been taking other substances, such as 
benzodiazepines. 
Breast feeding is encouraged not only because of its general advantages but also because some methadone may 
pass to the baby in very low doses and this in turn may help to reduce any withdrawal symptoms of the baby.  In 
case of HCV infection, the benefits of breast-feeding should be considered according to the mother’s viral load 
(Council of Europe, 2000).  Contra-indications for breast-feeding however are: if the mother has HIV disease or if 
she uses high doses of Benzodiazepines or if she continues illicit drug consumption. 
 
Finally, because pregnant women and young mothers may suffer from severe guilt feelings, psychosocial care and 
counselling is highly recommended. 
 
 
Parents of young children 
 
Drug use is not a reason to introduce care proceedings.  The needs of young children of drug dependant parents 
are, however, paramount. Workers in methadone programmes will need to include the care of the children in their 
treatment plan and have some means of supervision. There are special programmes co-ordinating the care of the 
parents and young children, case management of these service users is a key issue and the specific needs of the 
children should be considered explicitly (Children First Department of Health & Children – September 1999) 
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Young People 
 
Methadone is unlikely to be an appropriate treatment for people under 16 years of ages as they are unlikely to fit 
the criteria of: 
 
• Long term opioid use 
• Significant tolerance 
• Level of problematic opioid use which would not be possible to treat with another form of treatment and help. 
 
If methadone treatment was nevertheless considered, specialist assessment and management is advised.  
Parental consent is required.  In very rare circumstances treatment may be initiated after multidisciplinary/specialist 
review and legal opinion. 
 
 
People with HIV Disease 
 
It is strongly recommended that all people in treatment should be tested for Hepatitis B and those without protective 
antibodies, should be vaccinated (See Vaccination Schedule – ERHA Publication March 2001). 
 
Hepatitis C is a serious health problem for injecting drug users, both in terms of prevalence and its clinical effects.  
There is a great need for improved methods of diagnosis and management of people with hepatitis C.  The dose of 
methadone will have to be reviewed and analysed, according to the liver function of the service user.  Specialist 
referral should be arranged for assessment and possible treatment of HCV.  People who are stable on methadone 
can be very compliant with HCV treatment.  Finally, as is in the case of people with HIV, it is important to reiterate 
the avoidance of sharing injecting equipment. 
 
 
People with mental health problems 
 
A significant percentage of opioid users may suffer from mental health problems, including anxiety and depression.  
A percentage of opioid users presenting at services have suicidal and self-harm risk.  Entry into treatment has a 
significant positive impact on their psychological well being.  A minority (circa 10%) have severe enduring mental 
health problems that require close collaboration with mental health services (Marsden, et al., 2000). 
 
Dually diagnosed opioid dependant service users who survive early attrition, tend to stay in treatment longer than 
those without psychiatric co-morbidity do, when treated with higher methadone doses during the stabilisation phase 
(Maremmani et al, 2000). 
 
 
Poly Drug Users 
 
In order to deal with additional substance misuse, the health worker must be aware of other poly substance misuse 
including alcohol and benzodiazepines, so appropriate intervention can be made. It is vital to establish a good 
therapeutic relationship if these issues are to be addressed.  A good rapport based on trust and co-operation 
between prescriber and service user makes for good treatment.  
 
Strategies to reduce risk behaviour include: increasing the methadone dose and possibly other medication, the 
frequency of collection, supervised consumption, setting realistic treatment goals and finally, in some programmes, 
the suspension of methadone prescribing. 
 
 
 
 
 
Minority ethnic groups 
 
In many areas, opioid dependence can be a problem among ethnic minorities.  Often, services are developed for 
and run by people from the mainstream population and culture.  In order to make services more attractive to ethnic 
minorities, it is important to offer culturally appropriate services. 
 
 
People in prison 
 
People in prison should have the same access to the same treatment options as in a community setting.  In 1998, 
the Prison & Drugs Conference in Oldenburg, presented recommendations for drug services in a prison setting.  
They recommended that a wide range of drug services should be available to prisoners, including substitution 
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treatment (both detoxification and maintenance).  It was also recommended that prison staff needed to be trained 
on drugs and related (health) problems. 
 
Individuals on maintenance in the community should have the option to continue to be maintained upon entry to 
prison.  This option is important since discontinuing methadone maintenance treatment is likely to result in higher 
levels of risk behaviour (Swiss Methadone Report, 1996). 
 
People receiving substitution treatment in prison must be able to continue such treatment on release.  There is 
particularly high risk of overdose and death after release if service users have been abstinent from opioids (Darke 
et al, 1996).  Decisions on continuity should be taken in consultation with the treatment programme in which the 
prisoner participates once outside prison (European Recommendations, 1998), direct liaison arrangements are 
important in this regard.   
 
 
People in hospital 
 
It is important that general hospitals recognise and treat service user with opioid dependence.  After proper 
assessment and communication with the drug treatment service, service users should be able to continue their 
methadone medication and all other medications in such a way as to ensure the completion of the medical 
treatment for which the service user entered the hospital.  It is worth noting that general hospitals should not be 
considered as detox centres.  The drug treatment offered in hospital should allow for full treatment of the medical 
problem. 
 
The emergency department of a hospital will mainly encounter two situations: 
 
• The management of severe abstinence and or overdose; 
• The management of other drug related problems. 
 
Liaison between drug services, prison drug services and emergency departments are essential and joint policies 
between the two departments should be developed at local level. 
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Steps in Methadone Treatment 
 
 
Individual committed to prison 
↓ 
Assessment by nurse 
(day of committal) 
                                       ↓ 
 
Urinalysis         (6 A. Morph) 
↓ 
 
Verification with Central treatment list 
↓ 
 
                      Doctors’ assessment 
↓ 
 
Treatment plan (maintenance, detoxification) 
↓ 
 
Contract signed (copy to service user). 
 
1. Service user given detailed information on the treatment and on the risks of using other drugs 
 
2. Listed medications not to be used 
↓ 
 
Psycho-social follow up by Counsellor / Key Worker (where possible) 
↓ 
 
Stabilisation period to establish the right dose 
↓ 
 
Maintenance or detoxification regimen 
↓ 
 
Regular review to set new goals (depending on type of treatment) 
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Chapter 4: Psychological and Social Aspects of Care 
 
European Guidelines regarding the provision of Methadone programmes clearly state that Methadone treatment as 
a pharmacological intervention should not be an isolated activity but rather part of a comprehensive programme of 
care addressing the following elements – 
 
Multi-disciplinary assessment at the earliest stage. 
Development of through care plans and regular multi-disciplinary review of these. 
Provision of appropriate services to address the myriad of needs experienced by drug misusers. 
Programmes must have an active re-integration focus.   
 
Indeed meta-analytical studies demonstrate that Methadone programmes, which are shown to be the optimum 
treatment choice for opiate misuse, are the Methadone programmes which clearly incorporate adequate 
Psychological and Social components. 
 
The provision of Methadone programmes has implications for the positive sentence management of those on 
methadone, but also for the initial targeting of resources for the provision of comprehensive psycho-social 
interventions. There is a recognized need for the development of appropriate psycho-social interventions in line 
with best community and international practice. 
 
 
Critical Factors 
 
 
The development of Psychological/Social interventions in relation to Methadone programmes within prison requires 
attention to the following factors – 
 
Adoption of a care planning/ case management approach. 
 
This factor is well attested to in all literature concerning drug treatment initiatives in prison or the community. Such 
an approach might well integrate with the concept of positive sentence management envisaged by the strategy 
statements of the Irish Prison service. The adoption of a case management approach by definition, indicates that 
assessment and intervention should be broad based and multi disciplinary. Consequently the provision of a 
Methadone programme should involve best medical and psycho social practice and allied supports. 
 
The National Institute of Drug Abuse (NIDA) model of practice is a useful template upon which to construct 
methadone programmes.( Figure 1.overleaf) This model clearly locates the provision of pharmacotherapy such as 
Methadone, within a wider treatment and environmental context.  
 
Dale & Marsh (2000) emphasise the crucial importance of effective care planning and case management, as purely 
focusing on substance use related issues is rarely sufficient to produce enduring change.  
 
Counselling can effectively complement methadone programmes, however the research evidence points to the 
need for a more comprehensive approach to methadone programmes than the provision of methadone alone. 
Appropriate methadone programmes within a prison ( and affirmed by community treatment centres ), due to the 
multiple problems experienced by those in prison, require the adoption of a case management approach where 
there is assessment of and intervention for the myriad of problems faced by the individual such as accommodation, 
dual diagnosis, offending behaviour and family issues. The provision of methadone programmes within prison 
should be viewed in the context of reintegration. 
 
 
 
Guiding Principles
 
o The provision of a keyworker for every person commencing a Methadone programme. 
o A (through) care plan should be developed for each individual with built in regular review ( as 
per National Drug treatment strategy) 
o Plans and services to be tailored to the individual needs of the person. 
o Drug treatment care plans must integrate with Positive sentence management approaches.  
 
 
 
Pre/ Post- Release / ( Re) Integration Issues 
 
The NIDA model (Figure 1.)  Clearly demonstrates the importance of social factors in the ability of a person to 
maintain the stability that might be afforded to them from participation in a Methadone programme, and any other 
changes in lifestyle they may have attempted or are intending to make on release from prison. The ability to access 
or make linkages with a variety of relevant social services in the community is a critical factor to the person in 
making a successful transition to the community from prison. Methadone programmes must incorporate these 
considerations in the range of interventions offered and the skill mix of those offering them. Planning for those on 
Methadone programmes in relation to release/( re) integration will require the appropriate and coordinated 
involvement of statutory and voluntary agencies 
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Fig 1. 
Guiding Principle
 
o Through care plans should have an active (re) integration focus 
 
 
The creation of a therapeutic and supportive environment within the prison 
 
A critical success factor for the provision of any prison-based treatment programmes is the promotion of a 
programme-supportive environment. Attention must be paid to the physical, psychological, and social environment 
of a prison and the conditions prevailing in prison which are so different to those in the outside world. In addition 
significant preparatory work is needed to achieve the support and active collaboration of prison management and 
staff for any proposed programmes (Murphy 1998). There must be access to quality social and institutional 
supports, including non-drug using networks for those participating in methadone programmes.  It is also critical 
that prison –based programmes are structurally linked with community –based interventions. In the absence of this 
gains made in prison will not be maintained in the community. 
 
Drug dependence is not necessarily an idiographic, psychological deficit and treatment should be tailored not only 
to individual needs, but also mapped onto the context in which the individual finds him or herself 
 
It should be noted that those people entering prison with substance misuse problems are likely to be multi-problem 
individuals with a host of serious problems which will not remit or moderate even if stabilisation is achieved in 
relation to their current substance misuse. McKay & McLellan state (1998) that there is a strong argument for 
combining substance treatment with a broader array of services (“one-stop shopping”) where a more 
multidisciplinary approach can be taken to poly problem individuals. 
 
Guiding Principles
 
 
o The creation and maintenance of a supportive treatment  environment, where staff and 
participant efforts are understood and valued by all. 
 
o The need for appropriate adaptations to the physical environment, reflecting lower and higher 
threshold programmes. E.g. Kitchen/Communal dining opportunities for people on high 
threshold programmes. Multi purpose space for the provision of various types of programmes 
 
 
Continuing Care 
Financial 
Legal 
Services 
Educational 
Service 
AIDS/HIV 
Service 
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Use of evidence- based practice 
 
The National Drugs Strategy 2001-2008 (Government Publications,2001) , states that there is a need to 
consolidate  and further develop treatment approaches, which are proven to be effective and which are based on  
international evidence-based responses to substance misuse. 
 
The majority of drug misusing clients in prisons have multiple issues which can combine to create a complex case. 
Accordingly a clearly developed care plan, based on a broad based assessment model, should form the basis of all 
interventions.  Effective components of care planning with those on a methadone programme are: goal setting, 
motivational interviewing, problem solving and relapse prevention and management interventions. 
 
These interventions must however be offered in the context of the stepped care literature and consider the needs 
of the individual or population of individuals receiving the service, in order to integrate client factors into the 
process. 
 
Stepped care, based on the interaction between stage of recovery, individual needs and intervention, plays a 
critical role in the effectiveness of appropriate therapies. It is also essential to the development of services, within a 
prison context, as those in receipt of Methadone programmes are a very heterogenous group with widely differing 
needs and management issues.  
 
The National Institute on Drug Abuse (2000) has presented a summary of the evidence base of treatment 
effectiveness in this area, in the form of 13 general principles. (Fig 3)    
 
 
 
 
Guiding Principles 
 
o Adoption of a stepped care approach in recognition of the heterogeneity of the population on 
Methadone programmes 
o Use of evidence –based responses  
o Develop a variety of programmes for those in receipt of  Methadone detoxification , 
maintenance and reduction interventions e.g. Pre-entry programmes, motivational programmes, 
higher threshold programme 
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Figure 2. 
 
Given the increasing provision of methadone programmes within Irish prisons, which is compatible with community 
practice, there is a need to locate the provision of Methadone within programmes that have appropriately 
developed psycho-social interventions.  
 
Stepped Care Model for Treatment of Substance Misuse 
Problems. 
                                                                                                                       
(Wanigaratne,1996) 
 
 
Psychotherapy                                                                                 Drug 
Free/Maintained. 
 
 
 
 
Cognitive Behavioural (Relapse Prevention)                                   Reducing 
Drug Use/ 
And Counselling.                                                                                   
Maintenance. 
 
 
 
Cognitive Behavioural                                               Stable/Continuing use. 
(Motivational Interviewing) 
 
 
 
 
 
 
 
1. No single treatment is appropriate for all individuals. 
 
2. Treatment needs to be readily available. 
 
3. Effective treatment attends to multiple needs of individual, not just 
his/her drug use. 
 
4. An Individual’s treatment and service plan must be assessed 
continually and modified as necessary to ensure that the plan meets 
the needs. 
 
5. Remaining in treatment for an adequate period of time is critical for 
the treatment effectiveness. 
 
6. Counselling (individual and/or group)and other behavioural 
therapies are critical components of effective treatment of addiction. 
 
7. Medications are an important element of treatment for many patients, 
especially when combined with counselling and other behavioural 
therapies. 
 
8. Addicted or drug abusing individuals with co-existing mental 
disorders should have both disorders treated in an integrated way. 
 
9. Medical detoxification is only the first stage of addiction treatment 
and by itself does little to change long-term drug use. 
 
10. Treatment does not need to be voluntary to be effective. 
 
11. Possible drug use during treatment should be monitored 
continuously. 
 
12. Treatment programmes should be provide assessment for HIV/AIDS, 
Hepatitis B and C, Tuberculosis and other infectious diseases, and 
counselling to help patients modify or change behaviours that place 
themselves or others at risk of infection. 
 
13. Recovery from drug addiction can be a long- term process and 
frequently requires multiple episodes of treatment.    
 
 
 
 
Fig.3 NIDA (2000) 
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Chapter 5 
 
Practical issues of programme organisation 
 
Methadone treatment services are organised in a variety of ways throughout Europe.  Sometimes, local legislation 
only allows specialised centres to prescribe methadone while in other places general practitioners and community 
pharmacies are involved.  One argument at hand is whether methadone treatment is considered a specialised 
service or part of primary care.  This depends on local legislation and on the way health care is organised in a 
given area.  
 
When a treatment system is developed in any country, it should be planned as an integral part of the community’s 
overall resources to deal with health and social problems.  It should be ‘population-based’ (WHO Expert Committee 
on Drug Dependence, 1998). 
 
The following section focuses on the elements that are vital in organising best practice of methadone treatment.  
The elements discussed include staff requirements, the role of other services and the physical setting of 
programmes. 
 
 
 
Staff requirements 
 
There is a considerable variation across countries as to who can prescribe methadone medication for the treatment 
of drug dependence.  Nevertheless, it always involves a medical doctor, be it a specialist, general practitioner or 
psychiatrist. 
 
 
Training 
 
It goes without saying that a medical doctor needs to be knowledgeable about specific issues related to opioid 
dependence in order to be an effective clinician.  Training programmes are essential so that the doctor is equipped 
to carry out good clinical practice.  Whether these training programmes are organised as part of the general training 
of doctors or only given to those who start working in the drug field remains open and dependent on the local 
situation.  Obviously, the best practice would be a combination of the two.  Medical schools should include drug 
dependence and the different forms of treatment in their curriculum.  A specialised training programme should also 
be available to doctors who are about to start working in the field of drug dependence and methadone treatment 
(See ICGP Guidelines). 
 
Drug Treatment forms part of the induction training for nurses entering the prison service. 
 
Training possibilities are equally important for all other staff involved in the treatment of opioid dependence.  The 
content of these courses should include the pharmacological, toxicological, and clinical as well as psychosocial 
aspects of opioid dependence.  Regular seminars, supervision, and communication with colleagues always form an 
essential part in keeping abreast of current developments in any field of medicine. 
 
 
Team work 
 
Medical practitioners should not prescribe methadone in isolation.  A multidisciplinary approach to drug treatment is 
essential. This team work should reflect the interrelated medical, psychological and social aspects of an 
appropriately structured methadone programmes.  
 
 
Role of the medical doctor 
 
A doctor prescribing controlled drugs including methadone for the management of drug dependence should have 
an understanding of the basic pharmacology, toxicology and clinical indications for the use of the drug, dose 
regime and therapeutic monitoring strategy if they are to prescribe responsibly. 
 
Irrespective of the composition of the staff of a methadone treatment programme, prescribing is the sole 
responsibility of the doctor signing the prescription.  The responsibility cannot be delegated. 
 
It is the clinicians’ responsibility to make sure that the service user receives the correct dose and that efforts are 
taken to ensure that the drug is used appropriately and not diverted onto the illegal market.  Particular care must be 
taken with induction, especially in case of self-reporting dosage. 
Clinical reviews of service users should be undertaken regularly. 
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Role of the nurse 
 
As part of a multidisciplinary team the nurse provides a standard of nursing care to service users in a primary 
health care setting conforming to best practice, An Bord Altranais code of professional conduct. 
 
In addition to carrying out the initial assessment, prioritising for treatment, and co-ordinating care, the nurse 
completes a nursing assessment, initiates interventions and evaluates nursing care delivery to a caseload of 
service users. 
 
The nurse works in a variety of settings, which can influence the degree of primary care delivered.  However, the 
following common interventions and educational inputs are provided by the nurse in the IPS to all service users: 
 
 
¾ Virology for HIV/Hepatitis screening 
¾ Administration of methadone. 
¾ Vaccination regime as per protocol 
¾ Assessment, treatment and management of tissue viability  
¾ General health promotion 
¾ Family planning and safe sexual practices 
¾ Education on HIV/Hepatitis 
 
 
Role of the Pharmacist 
 
The Pharmacist is responsible for the dispensing and administration of methadone in the prison, for the stock 
control and ordering of methadone, as well as ensuring that records of all methadone use are maintained as legally 
required.  She/he will also have a significant role to play in the management of lofexidine detoxification procedures, 
as necessary. The Pharmacist also provides advice for clinicians and nurses on pharmacology and drug 
interactions of medications, and will work as part of the multidiscliplinary team. 
 
 
Record keeping 
 
Each intervention should be properly recorded and thorough, clearly written or computer records of prescribing 
should be kept (In accordance with IPS and An Bord Altranais Guidelines).  Other medical staff members who may 
see the service user should be informed of current treatment. 
There is enormous variation in regulations about confidentiality throughout Europe.  A central register where people 
receiving methadone are notified exists in this jurisdiction.  This register should not entail notification to any non-
medical service or institution in accordance with the regulations governing the Central Treatment List (CTL). Its 
main purpose is to protect the service, the service users and the service providers as well as to prevent multiple 
prescribing and to facilitate research or funding decisions (Irish Guidelines, 1997). Notification to the CTL is 
mandatory and should be complied with in full, as per the regulations. 
  
 
Dispensing 
 
The person whose name is on the prescription should be the only person to present for the prescribed methadone. 
Where possible methadone should be administered to the patient prior to his leaving the prison for court or other 
appointments or discharge.  At all stages of treatment in prison, methadone should be dispensed and supervised 
on a daily basis by a Pharmacist or two nurses in the absence of a pharmacist.   
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Other services 
 
As previously stated, the success of methadone treatment is partly influenced by the availability of other services 
apart from pharmacotherapy.  The importance of counselling and psychotherapy has been discussed above.  
Liaison with other medical and social services have also been discussed elsewhere in this report.  In case of co-
morbidity, contact with other services should be encouraged and possibly co-ordinated by the staff of the drug 
team. 
 
It is considered part of the treatment programme to try to resolve any social, legal or medical problems.  Other drug 
dependence services, namely the availability of clean injecting equipment either for sale or exchange and 
information on health and other risk behaviour, can form a welcome addition to the treatment programme.  Finally, 
the presence of an outreach project in the area can be helpful in contacting people who do not come to the existing 
services as well as keeping abreast of what happens on the drug scene. 
 
 
Physical setting 
 
A first condition for a programme is that it is safe. Safe in the sense that people can trust the workers and that 
personal information is treated according to medical standards and is not given to third non-medical parties.  It may 
seem obvious, but essential for a successful programme is that people are being treated with respect and that their 
privacy is ensured. 
A non-judgemental attitude of treatment staff is important.  Some research has shown that in a methadone 
maintenance programme where the staff can be identified as “abstinence orientated” service users will leave 
quicker than when a programme is maintenance orientated.  This difference ensued after correcting for methadone 
dosage. (Vosseberg, 1998) 
Another obvious pre-requisite for any medical service is that premises are clean.  It is recommended that all staff 
involved in the treatment of opioid dependence be immunised against hepatitis B and undergoes tuberculosis 
screening. 
 
   
Monitoring and Evaluation 
 
A great deal of research has been carried out on the different aspects of methadone treatment.  Monitoring and 
evaluating services and programmes are an essential part of good practice.  Most programmes will have some 
system of monitoring their activities: how many people are seen, with what frequency, how much methadone is 
prescribed, etc.  However, evaluation of the treatment outcome or a costs-benefit analysis of treatment is rarely 
carried out. 
 
One can argue whether a treatment that has shown to be efficacious, needs to be evaluated over and over again.  
The goal of the afore-mentioned Cochrane Collaboration is precisely to prevent having to ‘reinvent the wheel’ by 
providing the available on the electronic library published quarterly (http://www.updatesoftware.com) 
 
However, we have seen that the way in which treatment is offered is important for its outcome.  It is therefore 
important that any service offered to the public should have a mechanism to evaluate its own success.  It is 
important to have checking mechanisms to see if the different professionals are doing their work appropriately, or 
whether individual service users who are admitted into treatment are suited for that particular type of treatment. 
 
Monitoring of the different activities should be common practice in any programme.  Keeping records of activities is 
therefore essential, but even more important is giving attention to analysing these data.  A descriptive analysis on 
the basis of the monitoring of activities is always possible and when set off against the costs of a given intervention, 
a cost-benefit analysis can be made. 
 
For any type of evaluation of a given intervention it is essential to formulate a clear question, to define the 
objectives a priori and to assess the need of such intervention.  Furthermore, it is essential to verify whether you 
are measuring what you want to know. 
 
In addition to the well-known quantitative methods of evaluation, such as monitoring of activities and making a 
descriptive or cost-benefit analysis, one can consider other types of instruments.  A survey could be carried out 
among service users based on a questionnaire in order to check if service users are happy with what is being 
offered and the way in which it is offered to them. 
 
Assessment of the quality of the service could be measured with more qualitative instruments, such as through a 
‘focus group’, or in-depth interviews with workers, service users, consumer groups, neighbours, community leaders, 
police, etc. 
It is always useful to involve external experts for this type of evaluation.  Market researchers, management 
consulting or consumer groups could provide welcome suggestions to improve service delivery. 
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Evaluation should be an integral part of programmes, possibly by independent experts, and the results of these 
evaluations should be taken into account when designing new programmes.  In this field, the European Monitoring 
Centre for Drug and Drug addiction has issued, and will continue to issue, guidelines for evaluation of activities and 
models for the assessment of policies (Council of European Union, 1999). 
 
All evaluations internal and external should be appropriately disseminated to the all-relevant staff involved. 
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5. GUIDANCE FOR HEALTH CARE STAFF IN RELATION TO THE RESPONSIBILITY TO 
SAFEGUARD THE CONFIDENTIALITY OF MEDICAL INFORMATION CONCERNING PRISONERS 
 
 
(Taken from IPS Healthcare Standards – Administrative Policy 2) 
 
INTRODUCTION 
 
The Irish Medical Council1, An Bord Altrainais2, and the Pharmaceutical Society of Ireland3 in their various 
guidances highlight the fact that confidentiality is a time honoured principle of professional healthcare ethics and is 
fundamental to the therapeutic relationship.  Developments in various aspects of the practice and administration of 
health care have led to reconsideration of the issues involved4,5, 6.  Various national1 and international statements7, 8 
on the issue of ethical behaviour as applied to prisoners clarify that prisoners must be treated in the same way as 
other patients.  There is no diminution or derogation of professional responsibility in this respect when providing 
care to prisoners. 
 
 
Notwithstanding the fact that patient confidentiality is difficult to maintain in the prison setting it is, nevertheless, the 
responsibility of healthcare staff to ensure that a patient’s right to confidentiality is respected.  While a sick prisoner 
cannot easily prevent the nature of an illness being known to others sharing a cell or by prison officers this process 
should not be facilitated by unauthorised disclosure by healthcare staff.  Any presumption that discipline staff or 
others, because of their position, are entitled to unimpeded access to information regarding a prisoner’s health 
status must be clarified. 
 
 
CORE PRINCIPLES  
 
1. Information relating to a prisoner’s health status should be restricted to those with a genuine need to know. 
 
2. Any sharing of information amongst those who do need to know should ordinarily be with the prisoner’s 
consent, though exceptions may arise (see below). 
 
3. All clinical interviews and examinations should be conducted out of the hearing and sight of prison officers 
unless the doctor or nurse concerned requests otherwise in a particular case. 
 
 
 
 
 
EXCEPTIONS  
 
1. Notification of infectious diseases under the relevant Health Acts. 
 
2. Disclosure ordered by a Court. 
 
3. Disclosure to prevent risk to the patient – should be case specific and limited to relevant staff. 
 
4. Disclosure to prevent risk to others – would require a real and imminent risk to an identified individual.  The 
risk would have to be considered life threatening to sustain a decision to disclose confidential information. 
 
5. Child protection – under terms of relevant child protection legislation.    
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6. CRITERIA FOR TREATMENT PRIORITY 
 
A patient who is considered a treatment priority will commence methadone treatment as soon as it is safe for them 
to do so (after a definite diagnosis of dependence to opiates has been established or in a number of cases 
confirmed from associated outside agencies).  
 
Patients will be prioritised for treatment under the following circumstances: 
 
 Patients in receipt of prescribed methadone from other agencies  
Confirmation must be sought from the prescribing agency in relation to type of methadone substitution 
treatment, the current dose and last time and date of administration   
 
 Pregnancy 
A confirmatory pregnancy test must be performed before initiation of methadone treatment 
 
 Physical illness 
To include: 
1. Patients who are HIV positive 
2. Patients who are terminally ill 
3. Sub acute bacterial endocarditis 
4. Deep Vein Thrombosis or Pulmonary Embolism attributable to intravenous substance misuse 
5. Patients who are HCV positive who have been scheduled for treatment or who have commenced 
treatment that have subsequently destabilised and have a well-defined past history of opiate 
dependence  
6. Patients who have a serious physical illness where continued substance misuse could potentially 
be life threatening 
(in all of the above circumstances written confirmation of the diagnosis is required before initiation of 
methadone treatment) 
 
 Blood borne virus risk 
Patients who following a comprehensive assessment are considered at serious risk of acquiring or 
transmitting a blood borne virus 
  
 Patients under 18 years  
 
 Patients with learning disabilities 
 
Confirmation and further information should be sought from outside agencies where applicable or the 
patient must be assessed and diagnosed by a psychiatrist or psychologist as having a learning disability 
 
 Patients with a psychiatric condition  
 Patients with a major psychosis or depression (diagnosed)   
 Suicidal patients following a psychiatric assessment and recommendation to initiate 
methadone  
 
 Cases falling outside the above criteria 
Where cases fall outside the above criteria a doctor can, in consultation with a consultant specialist in 
substance misuse or appropriately experienced addiction specialist, determine a patient to be a treatment 
priority and initiate methadone treatment. 
  
 
Before a methadone maintenance programme is initiated a treatment place must be sought from and confirmed 
with the community agency who will provide follow-up care and methadone prescribing on release from prison. 
 
If a patient is commenced as a priority this must be clearly documented in their notes indicating the name of their 
community clinic.  This information must to be transferred with the patient on any movement within the IPS. 
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7. CENTRAL TREATMENT LIST 
 
 
1. It is the legal requirement that all patients prescribed methadone (either as a detoxification or a methadone 
maintenance programme) are registered on the Central Treatment List before commencing treatment.  It is 
the responsibility of the prescribing doctor to ensure that the patient is entered and voided from the Central 
Treatment List. 
 
2. Weekly contact with health care staff from the prison with staff in the Central Treatment List would ensure 
that the names of patients on methadone are kept up to date. 
 
3. Once a patient discontinues methadone treatment or is released from prison, their name needs to be 
voided from the Central Treatment List. 
 
4. The contact number for the Central Treatment List is 01-648 8600. 
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8. TOXICOLOGY SCREENING OF URINE 
INTRODUCTION 
The rationale for employing toxicology screening in the IPS is an effort to provide a safe secure environment for 
persons in custody, to identify those who may be in need of drug treatment.   
  
Urine toxicology screening can be used as an aid to assessing the level of addiction and/or need for treatment, 
monitoring therapeutic measures and ensuring compliance.   
 
This policy document will outline best practice guidelines in relation to such screening. It will take cognisance of 
issues such as procedures, process, personnel, training, facilities, recording and storage of results as well as 
issues of informed consent. 
 
FREQUENCY 
 
The frequency of urine samples will depend on the purpose of the urine screen.  All committals to prison, where 
there is concern about drug or alcohol abuse, should be screened prior to seeing the doctor. 
 
y The Methadone treatment Guidelines indicate that during assessment for treatment a series of samples be 
taken. It is recommended that 3 samples over a period of 10 days be taken (divided evenly over the ten days 
and one of which should be tested for 6-acetyl-morphine). 
y Patients who are unstable should be screened twice weekly.  Those stable on Methadone Maintenance should 
be screened randomly on a weekly basis.  
y Those on a detoxification programme, or not yet authorised on Methadone should be screened as clinically 
indicated. 
 
Frequency of Testing. 
 
 Reason for Urine Screening Duration Frequency 
1 Court report As dictated by courts. As dictated by courts 
2 As part of a methadone 
maintenance programme 
Duration of Treatment At least once weekly. 
  
3 To identify those who may be in 
need of drug treatment 
On committal Dependant on committal test 
results and recommendations of 
clinician. 
4 To assess for Methadone 
Maintenance Programme. 
 10 Days  3 samples over the designated 
period one of which should be 
tested for 6-acetyl-morphine 
(6AM). 
 
METHOD 
 
Drug Screening may be conducted in one of two ways i.e. Near Patient Testing (NPT) / dip-stick and Laboratory 
Testing.  Laboratory testing provides the clinician with external, objective, documentary evidence which will be 
upheld by the biochemists analyzing samples. This is a consideration when choosing a method of testing. 
Clinicians will require confirmatory testing by a laboratory. 
 
 
 Reason for Urine Screening Initial Test Confirmatory Test 
1  As part of a methadone 
maintenance programme 
Laboratory Testing Not Applicable 
2 To identify those who may be in 
need of drug treatment 
NPT or ‘Dip Stick’ 
technology 
 Laboratory Testing 
3 Induction to substitution treatment. Laboratory Testing  Laboratory Testing 
 
 
If on testing a sample, on committal, using the Near Patient Testing method a positive result is obtained, 
confirmation by Laboratory Testing should take place.
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FACILITIES 
Appropriate facilities will be installed in all prisons to allow urine sampling take place in line with best practice in a 
controlled environment.  
 
This procedure should be carried out with the utmost regard for the dignity of both the patient and the 
individual supervising the process. 
 
The following facilities must be made available: - 
 
1. A specially adapted room where only urine samples are taken, 
2. This room should be fitted out with toilet, appropriate hand washing facilities, mirrored walls, extractor 
fans.  
3. Second room, ideally should be linked to the urine sampling room, in   which urine samples can be 
processed for dispatch to laboratory and where NPT can be processed if necessary.  This room should 
have wash hand basin, lockable storage facility, appropriate testing equipment, safety equipment, and 
adequate facilities for any necessary clerical related work. 
   
RECORDS 
Accurate record keeping is an integral part of any urine screening process, particularly when on site testing is 
carried out. Decisions regarding the patient’s medical treatment may be made on the basis of these results. The 
records of all medically initiated testing should be held in the patient’s medical file. Records of tests carried out 
for other reasons should be held by the appropriately assigned personnel under the auspices of the 
governor of the institution.  
 
The recording of all samples taken, tested and results given is of great importance.  A register of all tests carried 
out and results obtained should be maintained by healthcare staff/healthcare administration. Scrupulous attention 
to detail is required in the taking, labelling, handling and recording of particulars surrounding the urine screening 
process.  In order to effectively deal with the volume of data that the urine screening will generate it is important 
that all such data is stored on a database, Prisoner Medical Records System (PMRS).  
 
Responsibility for maintaining the primary on going records of tests done outside the institution e.g. laboratory 
testing, is the responsibility of the testing laboratory. 
 
 
PERSONNEL 
 
The screening of urine is not a medical procedure and as such can be carried out by any competently trained 
individual.  The procedure should be carried out with the utmost regard for the dignity of both the patient 
and the individual supervising the process.  Due regard should be taken of the gender of the individual being 
screened and appropriate arrangements made to have same sex personnel involved.  Arrangements should be 
made to train all staff involved in screening urine.  Appropriate chaperoning arrangements should be in place in the 
interests of both staff and patients. 
  
 
MANAGEMENT OF URINE RESULTS 
 
It is not the philosophy of treatment providers to use urine test results to sanction patients. The clinician in charge 
of his/her cohort of patients will designate how urine test results will be acted on for his/her patients.  
 
Urine results may result in adjustment of methadone dose upwards or downwards depending on clinical 
circumstances. Dose adjustments need to be made only following a valid prescription. 
 
URINE DECLINES 
 
The clinician will have designated an immediate adjustment to the methadone dose, if any, for their own patient 
group. Any adjustment must be reflected in a valid prescription in the absence of pharmacists.  The clinician may 
provide written policy for their patient group. 
It is the policy of the IPS to standardise the methadone dispensing arrangements which in turn will facilitate 
standardisation of all processes relating to Methadone. 
Repeat refusals should be brought to the attention of the prescribing doctor. 
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POSITIVE URINES 
 
It may be necessary for adjustments to be made to methadone doses on clinical presentation and/or urine results.  
This adjustment must be made, by the prescribing clinician and with a valid prescription.  The clinician may provide 
written policy for their patient group. 
 
 
Confidentiality of medical urine results are guided by confidentiality policy. 
 
Appendix 2 – Urine Screening Procedure 
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9. USE OF METHADONE – 
ORDERING, DISPENSING, ADMINISTRATION AND  
RECORDING OF METHADONE. 
 
 
INTRODUCTION 
Methadone is controlled under Schedule 2 of the Misuse of Drugs Acts 1977 and 1984 and subsequent 
Regulations (1988 and 1993). It is therefore necessary to ensure compliance with the legal requirements set out in 
this legislation. This document does not purport to be a legal interpretation, but is rather a guide to best practice in 
relation to the use of methadone. 
 
Ideally all aspects of methadone usage – ordering, storage, administration, recording etc should be managed by 
pharmacists.  
 
In the current absence of any on-site pharmacists, methadone will continue to be supplied to the doctor in each 
prison for use in that prison and s/he can delegate responsibility for the use of methadone to the healthcare staff. A 
new contract has recently been agreed with for the supply of methadone jointly to the IPS and the HSE, and the 
following procedures have been agreed to ensure compliance with all legal requirements.  
 
These procedures are applicable in the absence of pharmacists. 
 
NOTE:  
In the absence of a pharmacist, where a nurse is on duty, s/he will be held responsible for the safe custody 
of Controlled Drugs and compliance with the regulations. 
 
 
RECORDING: 
 
Register: 
y A complete record must be kept of every transaction involving methadone.  
Administration 
• Recording of administration should be carried out by the pharmacist or the two nurses involved in 
administration.  
y As a daily record of the administration of Methadone is kept, it is acceptable to make a single daily 
entry in the register for the total amount of methadone dispensed each day. 
y The register and the daily issue forms constitute the complete record for the use of Methadone. 
 
 
Receipt: 
y A record of each new supply of methadone received must be made in the controlled drugs register, stating 
date, supplier, and quantity received. 
y The stock balance should be adjusted accordingly. 
y This entry must be signed by the pharmacist/ two nurses. 
 
PRESCRIPTION 
Methadone may only be administered on foot of a current valid prescription. 
 
 
ADMINISTRATION 
a. Methadone may only be dispensed and administered on foot of a current, valid prescription. 
b. Ideally methadone should be dispensed and administered by Pharmacists. 
In the absence of Pharmacists, dispensing and administration of methadone should be conducted by two Nurses. 
c.  Before administering methadone to a patient, the Nurse: 
            1)   check the patient’s name, photograph, number and location 
            2)   check the medication against the prescription 
d.  All methadone administration must take place in front of the Nurse. 
e.  To ensure that the patient has swallowed the dose of methadone: 
1) Each patient should take a drink of water after each dose of methadone 
2) The patient should be supervised, in so far as is possible, to ensure that the methadone has been 
swallowed 
           3) The patient should be engaged in conversation following medication    
administration, to assist in confirming that the methadone has been swallowed. 
4) Any suspicion of retention of methadone should be reported to the doctor. 
f.  Any wastage of controlled drugs should be recorded and the entry witnessed. 
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g.  A signed record should be appropriately entered on the patient’s file on PMRS. 
h.  The checking, preparation, administration or destruction of controlled drugs should be witnessed. 
 
TREATMENT OF OVERDOSE  
Narcan 
 
Facilities should have available to all health care staff protocols to treat acute 
opioid overdose. If there are no facilities and/or staff to treat and observe a 
patient who has overdosed on methadone for at least 24 hours, the patient 
should be transferred to another suitable facility. 
Naloxone (Narcan) should be available in all Prison Service Surgeries and may be administered, where 
appropriate, by clinical staff as outlined in the “IPS Clinical Guidelines on the use of Narcan in the treatment of 
opioid overdose” – Appendix 3.2 of IPS Healthcare Standards. 
 
 
NON-INGESTION OF METHADONE 
If vomiting takes place: 
while the patient is in the administration area and within 10-15 minutes of administration and is observed by 
healthcare staff the full dose is replaced. 
 
If vomiting takes place: 
within 15-30 minutes of administration and is observed by prison staff 
a half dose is administered. 
It is important to record this in the Daily Administration Sheet and in the patient’s file on PMRS. 
 
If vomiting takes place: 
after 30 minutes no replacement dose is administered. 
 
 
Appendix 3 – Use of Methadone Processes 
Appendix 4 – Disposal of Patient’s Legally Dispensed Methadone 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 36
10. MANAGEMENT OF VIRAL INFECTIONS 
 
All patients should be offered and have completed a full viral screen within a month of incarceration.  Refusals 
should be documented. 
Those found to be negative for the following viruses should be managed as follows: 
 
Hepatitis A virus – Receive vaccination with Havrix or Twinrix. 
 
Hepatitis B virus – Should have vaccination status checked and completed as appropriate.  Should receive 
information on how hepatitis B virus is transmitted and ways to protect themselves from being infected.  This advice 
should be documented in the chart. 
 
Hepatitis C virus – Receive information on modes of transmission and how they can protect themselves from 
being infected.  This should be documented in the chart. 
 
HIV virus - Receive information on modes of transmission and how they can protect themselves from being 
infected.  This should be documented in the chart.  All patients who test negative for any of the above should be 
advised of the window period of infection and if they had risk of exposure in this period.  They should then be 
advised of the necessity to retest.  Patient should also be advised of their potential risk of infecting others during 
this period. 
 
If patients test positive for the following virus: 
 
Hepatitis A – Reassured of nature of infection and of benign course 
 
Hepatitis B – Those diagnosed Hep B positive should be checked for E Antigen.  If found to be positive should be 
advised of infective nature and should be referred for consultant review.  Potential contacts should be offered 
testing.  (More appropriately done by Hepatology service) 
 
Hepatitis C virus – Those found to be positive should be offered a PCR test with genotyping.  If found to be PCR 
negative should be advised of possibility of re-infection and ways to avoid infection.  They should have a re-test 
done after year.  Infection should be notified to the public health department. 
 
If PCR positive patient should be assessed for suitability for treatment or assessed for needs to have a specialist 
opinion (e.g. alcohol abuse, dual infection) even if not deemed suitable for treatment. 
 
The patient should be made aware of current criteria for eligibility for Hep C treatment (drug stable etc.) and 
advised of need to work towards fulfilling the criteria.  Patient should be advised of other liver toxins (alcohol, drugs 
etc.).  Patient should be advised of their potential to infect others and should have a discussion around risk of 
sexual transmission, sharing of razors, toothbrush, etc.  Those deemed suitable for treatment should be referred 
directly to local hepatology service. 
 
After appropriate linking and follow up with hepatology service liaison should happen between drug treatment 
service, hepatology and Hep C liaison nurse.  Treatment option will depend on clinical criteria, patient and 
treatment setting.  All patients undergoing treatment need to be monitored closely by both hepatology and drug 
treatment service and should be offered appropriate support and interventions as required. 
 
All patients diagnosed HIV positive should be offered post test counselling and support and should be referred to 
local consultant HIV services.  Close monitoring and liaison should occur between services, and monitoring of CD4 
and viral loads and or appropriate therapy interventions.  Liaison should be very close on patients where 
compliance may be an issue.  Directly observed treatment should be utilised in a prison setting.  Potential contacts 
shall be offered testing and appropriate follow up.  Appropriate forms need to be filled out and sent to the virus 
reference laboratory. 
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11. IMMUNISATION GUIDLEINES 
 
 
(Taken from IPS Healthcare Standards – Healthcare Standard 6 Communicable Diseases) 
 
Standard 
 
1. All programmes of immunisation offered to prisoners will be in line with national guidelines recommended 
by the Department of Health & Children or by the HSE. 
          
 
Criteria 
  
 The responsibility for the application of the vaccines programme lies with the Primary Care Team. 
 
Hepatitis B immunisation will be offered to prisoners in line with prevailing policy guidelines. 
 
Hepatitis A vaccination will be offered to prisoners who are Hepatitis C positive and do not show evidence 
of previous Hepatitis A infection. 
 
 Meningitis C vaccination will be offered to prisoners under the age of 23 years who have not previously 
received this immunisation. (See HC Policy C/6 - ‘Meningococcal C Immunisation Programme’). 
 
 Young offenders who have not completed their programme of school-based immunisation will be offered 
the opportunity to complete these. 
 
Other immunisation programmes will be offered in line with pertaining Public Health guidelines.  (See HC 
Policy C/7 - ‘Influenza Vaccination for Prisoners’). 
 
Immunisation Guidelines for Ireland – 2002 Edition 
 
Available on: 
www.dohc.ie/publications/immunisation_guidelines_for_ireland.html
www.ndsc.ie/Publications/Immunisation/ImmunisationGuidelines
or in each surgery. 
 
Anaphylaxis packs, containing Adrenaline, must be available at all times before giving vaccines. 
 
See Appendix 3.3 - “Best Practice Guidelines in the Management of Anaphylaxis” 
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12. HIV TESTING 
 
Any patient who requests HIV testing should be able to avail of it within the prison medical service. 
 
Particular risk groups for HIV should be targeted for testing because of the availability of very effective early 
intervention for HIV disease. These groups include Injecting Drug Users (IDU) and partners of IDU, men who have 
sex with men (MSM) and prisoners from high endemic areas for HIV (sub-saharan Africa etc.). Patients who have 
tested previously should be offered retesting observing a 3 month window period from any new risk. 
 
While some patients may welcome the opportunity to test some feel that they could not cope with a positive result 
while incarcerated.  Pre-test discussion should be available for those who are deemed by the clinician to require it. 
Patients who may require pre test discussion are those belonging to high risk groups, those with an intellectual 
disability, those where English is not their first language and those with undue anxiety.  
Pre-test discussion may be undertaken by the healthcare staff. 
 
The issues which should be covered during a pre-test discussion session for HIV are as follows. 
 
1. Modes of acquisition and transmission of HIV 
2. Patient/client’s own risk of acquisition. 
3. Natural history of HIV, emphasising the very positive outlook at this time. 
4. What social /family support available to the patient in the event of a       positive result. Possible impacts on 
partner, family members etc. 
5. Issues around life insurance, mortgage protection etc. 
6. Issues around employment – i.e. no issue for employment except for surgery/dentistry. 
 
Phlebotomy for HIV testing and other routine bloods should be available within the prison health care unit. 
 
Confidentiality is of the utmost importance and no one other than the staff directly involved in testing should be 
aware that a patient is having a HIV test. 
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13. ADMINISTRATION OF HIV MEDICATIONS 
 
Correct administration of antiretroviral medication (ARV) and 100% compliance with ARV is absolutely crucial to the 
long term prognosis of HIV. The principles of HIV therapy are as follows: 
 
The virus has the ability to mutate itself in the presence of antiretroviral medication to make it resistant to the 
medication. Historically it is known that where AZT is used alone resistance develops to the drug in about 6 
months. Resistance to other ARV can develop much more quickly – even after one dose e.g. Nevirapine 
(Viramune) 
 
Three or more drugs are usually used together in an antiretroviral regime. Using 3 drugs drives the virus load 
down so low in the blood that the virus cannot acquire the mutations it needs to develop resistance. 
 
More than 95% of doses must be taken correctly to maintain viral susceptibility to medication. Some 
pharmaceutical companies own more than one drug and may have combined 2 or more drugs into one tablet so 
the patient may be taking 3 drugs while only taking one tablet twice a day. E.g. Trisivir contains AZT, 3TC and 
Abacavir. Reducing pill burden improves compliance. 
 
Discontinuation of ARV should be in consultation with the treating hospital as there are very significant differences 
in half lives of ARVs and they may need to be discontinued in a staggered fashion.  If a prisoner declines to attend 
their hospital appointment contact should be made with the HIV pharmacist in the Mater, St. James or in Beaumont 
for advice on discontinuation. 
 
Some drugs require to be taken fasting e.g. DDI and some drugs must be kept in the fridge e.g. Ritonavir. Ideally 
ARV in prison should be administered on a directly observed therapy (DOT) basis by a pharmacist. 
 
There are very significant interactions between ARV and other medications e.g. Proton pump inhibitors (losec) 
cannot be co administered with Atazanavir. 
If any patient on ARV requires co administration of other medication the HIV pharmacist in the relevant hospital 
should be contacted. (There is usually no problem with co administration of antibiotics). 
 
Side effects to ARV which are often prevalent in the first month of therapy usually subside over time and it’s 
important to support the patient through this. 
 
Efavirenz (Sustiva) is teratogenic and should not be administered in anyone contemplating a pregnancy. 
 
Some ARV interact with Methadone requiring an increase or decrease in Methadone dose. The treating HIV team 
should inform the prescribing doctor if this is the case. 
 
Any antiretroviral therapy supply left when a patient is released should be transferred to the patient’s drug 
treatment centre or if s/he is not attending for drug treatment returned to the treating hospital. Patients who are 
released should have enough medication to last them until they can reasonably expect to be seen and have their 
prescription renewed. 
 
Three monthly follow up at the hospital outpatients is the norm for HIV patients and it is very important that 
appointments are kept. Patients should not be allowed to continue antiretroviral therapy if they are not attending for 
hospital follow up. 
 
All HIV medication will be dispensed by the treating hospital. 
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14. ASSESSMENT AND TREATMENT OF BENZODIAZEPINE ADDICTION IN PRISON: 
BENZODIAZEPINE DETOXIFICATION GUIDELINES 
 
Assessment of benzodiazepine misuse and dependence in an IPS Setting. Medically assisted detoxification, 
ongoing BDZ prescribing and use of anticonvulsant medications to cover Benzodiazepine withdrawals 
 
1.0 Background 
 
 1.1. Misuse of benzodiazepines is an endemic problem in the Irish Prison population. The majority of 
prisoner patients will not require a medically assisted detoxification or an ongoing prescription for 
benzodiazepines. However they will require assessment of their levels of use and dependence on 
benzodiazepines and a documented clinical decision in respect of the assessed need for 
detoxification. If a diagnosis of benzodiazepine dependence is made then these patients should be 
offered a medically assisted detoxification. 
 
1.2 Benzodiazepines were developed in the last century and came into therapeutic use in the 1960s. Initially they 
were thought to be without a potential for misuse or dependence but by the early 1970s it became clear that 
these agents had a significant potential for both misuse and dependence  
 
1.3 Accordingly expert guidance on the rational and appropriate use of benzodiazepines has tightened. The usual 
significant indication remains the short term treatment of significant and disabling anxiety problems and/or 
disturbance of the sleep wake cycle.  Both the recent Guidelines from the Department of Health and Children 
in the Republic and the internationally respected UK British National Formulary (BNF) suggest that initial use 
should be restricted to a 2 to 4 week period. For those patients who are dependent on these drugs it 
suggests a gradual process of dose reduction in community settings. 
 
 1.4 In the Republic of Ireland there currently exists no specific extended regulation of the prescribing of 
Benzodiazepines. Use of these agents is amongst the highest levels in Western Europe. Misuse of these 
drugs is very significant and the majority of prisoner patients with a drug problem will have used 
benzodiazepine drugs at some point. Only those prisoner patients who meet the criteria for benzodiazepine 
dependence will require a medically assisted detoxification. 
 
 1. 5 Benzodiazepines in Irish Prison settings. 
Ideally prescribing of these medicines would be minimal and time limited. Significant progress has been 
made to rationalize the use of prescribed BDZs in IPS locations in Dublin. Illicit supplies are and remain 
plentiful in prison settings.  In the context of prison these medicines have a currency. They may be used to 
barter for other goods or services. Prisoners on benzodiazepines may and often are bullied to surrender their 
supply to other prisoners.  Benzodiazepines can have disinhibiting effects that are often associated with 
aggressive behaviours directed at other prisoners and staff.  A link has been argued to exist (by some 
Clinicians) between self harming behaviours and benzodiazepine use in prison settings.  A binge pattern of 
benzodiazepine use makes it very difficult to stabilize patients other drug use. When prescribed rationally 
with resulting therapeutic levels the use of prescribed benzodiazepines is not incompatible with psychological 
work. Comorbid psychiatric disorders (mood, anxiety or psychosis) may be present, and should be 
considered in the diagnostic work up of patients seeking to obtain benzodiazepines. Adjustment reactions to 
psychosocial stressors also occur and are usually better treated by referral to Counselling services (if they 
exist locally). 
 
 
2.0 Assessment of Benzodiazepine use 
 
2.1 Nursing assessment 
 
As part of the comprehensive Nursing assessment the following should be documented -  
Enquiry should be made as to the level of use and the agents involved. 
(a)I.e. What agent, 
 What quantities,  
 What frequency, 
 When last used  
 If ever withdrawal seizures. 
 
 (b)Concomitant alcohol use should be noted  
What alcohol type 
What quantity 
What frequency 
When last used 
Ever had withdrawal fits 
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Ever had DTs 
Screening tools such as the AUDIT may also be used. 
 
(c) A prior history of seizure activity should be recorded and the context involved. 
 
(d) Enquiry should establish if there are  any prescribed BDZs and the Community or Specialist prescriber involved. 
 
2.2  If a patient is clearly in withdrawals (tachycardia, elevated BP, tremor) and gives a history of alcohol  or BDZ 
use  a protocol should be agreed locally in each Prison between Nursing, Pharmacy, General Practice, and  
Addiction Psychiatry that would enable Nursing staff to administer a long acting Benzodiazepine(,e.g. 
diazepam or chlordiazepoxide) before a Medical Assessment. 
 
 
Emergency Administration Protocol 
If a patient who has given a history of benzodiazepine or alcohol use becomes clearly 
Tremulous 
Sweating 
Has a tachycardia (pulse > 90) 
Normal or elevated blood pressure 
 
Nurses may administer benzodiazepines on an emergency basis.  A protocol for emergency administration will be 
agreed locally. 
  
2.3 Assessment by GP 
This essentially confirms and extends the Nursing Assessment. At the completion of both assessments there 
should exist in the notes a description of last use, agents and quantities used, usual pattern of use and 
corroboration of prescribing from Addiction Treatment Centre, GP, Consultant Psychiatrist or  the DTCB. 
 
 
3.0 Treatment of Benzodiazepine withdrawal 
 
3.1  All prisoner patients who are assessed as having a current pattern of BDZ dependence (as opposed to 
misuse) should be offered a time limited medically assisted detoxification and this should be documented in 
the medical notes.  If a prisoner does not meet the ICD-10 Criteria for Benzodiazepine Dependence at the 
time of the assessment this should also be documented in the medical notes. 
  
3.2 There are several options in respect of the choice of agent to assist in withdrawal from Benzodiazepines. 
Essentially these presently are (a) to use a long acting benzodiazepine such as diazepam and reduce slowly 
in decremental manner or (b) Use of anticonvulsant medicine such as sodium valporate in those patients on 
methadone or carbamazepine in those who are not methadone maintained. The latter agents are used off 
label and off license but clinical experience exists to support this strategy subject to the usual cautions and 
contraindications for both agents (e.g. allergies, active liver disease etc). 
 
 
 
 
 
 
 
 
 
3.3  Suggested detoxification regimes 
 
       (a) Liquid formulation of long acting Benzodiazepine e.g. diazepam 10mg - 15 mg TID and reducing by 05mg 
every three days. 
 
      Day 01 Diazepam 15mg TID (morning, lunch time and night) 
      Day 04 Diazepam 10mg-10mg-15mg 
      Day 07 Diazepam 10mg-05mg-15mg 
      Day 10 Diazepam 10mg-0mg-15mg 
      Day 13 Diazepam 05mg-15mg 
      Day 16 Diazepam 15mg nocte 
      Day 19 Diazepam 10mg nocte 
      Day 21 05 mg nocte 
      Day 25 Cessation of medically assisted detoxification 
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Or 
 
       (b) 
             Day 1 Sodium valporate 200mg tid 
             Day 02 Sodium valporate 400mg tid 
             Day 03-10 Continue as above 
             Day 11 Sodium valporate 400mg bd 
             Day 13 Sodium valporate 200mg bd 
             Day 14 Sodium valporate 200mg nocte 
             Day 16 Cease 
              
 
3.4 If the level of BDZ use is reported as very high, and significant withdrawals are observed the  adjunctive  use of 
Sodium valporate is suggested in addition to a long acting benzodiazepine (see current BNF for dose 
induction recommendations, usual dose 1200mg daily in divided doses) and the period of dose reduction 
may be extended under medical supervision. 
 
4.0 Ongoing assessment 
 
4.1  Regular review is necessary as the patient may have either overstated or understated their levels of use. At 
a basic minimum the patient should have a documented nursing review with documentation of vital signs and 
seizure activity on a daily basis and be medically reviewed every 72 hours. 
 
4.2 If a patient presents as oversedated the dose reduction may be accelerated following medical review. 
 
5.0  Use of Carbamazepine in opioid dependent patients on methadone therapy 
 
 5.1 Carbamazepine (CBZ) should not be prescribed for any patient who is on any methadone programme 
(stabilization, maintenance or reduction) as there is a well documented interaction and increased metabolism 
of methadone. 
 
6.0  A minority of patients who are under the care of ether Consultants in General Adult Psychiatry or Consultants 
in Addiction Psychiatry may be on an extended non time limited prescription for BDZs.  This should be 
confirmed with the relevant Consultant and an individualized care plan drawn up in agreement with the 
Consultant Psychiatrist in the community to manage these patients’ ongoing care. The option of a medically 
assisted detoxification in addition to the option of ongoing benzodiazepine prescribing may be considered 
and the final decision documented in the medical notes. 
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15. PRESCRIPTION OF HYPNOTICS 
 
Some patients request from the GP to be prescribed night-time sedation.  In many instances sleeping tablets have 
been prescribed to these patients or obtained by them in the community on a regular basis.  Committal to a prison 
can be a very traumatic event which causes great anxiety and often sleep disturbance. 
 
Some points to be considered for prescribing clinicians: 
• There is no absolute indication for the prescription of night-time sedation 
• Long term sleeping tablet use has been shown to decrease the quality of sleep obtained and for this 
reason short term use only is recommended.  This is particularly the case with benzodiazepine (BDZ) 
sleeping tablets. 
• As with the use of BDZ’s for anxiety, the use of sleeping tablets encourages a ‘quick fix’ mentality which 
allows more important issues (social, relationships, depression, anxiety, lifestyle) to remain unaddressed. 
• Sleeping tablets have a currency within the prison system and the bartering of them can be a source of 
confrontation/bullying between prisoners. 
• Many patients have substance abuse problems and the use of sedatives represents an aspect of these 
problems. 
 
With these points in mind reasonable clinical policy would support: 
1. No BDZ sleeping tablets to be prescribed. 
2. No zopiclone sleeping tablets to be prescribed.  (Although these are non-BDZ, they have currency in the 
system at present). 
3. Other sleeping tablets (Phenergan, Stilnoct, Sonata) to be prescribed on a strictly limited basis e.g. for a 
short period of time after committal to allow for adjustment and then discontinuation. 
4. Counselling with regard to sleep hygiene, lifestyle, substance abuse and other factors which influence 
sleep should be provided and also more specific treatments associated with serious psychiatric / medical 
problems. 
5. If a patient has a significant (predominant) night-time benzodiazepine use they will have to be withdrawn 
from this. 
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16. LOFEXIDINE DETOXIFICATION GUIDELINES 
(Modified from The Maudsley's Protocol) 
 
Exclusion Criteria 
 
1. No patients with a history of heart disease, cerebral vascular accident. 
 
2. No pregnant or breast feeding mothers. Pregnancy testing should be carried out and a negative result 
confirmed if there is any chance of pregnancy. 
 
3. No heavy users of alcohol (more than 50 units per week for men, 35 units for women), or benzodiazapines 
(more than 40mg Diazepam daily). 
 
4. No patients receiving over 10mg of methadone. 
 
Entry Criteria 
 
1. Blood pressure and pulse within normal limits. The systolic B.P. must not be less than 90mm Hg, nor more 
than 30mm Hg below the client’s baseline blood pressure, before giving the dose. The pulse not below 55 
beats per minute. 
 
2. Urine sample positive for opiates/methadone. 
 
3. Patients using quantities of less than 1/2gm of heroin daily, preferably one bag (one quarter gm) would be 
suitable for direct placement on Lofexidine. 
 
4. Lofexidine is particularly suitable for young users who are smoking Heroin and who are at an early stage of 
drug use but who need some assistance in withdrawing from opiates. 
 
5. Patients should first be reduced to 10mg methadone for one week at least prior to commencing Lofexidine. 
It is possible to use Lofexidine to take patients down from methadone. However, normally here the advice 
would be to reduce the methadone as far as possible, perhaps as far as 5 - 10mg before switching over to 
Lofexidine. 
 
6. All clients to have attended for full assessment with nurse and GP or psychiatrist and fulfil these entry 
criteria and not fall into exclusion categories. 
 
Process 
 
1. All Lofexidine detoxes will commence on a Monday morning if possible. 
 
2. Baseline B.P. and pulse must be taken daily and before and after dispensing of lofexidine. 
 
3. All patients should be seen daily. The B.P. needs to be taken sitting and standing to check for postural 
hypotension.  This should be repeated after twenty minutes.  A drop of more than 30mgs Hg between 
sitting and standing necessitates withholding next dose and possible revision of dosage regime. 
 
4. If systolic B.P. is below 90mm Hg or 30mm Hg below baseline or pulse is below 55 bpm discuss dose with 
medical staff prior to administration. It may be necessary to lower the dose and for patient to be seen in the 
afternoon to have B.P. and pulse monitored before night dose is taken. 
 
5. Discuss effects of Lofexidine, including possible side effects and how these should be managed. This will 
also be given in writing to patients. 
 
6. Discuss contract and consent to treatment with all patients. 
 
7. Dispense three times daily (see protocol). 
 
8. The Lofexidine detox will be monitored daily and the use of Withdrawal Scale Questionnaire can be used. 
 
 
Dosage and Administration of Lofexidine 
 
 
1. The following table shows the dose of Lofexidine that should be prescribed. 
 45
 
2. If patient has been on methadone ideally the dose should be down to 5 -10mg or less on the day before 
commencement of the Lofexidine. Those who are on Heroin should not take any Heroin in the mornings 
when they are about to start the Lofexidine. 
 
 
Day Morning Lunchtime Night Total Daily No. of 
Tablets/Dose 
1 1 1 1 3 tabs/0.6mg 
2 2 2 2 6 tabs/1.2mg 
3 2 2 3 7 tabs/1.4mg 
4 3 3 3 9 tabs/1.8mg 
5 3 3 4 10 tabs/2.0mg 
6 3 3 4 10 tabs/2.0mg 
7 3 2 3 8 tabs/1.6mg 
8 2 2 3 7 tabs/1.4mg 
9 2 1 2 5 tabs/1.0mg 
10 1 1 1 3 tabs/0.6mg 
Lofexidine tablets – 1 tablet = 0.2mg 
 
 
Lofexidine – Information for Clients 
 
 
What is Lofexidine? 
 
Lofexidine is a tablet that is effective in reducing the symptoms associated with opiate withdrawal or “cold 
turkey” such as chills, sweating, stomach cramps, diarrhoea, muscle pain, runny nose and eyes. 
 
Although Lofexidine does help in withdrawal it should be noted that it does not suppress all withdrawal 
symptoms, for example insomnia and cravings. 
 
Lofexidine may have a mild sedative effect. Therefore it is advisable not to drive or operate machinery while on 
Lofexidine. 
 
How does it work? 
 
When opiates are stopped abruptly the brain produces too much of the chemical noradrenaline which causes 
the withdrawal symptoms. Lofexidine works by reducing the action of noradrenaline and so reduces the 
severity of symptoms. 
 
Is it addictive? 
 
No. It is not an opiate and has no addictive properties of its own. 
 
How do I take it? 
 
1. Clients using lower quantities of Heroin 1 or 2 Qs a day have the option to go directly onto Lofexidine 
(Patients with higher dose Heroin, ½ gm or more per day who have a Lofexidine detox may first be 
stabilised on methadone.) 
 
 
2. The methadone can be tailed off during the first 1 to 2 days that the Lofexidine is started, but it is best if it is 
stopped completely before commencing Lofexidine. 
 
3. The Lofexidine dose will be gradually built up to a maximum of 10 tablets in one day. 
 
4. Patients present to a nurse three times a day and have their blood pressure monitored. Their blood 
pressure should be taken before the Lofexidine is given. The B.P. needs to be taken sitting and standing to 
check for postural hypotension. This should be repeated after twenty minutes.  A drop of more than 30mgs 
Hg between sitting and standing necessitates withholding next dose and possible revision of dosage 
regime.  Patients failing to present for medication must be followed up by healthcare staff. 
 
5. At the end of the treatment the dosage should be reduced gradually rather than stopped suddenly as this 
could cause a rebound in blood pressure. Therefore it is important that clients do not drop out of treatment 
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without discussing it with the interdisciplinary team.  If discharged prior to completion of the detox, follow up 
arrangements/care must be put in place. 
 
Table showing how Lofexidine should be taken 
 
Day Morning Lunchtime Night Total Daily No. of 
Tablets/Dose 
1 1 1 1 3 tabs/0.6mg 
2 2 2 2 6 tabs/1.2mg 
3 2 2 3 7 tabs/1.4mg 
4 2 3 3 9 tabs/1.8mg 
5 3 3 4 10 tabs/2.0mg 
6 3 3 4 10 tabs/2.0mg 
7 3 2 3 8 tabs/1.6mg 
8 2 2 3 7 tabs/1.4mg 
9 2 1 2 5 tabs/1.0mg 
10 1 1 1 3 tabs/0.6mg 
 
 
6. Patients should be particularly careful when getting in and out of bed in the morning or after having a hot 
bath or shower as these are times when blood pressure is lowered and it is more likely to suffer the 
consequences of low blood pressure from Lofexidine. 
 
Are there any side effects? 
 
1. You may experience a dryness of the mouth, throat and nose. It would help to drink plenty of fluids (you 
could try some detox tea) to flush through the system and help compensate for the dryness of the mouth. 
 
2. You may feel slightly drowsy or dizzy and if you are affected do not drive or operate machinery. 
 
3. Lofexidine does not normally produce any significant effects on blood pressure and pulse. However, it does 
have potential to cause a reduction and thus your blood pressure and pulse will be carefully monitored 
throughout treatment. 
 
4. As mentioned above, Lofexidine should be gradually reduced at the end of treatment to prevent the risk of 
rebound increase in blood pressure. Therefore patients should have a discussion with their addiction nurse 
prior to stopping treatment. 
5. The safety of Lofexidine in pregnant women has not been established therefore precautions should be 
taken to prevent pregnancy during treatment with Lofexidine. 
 
 
6. Lofexidine will interact with sedative drugs e.g. alcohol, benzodiazepines, heroin. Therefore, such drugs 
should not be used during the detox. 
 
 
 
What should I do if I experience problems with Lofexidine? 
 
The main problem that you could possibly experience as outlined above is a fall in your blood pressure. If this 
occurs you may experience the following: 
 
Dizziness 
Feeling faint 
Pallor (Pale colour) 
Feeling sick 
Headache 
Feeling drowsy 
 
If you experience the above you should lie down fro half an hour or so and in most cases the blood pressure 
will return to normal. If the feeling persists you should reduce or omit the next dose of Lofexidine and discuss 
things with your addiction nurse or doctor. 
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Severity of Opiate Withdrawal Scale 
 
Name: _________________________ Date: ________________ 
 
Rate each symptom using the following scale: 
 
 
0 = Nil 1 = Mild 2 = Moderate 3 = Severe 
 
 
 
Day 1 2 3 4 5 6 7 8 9 10 
Dizziness           
Difficulty 
Concentrating 
          
Feeling Faint           
No Energy           
Drowsiness           
Headache           
Dry Mouth           
Total:           
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Prescription for Lofexidine 0.2mg Tablets
 
 
Medical Unit 
Mountjoy Prison 
Dublin 7 
 
 
 
Patient : ___________________________  D.O.B: __________________ 
 
 
 
Day Date No. of Tablets 8am 
Issued by 
No. of Tablets 1pm 
Issued by 
No. of Tablets 
10pm 
Issued by 
Day 1  1 1 1 
Day 2  2 2 2 
Day 3  2 2 3 
Day 4  3 3 3 
Day 5  3 3 4 
Day 6  3 3 4 
Day 7  3 2 3 
Day 8  2 2 3 
Day 9  2 1 2 
Day 10  1 1 1 
 Total Tablets 22 + 20 + 26 = 68 
 
 
Baseline Observations 
 
Date: ______________ BP: _____/______  Pulse: _______bpm 
 
 
Batch Number: __________________ Expiry Date: _________________ 
 
 
 
 
 
 
 
 
 
 
 
        Page 1 of 2 
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BP & Pulse Monitoring 
 
DAY DATE  8am 1pm 10pm 
Day 1   Sitting BP      Pulse BP      Pulse BP      Pulse 
  Standing BP      Pulse BP      Pulse BP      Pulse 
Post 20mins  Sitting BP      Pulse BP      Pulse BP      Pulse 
  Standing BP      Pulse BP      Pulse BP      Pulse 
Day 2  Sitting BP      Pulse BP      Pulse BP      Pulse 
  Standing BP      Pulse BP      Pulse BP      Pulse 
Post 20mins  Sitting BP      Pulse BP      Pulse BP      Pulse 
  Standing BP      Pulse BP      Pulse BP      Pulse 
Day 3   Sitting BP      Pulse BP      Pulse BP      Pulse 
  Standing BP      Pulse BP      Pulse BP      Pulse 
Post 20mins  Sitting BP      Pulse BP      Pulse BP      Pulse 
  Standing BP      Pulse BP      Pulse BP      Pulse 
Day 4   Sitting BP      Pulse BP      Pulse BP      Pulse 
  Standing BP      Pulse BP      Pulse BP      Pulse 
Post 20mins  Sitting BP      Pulse BP      Pulse BP      Pulse 
  Standing BP      Pulse BP      Pulse BP      Pulse 
Day 5   Sitting BP      Pulse BP      Pulse BP      Pulse 
  Standing BP      Pulse BP      Pulse BP      Pulse 
Post 20mins  Sitting BP      Pulse BP      Pulse BP      Pulse 
  Standing BP      Pulse BP      Pulse BP      Pulse 
Day 6   Sitting BP      Pulse BP      Pulse BP      Pulse 
  Standing BP      Pulse BP      Pulse BP      Pulse 
Post 20mins  Sitting BP      Pulse BP      Pulse BP      Pulse 
  Standing BP      Pulse BP      Pulse BP      Pulse 
Day 7   Sitting BP      Pulse BP      Pulse BP      Pulse 
  Standing BP      Pulse BP      Pulse BP      Pulse 
Post 20mins  Sitting BP      Pulse BP      Pulse BP      Pulse 
  Standing BP      Pulse BP      Pulse BP      Pulse 
Day 8   Sitting BP      Pulse BP      Pulse BP      Pulse 
  Standing BP      Pulse BP      Pulse BP      Pulse 
Post 20mins  Sitting BP      Pulse BP      Pulse BP      Pulse 
  Standing BP      Pulse BP      Pulse BP      Pulse 
Day 9   Sitting BP      Pulse BP      Pulse BP      Pulse 
  Standing BP      Pulse BP      Pulse BP      Pulse 
Post 20mins  Sitting BP      Pulse BP      Pulse BP      Pulse 
  Standing BP      Pulse BP      Pulse BP      Pulse 
Day 10   Sitting BP      Pulse BP      Pulse BP      Pulse 
  Standing BP      Pulse BP      Pulse BP      Pulse 
Post 20mins  Sitting BP      Pulse BP      Pulse BP      Pulse 
  Standing BP      Pulse BP      Pulse BP      Pulse 
 
 
Prescribing Doctor: _______________________________ 
 
 
  
 
         Page 2 of 2 
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17. GUIDELINES AND PROCEDURE FOR ADMINISTRATION OF NALTREXONE (NALOREX) 
 
 
Naltrexone is a non-addictive opoid antagoinist capable of blocking the effects of heroin and other opioid drugs. It 
does not block the effects of non-opiate drugs such as cocaine or amphetamines.  For 48 hours after taking the 
recommended dose, users cannot obtain a ‘high’ with opiate. 
 
Naltrexone works by blocking opiate receptors in the brain and spinal cord. 
 
Naltrexone blocks opiate-based pain relief i.e. cocodamol, solpadine, codeine.  It can also reduce the effectiveness 
of opioid-based cough and cold remedies and antidiarrhoeals. 
 
Naltrexone should form part of a programme of psychosocial support.  It has been shown that Naltrexone works 
more effectively if counselling and support also provided. 
 
Naltrexone must not be prescribed to pregnant women. 
 
 
Guidelines for administration of Naltrexone. 
 
Naltrexone is available as Nalorex 50mg tablets. 
 
Careful assessment is required. Naltrexone should only be prescribed by G.P. or Consultant experienced with its 
use. 
 
Naltrexone is available as a 50mg scored tablet. 
 
If on day 10 of Lofexidine detox, or for patients who are opiate free, an-on-the-spot urine test is opiate free then the 
patient will be offered Naltrexone for a period of 6-12 months for relapse prevention; (provided no abnormality 
of L.F.T.’s) 
 
If confident that patient is opiate free then: 
• a starting dose of 12.5mgs of Naltrexone can be given.   
• On day two a 25mgs tab can be given and  
• on day three 50mgs and  
• thereafter 50mgs on alternate days. 
 
Administration of tablet must be supervised by the pharmacist or healthcare staff member. 
 
Prescriptions must be written weekly. 
 
7.   When on Naltrexone liver function tests to be checked three monthly. 
 
8.   Pharmacist/Healthcare staff will provide a Medical Alert Card for service     
      user to carry to inform re Naltrexone treatment in case of accident. 
 
9 During this time patient to continue Counselling contact. 
 
10 Regular monitoring for side effects is essential and patients should be   
     reminded that their tolerance for opiates has decreased. 
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18. ASSESSMENT AND TREATMENT OF ALCOHOL WITHDRAWALS 
 
Adapted from the Maudsley Prescribing Guidelines 2005. 
 
1. Introduction: 
 
The diagnosis and treatment of patients with a history of harmful or hazardous drinking or who present with 
symptoms of alcohol dependence, is of high importance to prevent alcohol withdrawals.  
 
2. Definition: 
The Royal College of Physicians and The Royal College of Psychiatrists classification of drinking: 
 
Safe Drinking per week: Males: up to 21 units   Females: 14 units  
Hazardous Drinking: Males: 21-49 units  Females: 14-35 units 
Harmful Drinking:  Males: >50 units  Females: >36 units 
 
3. Alcohol Withdrawal  Symptoms  :   
Onset  :  Within  hours  of  the  last  drink.  Peak  at  24- 48  hours. 
Nausea,  vomiting,  restlessness,  sweating,  tremor,  anxiety,  agitation,  insomnia,  headache, loss  of  appetite, 
tachycardia, hypotension, seizures.   
 
4. SCREENING 
 
4.1 Stage 1 
Where harmful of hazardous alcohol intake is suspected but not confirmed the ‘Alcohol Use Disorders Identification 
Test - AUDIT (Appendix 1) can be completed. Where a score of over 8 is obtained proceed to stage 2. 
 
4.2 Stage 2 
 
Assessment  for  Alcohol  withdrawals: 
• History  and  assessment  of  current  alcohol  use.   
¾ Consumption  over  the  last  3  months,  a  typical  day’s  drinking,  frequency  of  drinking,  maximum  taken  
in  one  day,  alcohol  related  physical,  emotional  and  social  problems.  
• Previous  history  of  alcohol  withdrawals  and  DT’s 
• Time  of  most  recent  drink 
• Concomitant  drug  use 
• Severity  of  withdrawal  symptoms 
• Co-existing  medical / psychiatric  disorders 
• Physical  examination 
• Laboratory  Investigations: Blood Alcohol Concentration (BAC), FBC,  U&E,  LFT’s,  blood  glucose,  INR,  
urinary  drug screen. 
• Pulse  rate  and  B.P. measurement. 
 Alcohol  Withdrawal  scales  can  be  used :  
I. The  Clinical  Institute Withdrawal  Assessment  for  Alcohol – Revised  version:  CIWA -  Ar 
(Appendix 2) is a useful tool for the clinical quantification of the severity of the alcohol withdrawal 
syndrome. 
Objective Quantification of alcohol withdrawals: (Appendix 2) 
Severity  of  alcohol  withdrawals:  CIWA –Ar  score 
 Mild        <10 
 Moderate       10-20 
 Severe       20+ 
 
II. The Short Alcohol Withdrawal Scale. Self completion questionnaire. Symptoms cover the previous 24 
hours. Scores above 12 require pharmacotherapy. (Appendix 3) 
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5.1 Alcohol Withdrawal Treatment Interventions: 
Alcohol 
Withdrawals 
Supportive  
Care 
Medical  
Care 
Pharmacotherapy Setting 
Mild withdrawal 
symptoms: i.e. 
irritability, poor 
concentration, 
Intake < 50 units per 
week 
CIWA – Ar scale <10 
 
Moderate to 
high level 
Little required Little to none required. 
Maybe symptomatic 
treatment i.e. 
paracetamol, fluids, 
diet, symptomatic 
treatment of nausea, 
vomiting, diarrhoea 
Prison 
Moderate 
withdrawal 
Symptoms:  
i.e.tachycardia, 
nausea, tremor, 
sweats, headache, 
irritability, flu- like 
symptoms. 
Intake > 50 units per 
week 
CIWA – Ar scale 
10-20 
Moderate to 
high level 
Little required Symptomatic 
treatment. 
Substitution treatment 
of a reducing course 
of chlordiazepoxide 
and vitamin 
supplementation See 
guidelines 
Prison 
Severe  Withdrawal  
Symptoms: i.e. 
Above symptoms, 
Confusion, 
disorientation, 
clouding of 
consciousness, 
visual, tactile, 
auditory 
disturbances, “DTs” 
CIWA – Ar scale 20+ 
High Level Medical 
monitoring 
Symptomatic and 
substitution treatment 
required. Refer for 
inpatient treatment 
Hospital 
Complicated 
Withdrawals: i.e. 
CIWA –Ar > 10 plus 
medical problems 
High Level Medical 
Monitoring 
Symptomatic and 
substitution treatment 
required. Refer for 
inpatient treatment 
Hospital 
 
The  dose  of  benzodiazepine  prescribed  will  depend  on  the  severity  of alcohol  dependence  and  the  
severity  of  alcohol  withdrawals. 
 
5.2 Mild  dependence /Mild  withdrawals :   
Can  be  managed  without  medications  or  small  doses  of  a  reducing  course  of  chlordiazepoxide. 
 
 
5.3 Moderate  dependence / Moderate  withdrawals :   
A  typical  regime  might  be  Chlordiazepoxide 10-20mg  QDS  reducing  by  20%  daily  over  5 -7 days.  
 
Day 1 Chlordiazepoxide 20mg qds 
Day 2  Chlordiazepoxide 15mg qds 
Day 3 Chlordiazepoxide 10 mg qds 
Day 4 Chlordiazepoxide 5mg qds 
Day 5 Chlordiazepoxide 5mg bd 
 
A PRN dose of 5-10 mg of chlordiazepoxide can be prescribed within the first 24 hours if evidence of alcohol 
withdrawals and BP > 130 / 90 or PR > 100 bts per min. 
 
BP should be monitored on a daily basis by nursing staff. 
 
If a slower alcohol detoxification programme is required: 
¾ chlordiazepoxide can be reduced by 10% daily  
¾ and / or the rate of reduction could be every 2-3 days. 
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If there are concerns about adequate dietary intake oral Thiamine (200-300mg daily for 5-7 days) can be 
prescribed.  There is considerable doubt about the usefulness of oral thiamine as it is not adequately absorbed.  All 
patients admitted to hospital for an inpatient detoxification programme should be given parenteral thiamine as 
prophylaxis for Wernickes’s Encephalopathy. 
 
Diazepam: 
A typical initial regime is diazepam 5-10mg qds  
- reduce on subsequent days by 10 –20% or at a rate depending on symptomatology. 
 
Prophylactic anticonvulsant therapy: 
If there is a concern that a patient may be at risk of an alcohol withdrawal seizure then Diazepam may be used as a 
detoxification regime.  In addition anticonvulsant prophylaxis may be added such as Carbamazepine (and in the 
case of those on methadone Sodium Valproate).  
 
Severe  dependence / Severe  withdrawals :  
Requires  larger  doses  of  chlordiazepoxide  and  inpatient  specialist  medical  care.   
 
Inpatient  admission  for  the  medical  treatment  of  alcohol  withdrawals  in  a  hospital  setting  is  recommended  
when: 
 
• There is a history of  severe  alcohol  dependence i.e.  persistent  use  of  large  amounts  of  alcohol  
over  a  long  period  of  time. (See  Symptoms  of  Alcohol  Dependence) 
• Severe  alcohol  withdrawal  symptoms 
• History  of  seizures 
• History  and  risk  of  Delirium  Tremens ( See  symptoms) 
• Cognitive Impairment. 
• Comatose  state 
• Associated  acute  physical  illnesses  requiring  hospital  admission 
• Poor  nutritional  state 
• Persistent vomiting and dehydration. 
 
 
Aftercare: 
 
Patients  should  be  encouraged  to  attend   AA  and  counselling  or  other  aftercare  supports  on  release  from  
prison  i.e.  residential rehabilitation. 
 
 
Notes and definitions: 
 
Alcohol Dependence:  
If  3  or  more  of  the  following  have  been  present  together  at  some  time  in  the previous  year. 
- A strong desire or sense of compulsion to take alcohol 
- Difficulties in controlling alcohol taking behaviour 
- Evidence of a withdrawal state 
- Evidence of a change in tolerance to alcohol 
- Progressive neglect of alternative pleasures or interests. Increased amount  of  time  necessary  to  obtain  or  
take  alcohol  or  to  recover from  its  effects. 
- Persisting with alcohol use despite clear harmful consequences. 
 
Another characteristic feature includes “narrowing of the personal repertoire” i.e.  drinking  in  the  same  pattern  
despite  social  constraints  that  determine appropriate  drinking. 
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Delirium  Tremens :   
 
Impaired  consciousness,  confusion,  disorientation,  agitation,  tachycardia,  hypertension,  raised  temperature,  
visual  and  auditory  hallucinations  and  paranoid  ideation 
Risk  of  DT’s  : History  of  severe  alcohol  dependence 
   Severe  alcohol  withdrawal  symptoms 
   Older  age 
   History  of  Delirium  Tremens. 
   Concomitant  acute  physical  illness 
Long  history  of  alcohol  dependence  with  previous  inpatient  treatment. 
 
Hallucinations: Generally  respond  to  chlordiazepoxide  and  an  adequate  detoxification  regime. If  persistent,  
hallucinations  can  be  treated  with  an  antipsychotic.  Some  antipsychotics  may  reduce  the   seizure  threshold  
and  increase  the  risk  of  seizures.  Advice  should  be  sought  from  the  Drug  Treatment  Team  in  the  Prison. 
 
Wernicke’s  Encephalopathy  :  Ataxia,  confusion,  Memory  disturbance,  Hypothermia,  Hypotension,  
Opthalmoplegia / Nystagmus,  Coma / Unconsciousness. 
 
Korsakoff’s Syndrome: 80% of patients recovering from Wernicke’s encephalopathy develop Korsakoff’s 
syndrome: Anterograde and retrograde memory loss, apathy, normal level of consciousness, confabulation. 
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Audit  (Alcohol Use Disorders Identification Test )
1. How often do you have a drink, containing alcohol?
(0) Never (1) Monthly or less (2) 2-4 times a month
(3) 2-3 times a week (4) 4 or more times a week
2. How many units of alcohol do you drink on a typical day, when you are drinking?
(0) 1 or 2 (1) 3 or 4 (2) 5 or 6
(3) 7, 8 or 9 (4) 10 or more
3. How often do you have 6 or more units of aclohol on one occasion?
(0) Never (1) Less than monthly (2) Monthly
(3) Weekly (4) Daily or almost daily
4. How often during the last year have you found that you were not able to stop drinking 
once you had started?
(0) Never (1) Less than monthly (2) Monthly
(3) Weekly (4) Daily or almost daily
5. How often during the last year have you failed to do what was normally expected from 
you because of drinking?
(0) Never (1) Less than monthly (2) Monthly
(3) Weekly (4) Daily or almost daily
6. How often during the last year have you needed a first drink in the morining to get 
yourself going after a heavy drinking session?
(0) Never (1) Less than monthly (2) Monthly
(3) Weekly (4) Daily or almost daily
7. How often during the last year have you had a feeling of guilt or remorse after drinking?
(0) Never (1) Less than monthly (2) Monthly
(3) Weekly (4) Daily or almost daily
8. How often during the last year have you been unable to remember what happened the night 
before because you had been drinking?
(0) Never (1) Less than monthly (2) Monthly
(3) Weekly (4) Daily or almost daily
9. Have you or someone else been injured as a result of your drinking?
(0) No (2) Yes, but not in the last year
(4) Yes, during the last year
10. Has a relative or friend or doctor or another health worker been concerned about your 
drinking or suggested you cut down?
(0) No (2) Yes, but not in the last year
(4) Yes, during the last year
RECORD TOTAL OF SPECIFIC ITEMS HERE
If total over 8, alcohol disorder very likely
This questionnaire wwas developed by the World Health Organisation to identify persons whose
Alcohol consumption has become hazardous or harmful to their health.
Appendix 1
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Clinical Institute Withdrawal Assessment of Alcohol Scale
CIWA- AR
Appendix 2
Patient Name:_________________________ ______  Date____________ Time_____________
Pulse or Heart rate, taken for 1 minute____________________ Blood Pressure______________
NAUSEA AND VOMITING- Ask “Do you feel sick to
your Stomach? Have you vomited?” Observation.
0   No nausea and no vomiting
1
2 
3
4 Intermittent nausea with dry heaves
5
6
7 Constant nausea, frequent dry heaves and vomiting
TREMOR- Arms extended and fingers spread apart. 
Observation
0 No tremor
1 Not visible, but can be felt fingertip to fingertip
2
3
4 Moderate, with patient’s arms extended
5
6
7 Severe, even with arms not extended.
PAROXYSMAL SWEATS – Observation
0 No sweat visible
1 Barely perceptible sweating, palms moist
2
3
4 Beads of sweat obvious on forehead
5
6
7 Drenching sweats
Anxiety – Ask “Do you feel nervous?” Observation.
0 No anxiety, at ease
1 Mild anxious
2
3
4 Moderately anxious, or guarded, so anxiety is 
inferred
5
6
7 Equivalent to acute panic states as seen in severe
delirium or acute schizophrenic reactions
AGITATION – Observation
0 Normal activity
1 Somewhat more than normal activity
2
3
4 Moderately fidgety and restless
5
6
7 Paces back and forth during most of the interview,
or constantly thrashes about
TACTILE DISTURBANCES – Ask “Have you any itching, pins & needles 
sensations, any burning, any numbness, or do you feel bugs crawling under 
your skin?” Observation
0 None
1 Very mild itching, pins & needles, burning or numbness
2 Mild itching, pins & needles, burning or numbness
3 Moderate itching, pins and needles, burning or numbness
4 Moderately severe hallucinations
5 Severe hallucinations
6 Extremely severe hallucinations
7 Continuous hallucinations
AUDITORY DISTURBANCES – Ask “Are you more aware of sounds around 
you? Are they harsh? Do they frighten you? Are you hearing anything that is 
disturbing you? Are you hearing things that you know are not there?”  
Observation
0 Not present
1 Very mild harshness or ability to frighten
2 Mild harshness or ability to frighten
3 Moderate harshness or ability to frighten
4 Moderately severe hallucinations
5 Severe hallucinations
6 Extremely severe hallucinations
7 Continuous hallucinations
VISUAL DISTURBANCES – Ask “Does the light appear to be too bright? Is its 
colour different? Does it hurt your eyes? Are you seeing any thing that is 
disturbing you? Are you seeing things that you know are not there?” 
Observation
0 Not present
1 Very mild sensitivity
2 Mild sensitivity
3 Moderate sensitivity
4 Moderately severe hallucinations
5 Severe hallucinations
6 Extremely severe hallucinations
7 Continuous hallucinations
HEADACHE, FULLNESS IN HEAD – Ask “Does your head feel different? Does 
it feel like there is a band around your head? “ Do not rate for dizziness or 
lightheadedness. Otherwise, rate severity.
0 No present
1 Very mild
2 Mild
3 Moderate
4 Moderately severe
5 Severe
6 Very severe
7 Extremely severe
ORIENTATION  AND CLOUDING OF SENSORIUM – Ask “ What day is this? 
Where are you? Who am I?”
0 Oriented and can do serial additions
1 Cannot do serial additions or is uncertain about date
2 Disorientated for date by no more than 2 calendar days
3 Disorientated for date by more than 2 calander days
4 Disorientated for place/or person.
Total CIWA- Ar Score  
Rater’s Initials
Maximum possible score 67
Patients scoring <10 do
Not usually need additional
Medication for withdrawal
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Severity of Alcohol Withdrawals: CIWA-Ar Score
Mild <10
Moderate 10-20
Severe 20+
Quantification of Alcohol Withdrawals
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Appendix 3. 
 
The Short Alcohol Withdrawal Scale (SAWS) 
 
Short Alcohol 
Withdrawal 
Scale 
None 
(0) 
Mild 
(1) 
Moderate 
(2) 
Severe 
(3) 
Anxious     
Sleep 
Disturbance 
    
Problems with 
memory 
    
Nausea     
Restlessness     
Tremor     
Feeling 
Confused 
    
Sweating     
Miserable     
Heart Pounding     
 
Symptoms cover the previous 24 hour period. Scores above 12 require pharmacotherapy. 
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19.  COCAINE TREATMENT POLICY 
 
The interdisciplinary team provides treatment for cocaine abuse on an individual basis, at all locations as required.  
Primary cocaine users will be offered a range of treatments, including counselling treatment provided by 
counsellors, using evidence based approaches (e.g. CBT). 
 
Appropriate referrals are made for medical and psychiatric issues, which may arise from cocaine use. 
 
• Withdrawal from cocaine use can increase the patient’s risk of depression and suicidal behaviour. 
• All cocaine positive urines will be discussed with patients.  Early intervention may prevent a serious 
problem developing. 
• The doctor and care team has a full discussion with the patient around route of administration i.e. snorting, 
injecting, smoking (freebasing and crack) 
• The doctor and care team discuss with patient harm reduction measures i.e. use of clean needles and non-
sharing of drug using paraphernalia, link with HIV transmission and increased risk of sexually transmitted 
diseases (STD’s) because of unsafe and uninhibited sexual activity.  Patients are also made aware of the 
increased risk of medical complications e.g. DVT. 
• Persistent use requires more in-depth counselling.  In the absence of reliable and evidence based 
pharmacotherapeutic interventions, our service is concentrating on evidence based psychotherapeutic 
interventions as appropriate. 
• Special cocaine education/prevention groups will be set up on a needs basis in prison settings. 
• Clinical teams will continue the development and implementation of a cocaine awareness strategy. 
• The IPS will continue to monitor the cocaine problem and expand services to this patient group as required. 
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20.  PSYCHIATRIC ASSESSMENT OF SUBSTANCE MISUSE DISORDERS 
 
It is the policy of the IPS, in accordance with the community standard, to develop a dual diagnosis service for those 
patients requiring same in the prison service. 
 
Appendix 5 – Psychiatric Assessment of Substance Misuse Disorders 
Appendix 6 – Current Processes in the Medical Unit Involving Patients on a Methadone Maintenance 
Programme 
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21. THE ASSESSMENT AND TREATMENT OF 
PREGNANT PATIENTS 
 
INTRODUCTION 
Pregnancy may motivate women using drugs to change their lifestyle and engage services.  Equally, being 
committed to prison at this time may afford them the opportunity to reflect on issues affecting their health and that 
of their unborn child. 
Since both mother and child are affected by the drug-taking lifestyle, this makes it all the more imperative that high-
risk activities be avoided such as i.v drug use with exposure to HIV/viral hepatitis. 
 
OBJECTIVES OF CARE 
• The stabilisation of mother’s drug use 
• Retention of mother in obstetric and drug treatment service and ensuring adequate support and 
throughcare in the community. 
• To deliver a full-term baby with healthy birth weight 
• Avoidance of in utero exposure to HIV/hepatitis 
• Minimisation of the occurrence of neonatal abstinence syndrome 
• Promote and support positive physical, mental health and social wellbeing though out and after pregnancy. 
 
 
ASSESSMENT 
Nursing – Usual assessment with attention to present pregnancy history, past ob/gyn history and drug history. 
GP Assessment – Usual assessment with attention on examination to fundal height (? Consistent with EGA) and 
FHR. 
 
Methadone stabilisation and maintenance are the treatment of choice in pregnant opiate-dependent 
women.   
 
Refer to IPS Methadone Treatment Guidelines. 
 
1. Patient already on methadone maintenance treatment – continue and consult Drug Liaison Midwife and 
Drug Treatment Clinic with respect to dosage changes. 
2. Patient not on methadone treatment – contact GP Co-ordinator or Consultant Psychiatrist in Addiction for 
clinic in her area and the Drug Liaison Midwife for the hospital where she will deliver. 
 
TREATMENT 
Drug Liaison Midwife 
Co-ordinates care for the pregnant, opiate-addicted woman – liaises between maternity hospital, GP, Drug 
Treatment Centre and social services in the antenatal period. 
Linking with the Midwife on all matters to do with the pregnant women’s treatment is recommended especially 
including destabilisation and methadone dosage changes. 
Contact Rotunda, Coombe or Holles St. – for details of liaison midwives. 
 
Detoxification 
In the exceptional circumstance where detoxification is being considered then it should be done in the second 
trimester and with close liaison with the drug treatment and obstetric services. 
Dose Reduction 
Dose reduction is not recommended in the first (due to the risk of spontaneous miscarriage) or third trimester (due 
to the risk of preterm labour) and indeed occasionally patients may need a slight increase in dose at this time (due 
to the expanded blood volume). 
BDZ’s 
BDZ detoxification should be prescribed as per usual clinical protocol. 
Other psychotropics 
The clinical decision to continue medication should be made on reviewing the risk/benefit and specialist psychiatric 
and obstetric opinion may be required. 
Emergency Treatment 
The initiation of methadone should be done in consultation with the drug treatment services and Drug Liaison 
Midwife.  If the assessing clinician is in any way dissatisfied with the assessment, a specialist addiction clinician 
should carry out a further assessment.  Pregnant women are given priority access to community services. 
The Midwife, prison GP and GP Co-ordinator should liaise to identify the most appropriate treatment location for the 
patient. 
 
 
 
Confirm Pregnancy and Opiate Dependence
   ↓     ↓ 
        
 
   ↓     ↓ 
In Drug Treatment Already Not In Drug Treatment 
   
 
    
    
  
Continue Link With Drug Liaison Call GP Co-ordinator & Liaison  
Midwife. Referral To Substance  
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↓                                                 ↓ 
  
 
 
 
 
 
 
 
Abuse Specialist. 
Midwife If Not Already 
Support Pregnant Woman In Maintaining Healthy Lifestyle
 63
22. USE OF NUTRITIONAL SUPPLEMENTS 
 
INTRODUCTION 
While severe, clinically-apparent nutritional problems are rare, subtle nutritional deficiencies are common in the 
prison population.  These range from poor intake of fresh fruit and vegetables to drastically reduced intake of all 
types of food.  The drug-taking lifestyle is associated with anorexia which, combined with chronic viral disease, skin 
and lung infections can result in severe malnourishment. 
 
ASSESSMENT 
As well as the usual nursing and GP assessment, a patient suspected of having a nutritional deficiency should 
have a careful food and weight history taken.  On examination weight should be noted (usually recorded on 
committal) along with signs of anaemia, easy bruising, lanugo hair, lack of muscle mass, striae from weight loss 
etc.  Occasionally blood tests may be indicated as part of assessment. 
 
NUTRITIONAL SUPPLEMENTS 
These include high calorie meal replacements such as “Ensure” or those marketed to help chronic skin ulcer 
healing.  Also considered are individual vitamin and mineral supplements such as Thiamine, Folic Acid, Vitamin C, 
Iron and Multivitamin Tablets. 
 
NUTRITIONAL SUPPLEMENTS AND PRISON 
Some points to be noted with regard to nutritional supplement use in prison: 
 
• High-calorie supplements are almost never indicated in patients who have an intact gastro-intestinal tract. 
• Patients who are underweight and undernourished have poor appetite secondary to their lifestyle: the use 
of a high calorie supplement will only dull their appetite even more for fresh food which they do start eating 
as their chaotic habits are replaced by prison routine. 
• Prescription of high calorie supplements again encourages the ‘quick-fix’ culture/mentality which 
characterises drug addiction and fails to address the longer term psycho-social issues which have resulted 
in poor nutrition. 
• “Ensure” and other high calorie supplements have currency and are traded for cigarettes, drugs etc. 
• Occasional male patients develop an obsession with body-building and may request high calorie 
supplements if they perceive them as an aid to muscle/weight gain. 
• Severe chronic alcoholics should be routinely supplemented with Thiamine. 
• Folic acid supplementation is recommended for women at risk of pregnancy. 
• Iron deficiency is common in the female prison population. 
• Nutritional supplements prescribed from another source should be reviewed by the prison doctor before 
being prescribed. 
 
MEDICAL ROLE IN NUTRITION 
The nursing and GP role is to encourage the patient to eat a regular, balanced and healthy diet and also to take an 
appropriate amount of exercise.  Psycho-social aspects of nutritional problems, such as lack of education and 
depression should also be addressed using available services. 
 
Policy 
• High calorie supplements should almost never be prescribed in the prison setting. 
• Individual vitamins/minerals should be prescribed as suggested above: care should be taken when 
prescribing multivitamins not to cause overdosage e.g. hypervitaminosis A. 
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23. NICOTINE REPLACEMENT THERAPY 
 
 
It is IPS policy to provide smoking Cessation Treatment in line with what is provided under the GMS.  
 
HC Policy C/4 
 
NICOTINE REPLACEMENT THERAPY 
 
Treatments available under the GMS, including Nicotine Replacement Therapy (NRT), are made available to 
prisoners subject to clinical considerations.  Given the very high prevalence of smoking among prisoners we would 
seek to assist anyone genuinely motivated to give up cigarettes in any way possible.  Giving up cigarettes requires 
more than replacement therapy alone and the evidence is that combined approaches are more successful than 
single focussed ones.  In this context NRT prescription is fully justified in those indicating serious motivation, 
including active participation in any associated counselling programme.  Where such motivation is lacking a more 
cautious approach to prescribing NRT is recommended.   
Any decision to supply such therapy from within the prison healthcare budget should take this into account. 
 
 
 
Appendix 13 – Use of Nicotine Replacement Therapy 
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24. CHILD PROTECTION 
 
It is the policy of the IPS to provide a copy of “Children First (Summary)” to all of their staff working in prisons.  It is 
recommended that all staff receive training on ‘Children First. 
 
It is the responsibility of all agencies working within prisons to follow local and national guidelines in relation to the 
reporting of child abuse. 
 
It is the responsibility of staff to act quickly in relation to any child abuse concern and to keep accurate notes. 
 
In order to support children and families it is appropriate for agencies to adopt an effective, co-ordinated and joint 
working approach. 
 
Families affected by substance misuse will not be considered at risk of harm by virtue of the sole fact that their 
carer is a substance misuser.   
 
In relation to the Dóchas Centre, in some circumstances, there may be pre-birth risks and concerns which will 
require reporting and assessment.   
 
Children may be at risk from other forms of unacceptable behaviour (physical, sexual, emotional and neglect) which 
will require action under these guidelines. 
 
Reports should be made to the HSE if there are reasonable grounds for concern that any child may have been 
abused, or is being abused, or is at risk of being abused. 
 
The retrospective disclosure of child abuse from any one, no matter how old, may have implications, in terms of 
risk, for other children and these disclosures must be reported.  There are supportive services for victims making 
disclosures and they should be encouraged to contact, where possible, HSE services, An Garda Siochana or 
counselling services such as Laragh. 
 
Appendix 8 - ‘Children First’ 
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25. MONITORING AND EVALUATION 
 
 
• It is the policy of the IPS to carry out evaluation and audit of treatment interventions on a regular basis, and to 
modify practice on the results of such audit and evaluation.   
 
• It is the policy of the IPS to audit the implementation of policy. 
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26. LIAISON AND TRANSFER ARRANGEMENTS 
BETWEEN COMMUNITY AND PRISON DRUG 
TREATMENT SERVICES 
 
Contents 
 
Introduction 
 
1. Patients on methadone on admission to prison/community services 
 
 Confidentiality 
 Confirmation of treatment 
 Process 
 Written confirmation 
 Contact details 
   
2. Initiating treatment in prison 
 
3. Reporting to CTL 
 
4. Guidance on handling of patient’s methadone supply 
 
5. Treatment Planning for Release from prison 
 
 Planned release 
 Protocol for patients who, prior to admission to prison, had been treated in DTC 
 Protocol for patients who, prior to admission to prison, had been treated in satellite clinic, community pharmacy 
or from community G.P. 
 Protocol if unable to contact G.P. / Chief Pharmacist above 
 Unplanned release 
 Audit Report of Unplanned Arrival at Community Services 
 
6. Patients released over Christmas/New Year 
 
 
 
 
 
 
 
 
 
 
 
 
 
Introduction 
The Irish Prison Service in partnership with the HSE has a responsibility to ensure that prisoners have access to 
health services that are broadly equivalent to those the general public receives from the HSE. This means that both 
prisons and the community services should provide health education, patient education, prevention and other 
health promotion interventions within that general context. 
 
 
Issues Unique to Providing Methadone Treatment in Prison: 
 
Effective and efficient communication between both the IPS and the HSE is essential to ensure seamless 
care and safe and effective treatment for our patients. 
 
The following protocols have been developed to assist in ensuring safe, timely and appropriate transfer of patient 
information from one service to the other. 
 
1. Patients on Methadone Treatment on admission 
1.1. Confidentiality 
 
Patient confidentiality must be adhered to at all time by all doctors/pharmacy staff/ prison health care staff 
members. (See Confidentiality Policy  – Pg 37) 
 68
 
 Confirmation of treatment:  
 
To ensure that patient confidentiality is adhered to at all times, it must be confirmed that the individual requesting 
the information is from another institution i.e. prison, HSE or hospital where it can be confirmed that the query is 
genuine.  
 
To ensure the safe continuation of Methadone and/or medical treatment for patients transferring between 
community and prison drug treatment services, it is essential that verbal and written confirmation of the 
patient’s current Methadone and/or medication prescription is obtained before a new prescription is written 
or the next dose of methadone/medicines is administered. 
 
 
1.2.1 Verbal Confirmation 
 
When requesting patient details and providing patient information: 
a) Contact the relevant service provider, provide your name and  where you are calling from  (Prison , Drug 
Treatment Centres/Satellite, Community pharmacists and hospital ward-if relevant) and your status e.g. 
nurse or medical orderly, doctor, pharmacist etc.  
b) Provide the patient’s details: Name and D.O.B. 
c) Confirm dose and date last dispensed (direct person to person contact) 
d) Provide / Receive written details of patient history, treatment, and medications. 
 
1.2.2 Written confirmation 
 
The verbal confirmation of patient’s medications information must be verified by fax to the requesting service, by 
means of the “PRISON/COMMUNITY TRANSFER OF INFORMATION" form (Appendix 6) which must be 
completed and faxed to the requesting service. 
 
 
1.2.3 Lists for numbers of Drug Treatment Centres/ Satellite Clinics/Prison surgeries. 
 
The contact details for each clinic are included in Appendix 7.  
  
The prison surgery details are included in Appendix 8. 
 
 
2. Initiating Treatment in Prison  
 
Treatment may only be initiated in prison when confirmation of available places in the community is established. 
 
Before initiating methadone treatment in prison the prescribing doctor must communicate with the relevant 
personnel in the community (GP Co-ordinators, Consultant Psychiatrists and Chief Pharmacists in DTC and 
Satellite clinics).  
Written confirmation of such arrangement must be communicated by the prescribing doctor involved to relevant 
personnel in both the HSE and IPS and such confirmation must be retained as per local policy (Appendix 9). 
 
The issue of validation of address and suitability for community treatment need to be given consideration by the 
prescribing doctor before initiating treatment. 
 
 
 
3. Reporting to the Central Treatment List (CTL) 
 
To ensure accurate timely data input in the CTL for the purposes of audit and strategic planning of services: 
 
• The CTL requires the prescribing doctor to submit to the CTL a patient treatment form for each patient 
admitted to prison/community services who will be provided with Methadone Treatment in that service ( 
entry form) and when patients are released from the Prison/discharged from the community services (exit 
form). (See Appendix 10).  
• It is also necessary that if patients transfer within the prison services that the CTL is informed via the 
appropriate documentation. 
     
On committal to prison -  
 
IPS: 
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• The prescribing doctor in the prison must send an entry form to the CTL (Appendix 10) and inform them 
that the patient has been admitted to prison.  
 
 HSE: 
• The prescribing doctor in the community must also send an exit form to the CTL to inform them that the 
patient has been discharged from the community service.  
• On release from prison back to the community a similar process applies in reverse.  
 
IPS Staff see Chapter 5 in this document.   HSE staff see document prepared by Nihal Zayed.  
 
In cases of intermittent sentencing or in very short sentences (less than 30 days) other procedures may be more 
practical.  
 
Central Treatment List Fax no: 01 – 6771519 
 
 
 
4. Methadone brought into prison with a patient 
 
Methadone accompanying any patient on committal to prison should be discarded as per IPS Healthcare Policy 
A/20 and A/23 (or Appendix 3 in this document. 
 
The relevant dispensing service in the community should be informed of the destruction of methadone. 
 
5. Treatment Planning for Release 
 
One of two scenarios is usually encountered in this setting: 
 
• release date known  - planned release 
• release date unknown or unexpected – unplanned release 
 
 
5.1 Planned release 
 
When the release date of the patient is known arrangements should therefore be made in advance by the prison 
healthcare staff. 
 
5.1.1 Protocol for Patients who had, prior to committal to prison, been receiving their treatment in a Drug 
Treatment Centre (DTC): 
 
• Contact the prescribing doctor/Chief Pharmacist in that setting (DTC) 
• On Saturday/Sunday, contact the Pharmacist on the direct pharmacy number in each clinic. 
 
5.1.2: Protocol for patients who had, prior to committal, been receiving treatment in a Satellite Clinic or 
Community Pharmacy or from Community GP 
 
Contact the GP Co-ordinator/Chief Pharmacist who will arrange a suitable delivery of service in the nearest DTC 
until appropriate arrangements are made.  In this case, an entry form should be submitted by the prescribing 
doctor/Chief Pharmacist. 
 
 
5.1.3: If it is not possible to contact the GP/Chief Pharmacist the patient should be directed to the nearest 
DTC in their area. 
 
If the patient has been in the prison for a short period (30 days) his/her name will be still on the methadone 
prescription list (HSE Policy).  
 
 
5.2: Unplanned release - release date unknown or unexpected 
 
Patients are often released from custody directly from Court without the knowledge of the prison or may be 
released in advance of planned release date due to necessary operational decisions. 
Therefore: 
• the patient should always be dispensed his/her Methadone in the prison on the day of release/court attendance. It 
remains best practice however for the HSE service provider to check the last dose dispensed on the day of a Court 
appearance/release, to avoid any possibility of double-dosing/overdose. 
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There is a responsibility on prison management to inform healthcare staff of all discharges and transfers on a daily 
basis to facilitate healthcare staff preparing discharge summaries. 
 
Once prison healthcare staff are aware (i.e. their own dispensing records or through prison management) of 
discharge or transfer of patients appropriate information needs to be completed and forwarded to the relevant 
treatment agency in the community. 
 
 
5.3: Audit Report of Unplanned Arrival at Community Services 
 
In the event that a patient arrives unannounced to a community service provider (DTC/Satellite clinic/Community 
Pharmacy/GP) an Audit Report (Appendix 12) must be completed by the Pharmacist and returned to the Co-
ordinator of Drug Treatment Services (Prisons), Chief Pharmacist HSE and Co-ordinator of Pharmacy Services 
IPS. This will assist the IPS in putting in place appropriate arrangements/structures to ensure effective 
communication and safe continuity of treatment for all patients requiring Methadone Treatment, on release from 
prison.  As part of the audit process these reports will be reviewed by both HSE and IPS and changes made to 
procedure accordingly.   
 
Once healthcare staff become aware that a patient has been released or transferred they should ensure that the 
relevant information is communicated. 
 
 
6. Patients released over Christmas/New Year 
 
Arrangements have been agreed between the HSE/IPS for the safe continuation of Methadone treatment for those 
patients granted temporary release (TR) over the Christmas/New Year periods. See Joint HSE/IPS Policy 
(Appendix 11) 
 
The Co-ordinator of Pharmacy Services, IPS emails the details of such patients to the Chief Pharmacists in each 
area. 
 
The List includes the following 
• Name of service users 
• Date and duration of the release 
• Dose of methadone dispensed in the Prison   
• Strength and name of other medication received in Prison 
 
Arrangements are made by the Chief Pharmacist/ GP Co-ordinator/Consultant Psychiatrist in each area for the 
allocation of places and provision of services to facilitate such patients on TR. 
The signed methadone / medication prescription will be sent to the allocated settings from the GP Coordinator and 
in each setting the pharmacist or nurse will be phoned to make sure they have received the prescriptions to ensure 
smooth operation over this period. It is the pharmacists/clinical teams responsibility to give a list of the patients 
released over this period to the senior General Assistant (GA) in each setting to communicate the information to 
his/her staff. 
Allocation of a treatment site for TR does not guarantee treatment at that location for subsequent treatment events. 
 
Direct person to person contact is necessary to validate treatment details. 
 
 
 
Appendix 9 - Prison/Community Transfer of Information Form 
Appendix 10 - HSE Contact details  
Appendix 11 - IPS surgery contact details 
Appendix 12 – Application for a Community Treatment Place 
Appendix 13 - CTL entry/exit form 
Appendix 14 - Joint HSE/IPS Christmas release arrangements 
Appendix 15 - Audit Report of Unplanned Arrival at Community Services 
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APPENDIX 1 
 
CONSENT DOCUMENTS 
 
Consent Forms 
 
 
I __________________________________ consent to the following: 
 
Assessment: 
      Consent  Refusal     
      to consent 
 
             
 
 
SIGNED: _________________________ DATE: _____________ 
 
WITNESS: _________________________ DATE: _____________ 
 
 
Treatment: 
       Consent Refusal     
      to consent 
 
Methadone Substitution Programmes            
1. Stabilisation / Maintenance Programme            
2. Stabilisation / detoxification Programme             
3. Detoxification Programme                
 
Other Substitute Programmes         
 
Name:               
 
 
 
 
 
SIGNED: _________________________ DATE: _____________ 
 
WITNESS: _________________________ DATE: _____________ 
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Other Treatments 
           Consent Refusal to consent 
Counselling          
Lofexidine treatment            
Naltrexone treatment             
Referral to other agencies as appropriate          
 
Consent to interdisciplinary sharing of clinical information with the clinical interdisciplinary team: 
            
The team can include the following: 
- Doctor 
- Nurse 
- Counsellor 
- Psychiatrist 
- Pharmacist  
- Psychologist 
 
SIGNED: _________________________ DATE: _____________ 
 
WITNESS: _________________________ DATE: _____________ 
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Lofexidine – Consent to Use Unlicensed Treatment 
 
I consent to a lofexidine detox programme and I understand that it is an unlicensed medicine and provided on a 
named patient basis only 
 
SIGNED: _________________________ DATE: _____________ 
 
WITNESS: _________________________ DATE: _____________ 
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Release of Information 
 
I consent for the release of information to the following agencies: 
 
      Consent Refusal to consent 
                 
______________________________________________________________ 
 
______________________________________________________________ 
 
______________________________________________________________ 
 
SIGNED: _________________________ DATE: _____________ 
 
WITNESS: _________________________ DATE: _____________ 
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Withdrawal of Consent 
 
I withdraw my consent to the following: 
______________________________________________________________ 
 
______________________________________________________________ 
 
______________________________________________________________ 
 
on (date)  ______________________ for the following reasons: ___________ 
 
______________________________________________________________ 
 
______________________________________________________________ 
 
SIGNED: _________________________ DATE: _____________ 
 
WITNESS: _________________________ DATE: _____________ 
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HEPATITIS B, HEPATITIS C & H.I.V. PRE-TEST DISCUSSION 
 
 
I __________________have engaged in a pre-test discussion with ___________ 
Covering the following areas: 
 
• An explanation about the blood tests for Hepatitis C & H.I.V.  
• The meaning of a positive test result and the meaning of a negative test result. 
• Risk factors:   - safer sexual practices 
                                   - safer use of all drug-using equipment (needles, syringes,         filters, tooters
etc) 
                                   - importance of not sharing razors, toothbrushes, earrings etc. 
                                   - the risks to my health if I drink alcohol.  
• Support that is currently fully available to me from other people 
             (family, partner, friends, professional support) 
• Insurance and mortgage implications. 
• Harm to self and harm to others  
• Explanation of the ‘window period’. 
 
I fully understand the above discussion and explanations. 
 
Signed:___________________Witnessed: ________________Date:___________ 
 
 
I consent to have a H.I.V. test:  Yes:  _________  No:  ___________ 
 
 
Signed:___________________Witnessed: ________________Date:___________ 
 
 
I consent to have a Hepatitis B test:  Yes:  __________  No:  ___________ 
  
Signed:___________________ Witnessed:________________Date:___________ 
 
 
I consent to have a Hepatitis C test and PCR Test if required:  
Yes:  ______  No:  _______ 
 
 
Signed:_________________   Witnessed: ________________ Date:___________ 
 
 
I consent to have the following vaccinations and repeat antibody checks as appropriate:                                        
                   Yes     No 
 
Day 1   Twinrix (Smith Beecham) against Hep A & B  ____   ____ 
One month   Engerix B (SKB), Hepatitis B alone         ____   ____  
5 months later Twinrix (SKB)                                                   ____   ____                        
6 weeks later    Antibody levels for Hepatitis B                      ____   ____                            
1 year from start     Booster for Hepatitis A (Haverix, SKB)          ____   ____ 
 
Signed:___________________  Witnessed: ______________Date:___________ 
 
I ____________________________ have held a Hepatitis B, Hepatitis C, & H.I.V. pre-test discussion with the above
client, explaining the issues as mentioned above and am satisfied that the client fully understands the content of 
the discussion. 
 
Signed: _______________________________  Date: ___________________           
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Information Sheet 
 
 
Record Keeping 
 
1. This information sheet is designed to give you an understanding of: 
• What happens to the information you give us? 
• Who has access to this information? 
 
2. The information you give us is used to provide you with healthcare and related services.  We need a full social, 
psychological and medical history to make a proper assessment of your needs and to decide with you an 
appropriate treatment plan.  The information system is used to record the treatment and advice you will 
receive.  It will also be used for administrative purposes and to meet legal requirements in relation to the 
services we provide.  The information you give us is held on computer and/or paper. 
 
3. The information whether on computer or paper is normally only seen by staff member.  Staff members are 
members of the clinical interdisciplinary team.  
 
4. Some information will be sent with your blood or urine tests, this is so the laboratories know which client the 
test is from and to make sure it is correctly tested.  You will be informed of all tests that will be performed. 
 
5. Information about you will not normally be released to others without your written consent.  There are 
occasions when information may be released without your consent e.g. 
• When ordered by a court of law or a tribunal 
• When allowed or required by statute 
• When necessary to protect your interests 
• When there is a substantial and immediate risk to the welfare of yourself or (an)other /individual(s). 
 
6. In addition some information may be used for statistical or research purposes, but the information used will not 
identify you in any way. 
 
7. You have the right to information about your treatment.  If you have any queries please ask. 
 
I have read the information sheet and have been given a copy to keep.  I have had a chance to ask questions 
about the information, which is collected and kept about me, why it is kept and how it is used or disclosed.  I 
understand that the information is held on computer and/or paper.  I consent to this to the purposes for which the 
information is being collected, kept, used, and disclosed. 
 
The above information has been explained to me □  
 
Name of staff member who gave the information and explanation:   
 
________________________________ 
 
 
 
SIGNED: _________________________ DATE: _____________ 
 
WITNESS: _________________________ DATE: _____________ 
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Central Treatment List 
      
                                     Consent             Refusal to consent 
I consent to place my name with the 
Central Treatment List                
 
SIGNED: _________________________ DATE: _____________ 
 
WITNESS: _________________________ DATE: _____________ 
 
 
Pompidou Forms 
 
Your Pompidou form will be completed annually.  
 
SIGNED: _________________________ DATE: _____________ 
 
WITNESS: _________________________ DATE: _____________ 
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Methadone Information 
 
1. This is to certify that I have been opiate dependent (that is I have an opiate addiction).  I have requested to 
commence a methadone substitute programme. 
 
2. I understand that like any other medication methadone has side effects.  In particular I understand the risks 
of overdose and death (in certain cases), if I inject or use other opiates, including extra methadone, 
excessive amounts of alcohol, benzodiazepines and other sedative drugs ‘on top of’ my methadone. 
 
3. I also understand that I need to store any take home methadone in its proper childproof container and to 
store the bottle out of reach of children (relevant when released from prison). 
 
4. I understand that methadone itself does not cure the underlying drug dependency and may be even more 
difficult than heroin or morphine to detoxify from and if taken by those who are not dependant can create 
opiate dependency.  Rarer side effects such as reduced adrenaline excretion by the adrenals has been 
reported, as have allergic reactions.  A small proportion of males have experienced an anti-testosterone 
effect with methadone maintenance. 
 
5. If I become pregnant and am unable to detoxify then my baby will be exposed to opiates up to and 
including the time of birth.  This may cause neonatal abstinence in the baby, (a form of withdrawal state), 
after birth. 
 
6. It is important to remember that your methadone has its peak effect 2-4 hours after taking it.  Methadone 
will accumulate in your body over time and will have a greater effect on you in day 3-5 of starting treatment. 
 
7. Only patients who are stable on methadone would be safe to drive a car or operate machinery.  However 
those who are abusing cannabis or alcohol or other illicit or psychotropic medication would be considered 
unsafe to drive.  Certain patients who are stable, for example, on benzodiazepines prescription on a long-
term basis may be considered safe to drive a car.  You will need to discuss this with you prescribing doctor 
and you are strongly advised to take their advice. 
 
8. The potential benefit of methadone is that it gives me an opportunity to stabilise my drug addiction and 
lifestyle.  Weighing all of the risk and potential benefits I have decided that I wish to be placed on 
methadone substitute as the best approach to my current addiction.  All of the above has been explained to 
me and I agree to commence methadone substitute treatment. 
SIGNED: _________________________ DATE: _____________ 
 
WITNESS: _________________________ DATE: _____________ 
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Rules and Contract 
 
We welcome you to the Prison Drug Treatment Service for treatment of your drug problems.  We wish to provide 
you treatment in a professional and friendly environment.  To assist us in running the Prison Drug Treatment 
Service in a friendly, smooth and safe manner, we ask you to abide by the following rules: 
 
1. I agree to participate fully with the treatment programme offered to me and, when required, keep appointments 
with the doctors, counsellors, pharmacy, nurse and any other persons who are involved in my treatment. 
2. I agree to stabilise my drug use while on treatment 
3. I agree that verbal or physical aggression towards staff or other clients may lead to a sanction.  It is not 
permitted to possess or produce any instrument that can be used as a weapon while in treatment.   
4. I agree to attend daily for methadone, which will be taken under supervision between ______ and _________.  
Failure to attend for two or more days will result in receiving half doses for safety reasons. 
5. I agree to give a urine specimen as requested. Small amounts of urine are not accepted.  In the event I’m 
unable to supply a specimen I understand I will be allowed 15 minutes to produce a specimen.  If I fail to 
produce a specimen it will count as a refusal and will be documented as a refusal. The provision of a false 
urine sample will be documented and discussed with your doctor / clinical interdisciplinary team 
6. I may be asked to be breathalised by a member of staff/pharmacy at anytime.  If I have a level of alcohol above 
a certain limit I may have to have the methadone reduced or not dispensed that day. 
7. I accept that if I give persistently positive urines for opiates or other drugs, or that I do not comply with the 
conditions of treatment, that my methadone treatment will need to be reviewed and options include: 
¾ A reduction in my dose 
¾ Placement on a low dose programme 
¾ A change of treatment programme 
¾ A recommendation to the Governor requesting transfer from the Medical Unit 
8. I have received a list of drugs which are not allowed and understand it is my responsibility to check out every 
drug with a member of staff before I take it, not after. 
9. Letters for courts will only be given upon written request from a solicitor or probation officer.  A minimum of two 
weeks notice is necessary for receipt of a letter. 
 
 
SIGNED: _________________________ DATE: _____________ 
 
WITNESS: _________________________ DATE: _____________ 
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Specific Programmes: 
 
F6: A separate contract needs to be signed with the Governor. A failure to comply with this contract may lead to the 
Governor referring to the Clinical Interdisciplinary Team for assessment. 
 
F3 + F4: I accept that if I give a positive urine for opiates or other drugs, or that I do not comply with the conditions 
of treatment, that my methadone treatment will be reviewed and a warning and a date to clear given. Subsequent 
positive urines will be subject to a disciplinary report to the Governor resulting in a transfer out of F3 or F4.  
 
 
SIGNED: _________________________ DATE: _____________ 
 
WITNESS: _________________________ DATE: _____________ 
 
 
F5; Drug Treatment / Detoxification Programme 
 
In addition to the above contract: 
 
1. I fully accept that Occupational, recreational and Group Therapy are part of the treatment programme and 
that my participation is compulsory in the follow-up group in the Training Unit for the first three weeks there. 
2. I agree not to request temporary release while I am on this programme. 
3. I agree to contact being made with my family or significant others to inform them about the programme and 
to offer them support meetings during the programme. 
4. Participants will agree to visits at specific times and only specific people will be permitted to visit. 
Participants can have two visits per week from either two adults or one adult and their own children. 
Visiting times are Thursday 2.00pm to 4.00pm and Saturday 10.00am to 12.00pm and 2.00pm to 4.00pm. 
The names of these visitors will be given at the start of the programme and must be the only visitors during 
the programme. 
 
a. Each visit will last for 30 minutes 
b. No physical contact is permitted during visits 
c. No smoking during visits 
d. No packages or money may pass from visitor to client 
e. No visits from family in prison or from drug users 
 
SIGNED: _________________________ DATE: _____________ 
 
WITNESS: _________________________ DATE: _____________ 
 
 
 83
Responsibilities of the Healthcare Staff: 
 
Is to provide: 
 
• A structured methadone treatment programme 
• Team confidentiality 
• Professional behaviour and respect from the staff 
• Medical advice and attention 
• Counselling 
• Viral screening 
• Rehabilitation/Integration options  
 
We agree that all staff treat you in professional manner with dignity and respect at all times. 
 
We agree to be available to you for consultation around your treatment and any other issues we can deal with 
ourselves or with referrals to other agencies. 
 
We agree that a complaints procedure be available to you to pursue issues around your treatment, with the 
assistance of a member of staff if needed. 
 
Please refer to the patients’ charter which will make you aware of your rights. 
 
I agree to abide by the above rules and understand that it is my responsibility to do so.  I have received a copy of 
the rules and understand that any difficulty I may have in respect of the above can be discussed with a member of 
staff of my choosing and the same will be given due attention. 
 
 
This contract has been read to by _______________________/by me and  
 
signed by me _______________________     Date ___________________ 
 
Witnessed __________________________ Date  ___________________ 
 
We refer you to patients of charter of rights as a document to make your more aware of your rights.   
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APPENDIX 2 
 
URINE SCREENING PROCEDURE 
 
(Policy 8: Toxicology Screening of Urine) 
 
Basic Principles       
y The taking of urine is not a medical procedure and as such does not require trained medical staff to carry out 
the process.  Best practice would dictate that an explicit contract be signed by the client agreeing to the 
process, after the rationale had been fully explained. Confirmation of the name and date of birth confirmed 
between the patient and the staff member supervising the process.  In the case of on site testing the patient 
where possible should witness the process, initial the sample and be made aware of the results. 
 
y It is established best practice in Ireland that same sex supervision take place, i.e.  It is inappropriate for male 
members of staff to supervise female urine screening patients and likewise female members of staff to 
supervise males. 
 
y The dignity of the patient must be maintained at all times. Personnel taking urine sample must be gender 
appropriate to the patient whose urine sample is being taken.  
 
y Protective gloves must be worn during the procedure in the interest of hygiene and safety (universal 
precautions). 
 
y A properly labeled bottle must be used, the details on the label should be shown and checked with the patient. 
This practice can save argument at a later date re; ‘wrong person’ ‘wrong bottle’ ‘wrong date’ etc. 
 
y The patient should be directly observed giving the sample either through the aid of a mirror or by close 
supervision. Mirrors are probably a better option, as close supervision can be intimidating. The officer should 
observe for paraphernalia that may indicate the intention to give a false sample, small tubing, Lemon Jiff bottles 
etc. 
 
y The specimen bottle should be at least half full. When the lid is secured on the sample a small condensation 
line should appear for a few seconds, this would normally indicate the sample is of body temperature. 
 
y Specimen bottles should be packaged for transport in line with current best practice guidelines, i.e. shatter 
proof containers, clearly labeled, lids tightly secured etc, and transported in accordance with current legislation.   
 
y Packaging and dispatch of samples should comply with the Carriage of Dangerous Goods by Road 
Regulations 2001. 
 
y Labeling of samples must comply with labeling policy as outlined in the contract with Claymon Labs, as follows: 
  
“The sample container should then be closed tightly and a tamper evident seal placed across the lid and down 
either side of the specimen container.  The patient should place their initials on the seal, for authentication 
purposed.  If the patient merely makes their mark on the seal, the Officer should authenticate this mark with 
their own initials. N.B. It is the responsibility of the collecting Officer to ensure that the specimen lid has been 
secured prior to placement of the tamper-evident seal.” 
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APPENDIX 3 
 
USE OF METHADONE PROCESSESS 
 
(Policy 9: Use of Methadone – Ordering, Dispensing, Administration & Recording) 
 
 
1. ORDERING PROCESS: 
a). Ordering: 
y A book of pre-printed requisition forms is available in each surgery, in duplicate form. 
y A new requisition form must be used for each order. This may be completed by a healthcare staff member but 
must be signed by a doctor. 
y The completed and signed requisition is then sent to the stores department, where it is assigned an order 
number and is then faxed to the supplier. 
 
b). Receipt of Supplies: 
y Ideally any supplies of methadone should then be delivered to the doctor and the delivery note signed by the 
doctor. This task can however be delegated by the doctor to another healthcare staff member, who has been 
named as an authorised messenger and who can accept delivery on behalf of the doctor. 
y The order will then be delivered directly to the surgery areas, as per agreed local arrangements.  
y The delivery will then be accepted by an authorised member of the healthcare staff who will be required to sign 
the delivery note and return the top copy to the delivery person. 
y A copy must also be sent to stores. 
y The duplicate requisition must also be signed by the healthcare staff member who accepted the new supply. 
 
2. RECORDING:  
 
Register: 
y A complete record must be kept of every transaction involving methadone.  
2a). Administration 
• Recording of administration should be carried out by the pharmacist or the two nurses involved in 
administration.  
y As a daily record of the administration of Methadone is kept, it is acceptable to make a single daily 
entry in the register for the total amount of methadone dispensed each day. 
y The register and the daily issue forms constitute the complete record for the use of Methadone. 
 
 
 
2b). Receipt: 
y A record of each new supply of methadone received must be made in the controlled drugs register, stating 
date, supplier, and quantity received. 
y The stock balance should be adjusted accordingly. 
y This entry must be signed by the pharmacist/two nurses. 
 
2c). Supply:  
Daily Issue Sheets: 
a. A daily record of the administration of Methadone must be kept, to comply with record keeping requirements. 
As outlined above, daily recording on both the daily sheets and a single daily entry in the register constitutes an 
acceptable record of methadone usage. 
b. Methadone may only be dispensed and supplied on foot of a current valid prescription. 
c. The pump must be calibrated each day before use, as recommended by the manufacturer. 
d. The daily sheet must state each individual prisoner’s name, DOB, PRIS, quantity administered to each patient. 
In addition it must state the total quantity issued on each day and must be signed by the pharmacist/two nurses. 
e. A stock check should be carried out at the end of each daily administration i.e. 
• The total quantity administered as per daily sheet should be subtracted from the opening balance. This is 
the calculated balance. 
• The actual balance is then measured – this is the actual quantity left in stock. 
• The calculated balance and the actual balance should be identical, however due to the viscosity of the 
liquid, there may be a slight positive discrepancy. 
• Any positive balance (i.e. actual balance greater than the calculated balance) should be recalculated into 
the total stock. 
• A negative balance (i.e. actual balance less than the calculated balance) is never acceptable. Should this 
occur, it should be reported on the day to Deirdre O’Reilly or Frances Nangle-Connor by phone, email or 
hard copy. This will then be fully investigated. 
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• The balance forward is the actual amount in stock at the end of the day and this is then carried forward as 
the opening balance for the next day. 
 
Register: 
f. An entry is then made in the CD register, stating the actual balance remaining at the end of each day. 
 
 
3.  ADMINISTRATION  
c. Methadone may only be dispensed and administered on foot of a current, valid prescription. 
d. Ideally methadone should be dispensed and administered by Pharmacists. 
In the absence of Pharmacists, dispensing and administration of methadone should be conducted by two Nurses. 
c.  Before administering methadone to a patient, the Pharmacist/Nurse: 
            1)   check the patient’s name, photograph, number and location 
            2)   check the medication against the prescription 
d.  All methadone administration must take place in front of the Pharmacist/Nurse. 
e.  To ensure that the patient has swallowed the dose of methadone: 
1) Each patient should take a drink of water after each dose of methadone 
2) The patient should be supervised, in so far as is possible, to ensure that the methadone has been 
swallowed 
           3) The patient should be engaged in conversation following medication    
administration, to assist in confirming that the methadone has been swallowed. 
4) Any suspicion of retention of methadone should be reported to the doctor. 
f.  Any wastage of controlled drugs should be recorded and the entry witnessed. 
g.  A signed record should be appropriately entered on the patient’s file on PMRS. 
h.  The checking, preparation, administration or destruction of controlled drugs should be witnessed. 
 
 
4. STORAGE  
 
Schedule 2 and 3 Controlled Drugs, including methadone should be stored in a locked safe. 
No other items, except controlled drugs, should be stored in this safe. 
The key of this safe should at all times be kept on the person of one accountable staff member (pharmacist/nurse) 
who is accountable for the controlled drugs and should be passed on to the staff member taking over on the next 
shift. It should be kept separate from all other keys and should never be left in the lock, in a drawer or any other 
area. No other person should have access to this key. 
 
The stock should be checked and signed off at each change over of staff by two nurses. 
 
 
5. EMPTY METHADONE CONTAINERS  
 
All empty methadone containers will be collected by the supplier, for recycling as follows: 
 
y All empty methadone containers should be rinsed out. 
y They should then be replaced, without the caps, in the original box in which they were received. 
y When the box is full, it will be collected from the surgery by the supplier. 
 
 
 
 
6. DISPOSAL OF PATIENT’S METHADONE 
 
As a safety measure and to assist in risk management, any methadone found on the person of a patient committed 
to prison will be removed from that person and will not be returned on release. 
 
Any such quantities should then be disposed of as outlined in IPS “Policy on Disposal of Patient’s Legally 
Dispensed Methadone” – See Appendix 4. 
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APPENDIX 4 
 
DISPOSAL OF PATIENT’S LEGALLY DISPENSED METHADONE 
 
(Policy 9: Use of Methadone - Ordering, Dispensing, Administration & Recording) 
 
IPS Healthcare Standards A/23 
 
This policy assumes that any green liquid whether labelled as Methadone or not, found on the person of a prisoner, 
is and will be treated as Methadone. 
  
1. Should a quantity of legally dispensed Methadone be found on the person of a prisoner on committal to prison, 
this should be immediately taken from the prisoner. 
 
2. It should then be taken to the surgery and handed to a member of the healthcare staff. 
 
3. The approximate volume should be estimated by the healthcare staff member. 
 
4. An entry should be made in a separate section of the Controlled Drug Register, stating: 
 
y Date received in surgery. 
y Name, DOB, PRIS of prisoner on whose person Methadone was found. 
y Name of clinic/pharmacy where supply dispensed 
y Date on which dispensed.       
y Approximate volume. 
y Signature of two members of healthcare staff. 
  
5. This supply should then be stored in the controlled drugs safe, separate from surgery stock. 
 
 
6.  Disposal - All Dublin prisons: 
 
y Pinewood Healthcare have agreed to accept, for disposal, all such Methadone stock from each of the Dublin 
prisons. 
y At regular intervals, when there is a reasonable amount of such Methadone in stock,  
David Brannigan, Pinewood Healthcare should be contacted on  
087 8118209 
y He will then, by arrangement, call to the prison surgery to collect this Methadone. 
y He will supply the necessary paperwork, which should be completed, and signed by both a healthcare staff 
member and himself. 
y An entry should then be made in the register, stating: 
1)            Date supply collected by Pinewood. 
2)            Total quantity collected. 
3)            Signature of two staff members. 
y A copy of the completed Pinewood paperwork should be retained in the surgery, in the Controlled Drug 
Register. 
 
7. Disposal - all other prisons: 
Please inform the Co-ordinator of Pharmacy Services at 01 4616121 or  
087 9292539, whenever there is a supply for disposal and appropriate local arrangements will be made. 
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APPENDIX 5 
 
PSYCHIATRIC ASSESSMENT OF SUBSTANCE MISUSE DISORDERS 
 
(Policy 20: Psychiatric Assessment of Substance Misuse Disorders) 
 
Aims: 
 
• Identify the main diagnosis: 
 
 Identify the quantity, pattern, and frequency of drug use 
 Evidence of features of dependence vs. harmful use 
 Evidence of withdrawal symptoms 
 
• Assessment of co-morbid conditions: psychological, psychiatric and physical 
 
• Identify the consequences and risk of use 
 
 
• Assessment of motivation for treatment and “readiness to change”  
 
 
• Establishment of a therapeutic rapport in order to enhance an individuals motivation 
 
 
• Identify areas that require interventions, so that goals can be set and a care plan developed. 
 
 
• Assessment is an ongoing process, where reviews are required to adjust an individual’s treatment 
plan 
 
 
 
Assessment of the following: 
 
1. Diagnosis 
ICD 10 Definitions 
 
F10 –F19: 
Mental and behavioural disorders due to the use of alcohol, opioids, cannabinoids, sedatives or hypnotics, 
cocaine, stimulants, hallucinogens, tobacco, volatile solvents, multiple drug use and use of other 
psychoactive substances. 
 
Clinical states: 
•Acute intoxication: a transient disorder resulting in disturbances in level of consciousness, cognition, perception, 
affect, behaviour or other psychophysiological functions and responses. 
 
•Harmful use: A pattern of psychoactive substance use that is causing damage to health:  physical and mental 
health. 
 
•Dependence Syndrome:  
If 3 or more of the following have been present together at some time in the previous year. 
 - A strong desire or sense of compulsion to take the drug 
 - Difficulties in controlling substance-taking behaviour 
 - Evidence of a withdrawal state 
 - Evidence of a change in tolerance  
- Progressive neglect of alternative pleasures or interests. Increased amount of time necessary to obtain or 
take the substance or to recover from its effects. 
 - Persisting with substance use despite clear harmful consequences. 
 
Another characteristic feature includes “narrowing of the personal repertoire” i.e. drinking in the same pattern 
despite social constraints that determine appropriate drinking. 
 
• Withdrawal State  
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• Withdrawal state with delirium I.e. DTs. 
 
• Psychotic Disorder: A cluster of psychotic symptoms that occur during or immediately after psychoactive 
substance misuse: Includes vivid hallucinations, misidentifications, delusions + / or ideas of reference, 
psychomotor disturbances, abnormal affect. Usually resolves within 1 month and fully at 6 months 
 
• Amnesic Syndrome:  
 
Impairment of recent memory and learning new material, - Disturbances of time sense and telescoping of 
repeated events into one.  
Absence of impairment of immediate recall, consciousness or generalised cognitive impairment. 
Confabulation may be present. History of chronic substance use. Korsakoff’s Psychosis. 
 
• Residual and late onset psychotic disorder: 
Psychoactive substance induced changes in cognition, affect, personality, or behaviour persist beyond the 
period during which a psychoactive induced effect might reasonably be assumed to be operating. 
 
 
 
 
2. Withdrawal State 
A group of symptoms of variable clustering and severity occurring on withdrawal of a substance after repeated or 
prolonged and or high dose use of the substance  
 
Alcohol withdrawal Syndrome: 6-24 hours after their last drink 
Sweating, anxiety, diarrhoea, insomnia, restlessness, tremors, tachycardia, nausea, vomiting, headaches, 
weakness, seizures,  
Delirium tremens: Confusion and clouded consciousness, distortion of perception, sensation and arousal 
giving visual and auditory hallucinations. Death can occur 
 
Opiate withdrawal Syndrome: 
Onset 8-12 hrs, peak 48-72 hrs. 
“Cold-turkey”, Nausea, Vomiting, Diarrhoea, Muscle cramps, Insomnia,  rhinorrhoea, dilated pupils, goose 
flesh, yawning, sweating, runny eyes,  increased pulse rate. Disappears within 7-10 days 
Protracted abstinence syndrome: fatigue, malaise, craving for opioids, poor tolerance of stress. May last 
months 
 
Sedative / hypnotic withdrawal syndrome: 
Tremors, nausea, vomiting, tachycardia, postural hypotension, agitation, headaches, insomnia, weakness, 
seizures, transient hallucinations: visual, auditory, tactile, illusions, paranoid ideation. 
 
Stimulant Withdrawal Syndrome i.e. cocaine 
“Crash”, depressed mood, agitation, anxiety, insomnia, anorexia, suicidal ideation, craving: 9 hrs – 4 days.   
Later symptoms include exhaustion, hypersomnolence, depression,  hyperphagia, anxiety, inactivity, 
amotivation, fatigue and anhedonia, craving 
 
3. Physical Health Problems 
 
4. Psychological / Psychiatric problems 
Increased risk of anxiety, depression, suicidal ideation and suicide. 
 
5. Risk Taking Behaviour 
Injecting: increased risk of HIV and Hepatitis C if share equipment, needles, spoon, filter, barrels. 
Risk of overdose: polysubstance misuse, mixing opiates with benzodiazepines and alcohol, injecting alone. 
 
6. Stages of Change: 
Pre-contemplative stage: The person is not considering change. They wish to continue to enjoy using 
drugs.  
Contemplative Stage: Person is aware of the costs and negative effects of using drugs but is ambivalent 
about change 
Preparation Stage: 
Individuals want to change and are looking for direction on how to do this 
Action Stage: Individuals are engaged in attempts to reduce or to stop drug use 
Maintenance Stage: Individuals are continuing to maintain stability or abstinence. Relapse prevention is a 
key goal. 
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7. Identify the quantity, pattern, and frequency of drug use. 
 
Previous attempts to reduce or to stop. 
 What has worked in the past? 
 What are possible triggers or relapse? 
 
History: Psychiatric and Medical History 
 
 
Current Drug Use ( Last 30 days)  
Identify the quantity, pattern, and frequency of drug use. 
 
Heroin:  
Amount per day: 1 bag approximates to ¼ grm of heroin. 
Frequency: daily, 2-6 times per week, weekly, monthly etc. 
Duration of current use 
Mode of use: IV, smoking, skin-popping 
Age of first use 
 
Assess for use of benzodiazepines, zimovane, cocaine, amphetamines, extra methadone, ecstasy, alcohol, 
hallucinogens, cannabis and any other drug:  
Amount, frequency, duration, mode and age of first use. 
Assess a typical daily pattern of use. 
 
Assess for current withdrawal symptoms 
 
Assess for risk for HIV and Hepatitis C. 
Have they ever shared any part of their equipment: spoon, filter, needle, barrel. 
Have they shared with their partner? 
Have they ever been tested for HIV and Hepatitis B+C 
Date of last test? 
If injecting in the last month, have they shared in the last month 
Do they require further testing due to continued sharing? 
 
Assess for psychiatric illness/ psychological morbidity: 
 Nature of symptoms 
 Duration and mode of onset of symptoms 
 Progression of symptoms over time 
 Relationship of symptoms with drug use 
 
 
 
Past Drug use and Progression of drug use: 
 
 Age of first drug used and duration of use. 
 Progression of drug use over time 
 Age of first injecting 
 
Past treatments for drug use. 
 
Number of past detoxification programmes and methadone maintenance programmes received, dates and 
site of programmes 
 
 
Past Medical History: 
Any physical complications from alcohol and drug use 
 Are they diagnosed with HIV/ Hepatitis? 
 Has a specialist assessed them? 
 Are they receiving treatment? 
 Have they been vaccinated for Hepatitis? 
 
Past Psychiatric History: 
 
Any previous treatments for a psychiatric illness. Diagnosis? Where? What was the treatment received? 
Any episodes of deliberate self-harm and when was the last episode 
Are they attending a psychiatric service currently and what is the medication they are receiving? 
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Family History: 
 
Any family history of addiction or psychiatric illness 
 
Personal History: 
Early life, childhood,  
Schooling: Age of starting and leaving school. ? Exams,? Difficulties in school? i.e. learning, discipline, truancy 
Training and Occupations 
 
Psychosexual History: 
Current sexual practices, sexual orientation, current relationships 
 
Marital History / Partners 
 
? partner using drugs 
Children: ? children in care 
 
Forensic History: 
Past convictions, past prison sentences 
? impending charges / court cases 
 
 
Social History: 
Living arrangements and composition of household on release from Prison 
? on social welfare 
? Homeless, B+B, rented accommodation etc on release from prison. 
 
Premorbid personality 
 
 
Mental State Examination: 
 
Appearance and Behaviour 
Speech 
Mood: Subjectively and objectively 
Evidence of suicidal ideation and intent 
Evidence of homicidal ideation or intent 
Thoughts: preoccupations, abnormal thoughts, thought disorder 
Perceptions:  
Abnormal perceptions: illusions, hallucinations 
 
Cognitive function: 
Orientation, attention and concentration, memory: immediate, recent and long term 
Intelligence 
Insight: 
Precontemplative (no motivation), contemplative (ambivalent), Motivated. 
 
Formulation 
 
Diagnosis 
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APPENDIX 6 
  
CURRENT PROCESSES IN THE MEDICAL UNIT INVOLVING PRISONERS ON A METHADONE 
MAINTENANCE PROGRAMME 
 
(Policy 20: Psychiatric Assessment of Substance Misuse Disorders) 
 
 
Type of Patient: multiple health needs, on higher doses of methadone and other medications, mental health 
needs, motivated to stabilise drug use. 
 
• The Consultant Psychiatrist in Addiction/ their Deputy is responsible for patients on a methadone 
maintenance programme in the Medical Unit, specifically patients on F1, F2, F4, and attends the 
Medical Unit, once a week for a clinical session.  
 
• A full history of current and past drug use, risk behaviours and a full psychiatric assessment is 
completed. An Initial Treatment Plan is discussed. Options include: 
 
A Detoxification programme,  
A Stabilisation / Detoxification Programme,  
A Methadone Maintenance programme. 
 
• The methadone maintenance programme is adjusted accordingly based on the history obtained. 
• Antidepressants / antipsychotics and other medications are prescribed based on the prisoner’s mental 
state examination. 
• The conditions of their contract for treatment is explained and if not already signed, will be signed by the 
patient. 
• The treatment programme is explained to the patient and involves: 
• Giving the patient time to stabilise their drug use and a number of “Dates to clear” are given i.e. 
-7 days for opiates, cocaine, amphetamines 
-4 weeks for benzodiazepines. 
• If urines remain positive for drugs over a persistent period of time and various treatment interventions 
have been explored i.e. increased methadone doses, referral for counselling, other medications etc, 
then other options outlined in their contract of treatment are explored i.e.  a reduction of their dose, a 
low dose programme for 2 weeks, recommended transfer to the main prison. 
• Referrals are made to the psychologist / probation and welfare / GP and other agencies where appropriate, 
i.e. Consultant Hepatologist / Consultant in Infectious Diseases. 
• Referral to a counsellor will be made when available to patients 
• Need for testing for HIV and Hepatitis is assessed 
• Pre-test discussion for viral testing is provided 
• Referral to phlebotomy services is made. 
• Consent can be given to obtain results from the Virus Reference Laboratory. (Standard Letter in Medical 
Unit) 
• A letter is forwarded to the community treating agency requesting confirmation of a treatment place for an 
ongoing methadone maintenance programme on release from prison. ( Standard Letter in Medical Unit) 
• Nurses / Doctor complete the Entry Form to the Central List with the patient’s signature. 
• 2x weekly urine samples are taken. 
• Nurses fill in urine results in the charts of all patients. 
• Cumulative urine results from Claymon Laboratories are filed in a folder. 
• Patients are reviewed depending on urine results, mental health issues, at their request, at the request of 
other professionals, or prior to discharge (if possible). 
• Feedback is given to Healthcare staff on decisions made after each clinic. These decisions are 
documented in a Healthcare diary. 
• Discussions about treatment and aftercare needs are discussed with the Probation and Welfare services 
with the patient’s consent. 
• If the patient is for release, a discharge letter is completed by the Healthcare staff in the Medical Unit and 
forwarded to the treating agency. 
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APPENDIX 7 
 
USE OF NICOTINE REPLACEMENT THERAPY 
 
(Policy 17: Nicotine Replacement Therapy) 
 
1. Call to Surgery for a talk on smoking cessation and NRT 
2. Programme to be recorded on this sheet 
3. NRT must be prescribed. 
4. One box of patches to be given at a time 
5. Empty box with used patches to be returned to surgery for disposal and replacement. 
6. Please report any allergies or sensitivities to the patches 
7. Smoking whilst using patches is not permitted 
8. Patches are strictly not to be shared with anyone else 
9. One attempt at NRT within a 6 month period 
 
Details 
 
Name:  _______________________ D.O.B.: _____________ 
How many cigarettes smoked per day?: __________  
How many years smoking?  __________ 
Date ceased or to cease smoking?: __________  
Brief Intervention    YES/NO 
Has patient taken NRT before?:  YES/NO 
If so, which one?:    __________ 
When was last time NRT was taken?: __________ 
Has there ever been a reaction to NRT? __________ 
 
Programme 
 
(If you smoke >10 cigarettes a day follow 3 steps below.  If you smoke <10 daily take step 2 for 6 weeks followed 
by step 3 for 2 weeks) 
 
STEP 1   STEP2   STEP3 
Week 1 ________  Week  1 ________  Week 1 ________  
Week 2 ________  Week  2 ________  Week 2 ________ 
Week 3 ________  Week  3 ________  Week 3 ________ 
Week 4 ________  Week  4 ________  Week 4 ________ 
Week 5 ________  Week  5 ________  Week 5 ________ 
Week 6 ________  Week  6 ________  Week 6 ________ 
 
 
I have been informed of the above programme and conditions and agree to its conditions in 
 _______________  (Name of Institution). 
 
Signed: _______________  Witnessed: _______________  
Date: _______________ 
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APPENDIX 8 
  
CHILDREN FIRST 
 
(Policy 24: Child Protection) 
 
Children First 
National Guidelines 
for the Protection and 
Welfare of Children 
A Summary 
September 1999 
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Chapter One 
Introduction 
New guidelines, entitled ‘Children First: National Guidelines for the 
Protection And Welfare of Children’ were introduced in 1999. These 
guidelines are intended to assist people in identifying and reporting 
child abuse and to improve professional practice in both statutory and 
voluntary agencies and organisations that provide services for children 
and families. 
This booklet offers a summarised version of ‘Children First’. It is 
expected that these National Guidelines will be complemented by 
local guidelines specific to the needs of regional health boards, as well 
as individual disciplines and organisations. Any such guidance must 
adopt the basic aims and objectives outlined in this document. 
These guidelines aim to offer a comprehensive framework to assist 
professionals and other persons who have contact with children and 
wish to deal with any concerns they may have in relation to their safety 
and wellbeing. The guidelines embody the principles contained in the 
UN Convention on the Rights of the Child which was ratified by Ireland 
in 1992. (It should be noted that the Child Care Act, 1991, provides 
the legislative basis for dealing with children in need of care and 
protection)1. 
Objectives 
The objectives of the National Guidelines are to improve the 
identification, reporting, assessment, treatment and management of 
child abuse, clarify the responsibilities of various professionals and 
1 For a comprehensive discussion of other key legislative provisions, see the 
full version of ‘Children First: Guidelines for the Protection and Welfare of 
Children’. 
5 
individuals within organisations and enhance communication and coordination 
of information between disciplines and organisations. 
Protecting and supporting children frequently involves the 
collaboration of a variety of personnel 
Duty to Protect Children and Support Families 
Parents/carers have primary responsibility for the care and protection 
of their children. When parents/carers do not or cannot fulfil this 
responsibility, it may be necessary for health boards to intervene. The 
wider community also has a responsibility for the welfare and 
protection of children. All personnel involved in organisations working 
with children should be alert to the possibility of child abuse. They 
need to be aware of their obligations to convey any reasonable 
concerns or suspicions to the health board and to be informed of the 
correct procedures for doing so. 
Principles for Best Practice in Child Protection 
The principles that should inform best practice in child protection 
include the following: 
(i) the welfare of children is of paramount importance 
(ii) a proper balance must be struck between protecting 
children and respecting the rights and needs of 
parents/carers and families; but where there is conflict, the 
child’s welfare must come first. 
(iii) children have a right to be heard and taken seriously. 
Taking account of their age and level of understanding, 
they should be consulted and involved in relation to all 
matters and decisions that affect their lives. 
6 
(iv) early intervention and support should be available to 
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promote the welfare of children and families, particularly 
where they are vulnerable or at risk of not receiving 
adequate care or protection. 
(v) parents/carers have a right to respect and should be 
consulted and involved in matters which concern their 
family. 
(vi) actions taken to protect a child, including assessment, 
should not in themselves be abusive or cause the child 
unnecessary distress. Every action and procedure should 
consider the overall needs of the child. 
(vii) intervention should not deal with the child in isolation; the 
child must be seen in a family setting. 
(viii) the criminal dimension of any action cannot be ignored. 
(ix) children should only be separated from parents/carers 
when all alternative means of protecting them have been 
exhausted. Re-union should always be considered. 
(x) effective prevention, detection and treatment of child 
abuse require a co-ordinated multi-disciplinary approach. 
(xi) in practice, effective child protection requires compulsory 
training and clarity of responsibility for personnel involved 
in organisations working with children. 
(xii) early intervention and support should be available to 
promote the welfare of children and families, particularly 
where they are vulnerable or at risk of not receiving 
adequate care or protection. 
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Chapter Two 
Definition and Recognition of 
Child Abuse 
Introduction 
Child abuse can be categorised into four different types: neglect, 
emotional abuse, physical abuse and sexual abuse. A child2 may be 
subjected to more than one form of abuse at any given time. The 
National Guidelines have adopted the following definitions of child 
abuse: 
Neglect 
Neglect is normally defined in terms of an omission, where a child 
suffers significant harm or impairment of development by being 
deprived of food, clothing, warmth, hygiene, intellectual stimulation, 
supervision and safety, attachment to and affection from adults, or 
medical care. 
Harm can be defined as the ill treatment or the impairment of the 
health or development of a child. Whether it is significant is determined 
by his/her health and development as compared to that which could 
reasonably be expected of a similar child. 
Neglect generally becomes apparent in different ways over a period of 
time rather than at one specific point. For instance, a child who suffers 
a series of minor injuries is not having his or her needs met for 
supervision and safety. A child whose ongoing failure to gain weight 
2 For the purposes of these guidelines, a ‘child’ means an unmarried person 
under the age of 18 years. 
9 
or whose height is significantly below average may be being deprived 
of adequate nutrition. A child who consistently misses school may be 
being deprived or intellectual stimulation. The threshold of significant 
harm is reached when the child’s needs are neglected to the extent 
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that his or her well being and/or development are severely affected. 
Emotional Abuse 
Emotional abuse is normally to be found in the relationship between a 
caregiver and a child rather than in a specific event or pattern of 
events. It occurs when a child’s needs for affection, approval, 
consistency and security are not met. It is rarely manifested in terms of 
physical symptoms. Examples of emotional abuse include: 
(i) persistent criticism, sarcasm, hostility or blaming; 
(ii) conditional parenting, in which the level of care shown to 
a child is made contingent on his or her behaviours or 
actions; 
(iii) emotional unavailability by the child’s parent/carer; 
(iv) unresponsiveness, inconsistent or inappropriate 
expectations of a child; 
(v) premature imposition of responsibility on a child; 
(vi) unrealistic or inappropriate expectations of a child’s 
capacity to understand something or to behave and control 
himself in a certain way; 
(vii) under or over or under protection of a child; 
(viii) failure to show interest in, or provide age appropriate 
opportunities for, a child’s cognitive and emotional 
development; 
(ix) use of unreasonable or over harsh disciplinary measures; 
(x) exposure to domestic violence. 
 
 
 
10 
Children show signs of emotional abuse by their behaviour (for 
example, excessive clinginess to or avoidance of the parent/carer), 
their emotional state (low self-esteem, unhappiness), or their 
development (non-organic failure to thrive). The threshold of significant 
harm is reached when abusive interactions become typical of the 
relationship between the child and parent/carer. 
Physical Abuse 
Physical abuse is any form of non-accidental injury that causes 
significant harm to a child, including: 
(i) shaking; 
(ii) use of excessive force in handling; 
(iii) deliberate poisoning; 
(iv) suffocation; 
(v) Munchausen’s syndrome by proxy (where parents fabricate 
stories of illness about their child or cause physical signs of 
illness); 
(vi) allowing or creating a substantial risk of significant harm to 
a child. 
Sexual Abuse3 
Sexual abuse occurs when a child is used by another person for his or 
her gratification or sexual arousal, or for that of others. For example: 
(i) exposure of the sexual organs or any sexual act 
intentionally performed in the presence of a child; 
3 The definition of child sexual abuse presented here is not a legal definition, 
and is not intended to be a description of the criminal offence of sexual 
assault. 
11 
(ii) intentional touching or molesting of the body of a child 
whether by a person or object for the purpose of sexual 
arousal or gratification; 
(iii) masturbation in the presence of a child or involvement of 
the child in the act of masturbation; 
(iv) sexual intercourse with the child, whether oral, vaginal or 
anal; 
(v) sexual exploitation of a child; 
(vi) consensual sexual activity between an adult and a child 
under 17 years. In relation to child sexual abuse, it should 
be noted that, for the purposes of the criminal law, the age 
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of consent to sexual intercourse is 17 years. This means, 
for example, that sexual intercourse between a 16 year old 
girl and her 17 year old boyfriend is illegal, although it 
might not be regarded as constituting child sexual abuse. 
Recognising Child Abuse 
The ability to recognise child abuse depends as much on a person’s 
willingness to accept the possibility of its existence as it does on 
knowledge and information. It is important to note that child abuse is 
not always readily visible, and may not be as clearly observable as the 
‘text book’ scenarios outlined in these guidelines suggest. The 
recognition of abuse normally runs along three stages, 
(i) considering the possibility — if a child appears to have 
suffered an inexplicable and suspicious looking injury, 
seems distressed without obvious reason, displays unusual 
behavioural problems or appears fearful in the company of 
parents/carers. 
 
 
12 
(ii) observing signs of abuse — a cluster or pattern of signs is 
the most reliable indicator of abuse. Children may make 
direct or indirect disclosures, which should always be taken 
seriously. Less obvious disclosures may be gently explored 
with a child, without direct questioning (which may be 
more usefully carried out by the health board or An Garda 
Sı ´ocha´na). Play situations such as drawing or story telling 
may reveal significant information. Indications of harm 
must always be considered in relation to the child’s social 
and family context, and it is important to always be open 
to alternative explanations. 
(iii) recording of information — it is important to establish the 
grounds for concern by obtaining as much detailed 
information as possible. Observations should be recorded 
and should include dates, times, names, locations, context 
and any other information which could be considered 
relevant or which might facilitate further assessment/ 
investigation. 
13 
 
Chapter Three 
Reporting Child Protection 
Concerns 
Introduction 
Child abuse is a difficult subject, and it is understandable that people 
may at times be reluctant to acknowledge its existence. Members of 
the public or professionals may be afraid of being thought insensitive, 
afraid of breaking confidence or afraid of being disloyal if they report 
suspected child abuse to the health board or An Garda Sı ´ocha´na. 
However, early intervention may reduce the risk of serious harm 
occurring to a child in the future. Persons uncertain about the validity 
of their concerns may discuss them with a health board social worker 
or public health nurse. This may enable them to decide whether or not 
to make a formal report. 
The Protection for Persons Reporting Child Abuse Act, 1998 provides 
immunity from civil liability to persons who report child abuse 
‘reasonably and in good faith’ to designated officers* of health boards 
* In accordance with the power granted to him under Section 2, subsection (2) of the Act, the Minister has directed 
(January 1999) that the Chief Executive Officer of each health board should appoint as designated officers each 
person falling within the following categories of officer of the health board: 
Social Workers 
Child Care Workers 
Public Health Nurses 
Hospital Consultants 
Psychiatrists 
Non-Consultant Hospital Doctors 
All other health board medical and dental personnel 
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Community Welfare Officers 
Speech and Language Therapists 
All health board nursing personnel 
Psychologists 
Radiographers 
Physiotherapists 
Occupational Therapists 
Health Education Officers 
Substance Abuse Counsellors 
Care Assistants. 
15 
or any member of An Garda Sı ´ocha´na. This means that, even if a 
reported suspicion of child abuse proves unfounded, a plaintiff who 
took an action would have to prove that the reporter had not acted 
reasonably and in good faith in making the report. 
Giving information to others for the protection of a child does not 
constitute a breach of confidentiality. 
 
 
 
Responsibility to Report 
Any person, who suspects that a child is being abused, or is at risk of 
abuse, has a responsibility to report their concerns to the health board. 
This responsibility is particularly relevant to professionals such as 
teachers, child care workers and health professionals who have regular 
contact with children in the course of their work. It is also an important 
responsibility for staff and volunteers involved in sports clubs, parish 
activities, youth clubs and other organisations catering for children. 
The following examples would constitute reasonable grounds for 
concern: 
(i) a specific indication from a child that (s)he was abused; 
(ii) a statement from a person who witnessed abuse; 
(iii) an illness, injury or behaviour consistent with abuse; 
(iv) a symptom which may not in itself be totally consistent 
with abuse, but which is support by corroborative evidence 
of deliberate harm or negligence; 
(v) consistent signs of neglect over a period of time. 
A suspicion, which is not supported by any objective signs of abuse, 
would not constitute a reasonable suspicion, or reasonable grounds 
for concern 
Standard Reporting Procedure 
If child abuse is suspected or alleged, the following steps should be 
taken by professionals and members of the public who come into 
contact with children 
16 
(i) a report should be made to the health board in person, by 
phone or in writing. Each health board has a duty social 
worker who is available each day to meet with or talk on 
the telephone to persons wishing to report child protection 
concerns. (A list of contact numbers is available in 
Appendix 1) 
(ii) it is generally most helpful if personal contact is made with 
the duty social worker by the person who first witnessed 
or suspected the alleged child abuse. 
(iii) in the event of an emergency or the non-availability of 
health board staff, a report may be made to An Garda 
Sı´ocha´na at any Garda Station. 
NOTE: A suggested template for the Standard Reporting 
Procedure is contained in Appendix 2, which may be of 
use for staff or volunteers in organisations who work with 
children or are in contact with children. 
The health board or An Garda Sı´ocha´na, on receiving a report, will 
require as much as possible of the following information: 
(i) names and addresses of the child, parents/carers and any 
other children in the family; 
(ii) name and address of the person alleged to be causing 
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harm to the child; 
(iii) a full account of the current concern about the child’s 
safety or welfare; 
(iv) the source of any information which is being discussed with 
the health board; 
(v) dates of any incidents being reported; 
(vi) circumstances in which the incident or concern arose; 
(vii) any explanation offered to account for the risk, injury or 
concern; 
(viii) the child’s own statement if relevant; 
17 
(ix) any other information about the family, particularly any 
difficulties which they may be experiencing; 
(x) any factors relating to the family which could be 
considered supportive or protective, e.g. helpful family 
members, neighbours or services; 
(xi) name of child’s school; 
(xii) name of child’s general practitioner; 
(xiii) reporter’s own involvement with child and parents/carers; 
(xiv) details of any action already taken in relation to the child’s 
safety and welfare; 
(xv) names and addresses of any agency or key person involved 
with the family; 
(xvi) identity of person reporting, including name, address, 
telephone number, occupation and relationship with the 
family. 
In cases of emergency, where a child appears to be at immediate and 
serious risk, and a duty social worker is unavailable, An Garda Sı ´ocha´na 
should be contacted. Under no circumstances should a child be left 
in a dangerous situation pending health board intervention. 
Co-operation with Parents/carers 
Any professional who suspects child abuse should inform the family if 
a report is likely to be submitted to the health board or An Garda 
Sı ´ocha´na, unless doing so is likely to endanger the child. Co-operation 
with the family is essential in order to ensure the safety of the child; it 
is more likely to be achieved if professionals can develop an open and 
honest relationship with parents/carers. 
Involvement in a child protection assessment can be difficult for 
parents/carers. Families may have rights to know what is said about 
them and to contribute to important decisions about their lives and 
those of their children. Sensitivity must be used, and parents/ carers 
should be made fully aware of what is expected of them. Professional 
staff must strike a balance between showing respect for families and 
using authority appropriately. 
18 
Chapter Four 
Joint Working and Co-operation 
Roles and Responsibilities of 
Agencies and Personnel Working 
with Children 
Introduction 
The health board has overall responsibility for the assessment and 
management of child protection concerns. At the same time, An Garda 
Sı ´ocha´na has responsibility for the investigation of alleged offences. 
Other organisations have major contributions to make to the safety 
and welfare of children. No one professional or agency has all the skills, 
knowledge or resources necessary to comprehensively meet all the 
requirements of an individual case. It is essential therefore that a coordinated 
response is made by all professionals involved with a child 
and his or her carer/s. 
Effective inter-agency co-operation will depend on 
(i) understanding and acceptance by all professionals and 
persons working with children of their responsibilities and 
roles in the promotion of child welfare 
(ii) mutual trust and sharing of information 
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(iii) willingness of personnel to respect the contributions made 
by each other, irrespective of status and position within 
agencies and organisations. 
19 
Inter-agency co-operation is as important in the later stages of child 
protection work as it is at the outset. Efforts should be consistently 
made by all personnel involved in a case to remain in contact, and to 
communicate any relevant information to the key worker, who is 
usually the health board social worker. 
Individual and Corporate Responsibilities in Reporting 
Child Abuse 
All organisations, whether statutory or voluntary, have an overall 
corporate responsibility to safeguard children, and should pay 
particular attention to 
(i) safe and clearly defined methods of selecting staff and 
volunteers 
(ii) developing effective procedures for the reporting and 
management of child protection concerns 
(iii) identifying a designated staff member/volunteer to act as a 
liaison with outside agencies and a resource person to any 
staff member or volunteer who has child protection 
concerns. The designated person will be responsible for 
reporting allegations or suspicions of child abuse to the 
health boards or An Garda Sı ´ocha´na 
The Protection for Persons Reporting Child Abuse Act, 1998 makes 
provision for the protection from civil liability of persons who have 
reported child abuse ‘reasonably and in good faith’. This protection 
applies to organisations as well as individuals. It is considered therefore 
that, in the first instance, it is organisations that employ staff or use 
volunteers that should assume responsibility for reporting child abuse 
to the appropriate authorities. Reports to the health boards or An 
Garda Sı ´ocha´na should be made following the Standard Reporting 
Procedure (See Chapter Three). 
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In those cases where the organisation decides not to refer concerns to 
the health board or An Garda Sı ´ocha´na, the individual staff or volunteer 
who raised the concern should be given a clear written statement of 
the reasons why the organisation is not taking action. The staff or 
volunteer should be advised that if they remain concerned about the 
situation, they are free to consult with, or report to, the health board 
or An Garda Sı ´ocha´na. 
Schools/ Clubs / Organisations 
If a child alleges that he or she is being harmed or is at risk of harm 
from a parent/carer or any other person, the person who receives the 
information should listen carefully and supportively. This also applies if 
a parent/carer or any other person discloses that he or she has harmed 
or is at risk of harming a child. 
The child should not be interviewed formally or in detail, as this may 
be best done by the health board or An Garda Sı ´ocha´na. The staff 
member/ volunteer needs to gather enough information to establish 
grounds for concern, record the conversation accurately and then 
inform the person in the school, club or organisation who is 
responsible for reporting the matter to the health board or An Garda 
Sı ´ocha´na. 
Health Professionals 
Health professionals in statutory, voluntary and private services are well 
placed to identify child protection concerns and to participate in initial 
assessment and even longer-term management. These professionals 
include general practitioners, medical consultants, dentists, those 
working in hospitals, disability services, therapeutic services, adult 
mental health services and child and adolescent psychiatric services 
Any health professional who is satisfied that there are reasonable 
grounds for suspecting that a child is being harmed or is at risk of harm 
21 
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should immediately inform the health board in line with the Standard 
Reporting Procedure. 
Health professionals who are involved in the initial or longer-term 
treatment of children who are considered to be at risk should attend 
child protection conferences and child protection reviews when 
invited. In addition, they must record and communicate any ongoing 
concerns to the key worker involved, who will normally be the health 
board social worker. 
Welfare Services 
Community welfare officers, housing welfare officers, probation and 
welfare officers, school attendance officers and others working in a 
welfare capacity may encounter situations which give rise to suspicions 
of child abuse in the course of their daily work. Reports should be 
made to the health board using the Standard Reporting Procedure. Any 
child protection concerns which later arise in relation to these children 
and families should also be communicated to the health board. 
Confidentiality must never be promised to a person making a 
disclosure. The requirement to report to the health board must be 
explained in a supportive manner to the child. The parents/carers 
should also be informed of the intention to report unless it is 
considered that doing so would put the child at risk. 
22 
Chapter Five 
Child Protection Practices 
Operated by the Health Boards 
and An Garda Sı´ocha´na 
Introduction 
A joint protocol has been agreed between the health boards and An 
Garda Sı ´ocha´na, whereby each organisation will notify the other of all 
reports of suspected child abuse which are made to them, and both 
are obliged to conduct a preliminary assessment/investigation in 
consultation with each other. Reports which are made anonymously 
will be followed up, but reporters will be informed that anonymity may 
greatly restrict the ability of professionals to intervene to protect a 
child. 
It is important to note that the ability of the health board and An 
Garda Sı´ocha´na to respond to reports of suspected child abuse will 
depend on the quality and extent of information that is reported to 
them. 
Emergency Action to Protect a Child 
If it appears, on receipt of a report of suspected child abuse, that a 
child has been harmed or is at immediate risk of harm, emergency 
action will be taken by the health board or An Garda Sı ´ocha´na. This 
may involve having the child medially examined, and/or moving the 
child to a safe environment such as a foster home, or to the home of 
relatives. This intervention may be made voluntarily with the 
parents/carers’ consent, or may involve an Emergency Care Order 
under the Child Care Act 1991. 
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Assessment and Investigation 
Where the perceived harm or risk to the child does not appear to 
warrant emergency action, the assessment/ investigation will be carried 
out as quickly as possible in a co-ordinated manner, in consultation 
with any other professionals who are involved with the child and 
parents/carers. This will involve interviews with the child and 
parents/carers, and possible referral to medical or specialist services 
for more detailed assessment. An Garda Sı ´ocha´na will prepare a file 
for the Director of Public Prosecutions if appropriate. 
Notification to the Child Care Manager/designate 
The Child Protection Notification System is a health board record of 
every child about whom, following a preliminary assessment, there is 
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a child protection concern. Notifications are first made to the Child 
Care Manager by the health board staff member who carries out the 
initial assessment of a child protection concern. The Child Care 
Manager will ensure that all notified reports are reviewed initially and 
at six monthly intervals until a final outcome of assessment is known 
and an agreed intervention has been put in place. 
Child Protection Meetings. 
Three types of child protection meeting may be organised by the health 
board during the management of a case 
(i) A strategy meeting, which may be held at the outset of a 
child protection assessment, when it appears that a child is 
at serious risk and in need of immediate protection or at 
any point in an assessment when it is deemed appropriate. 
This meeting will normally involve health board staff and 
members of An Garda Sı ´ocha´na, but may involve any or 
all other professionals involved. Its main aims are to share 
information and plan a strategy for early intervention and 
further assessment. 
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(ii) A child protection conference, which may take place 
when initial enquiries and any necessary emergency 
actions have taken place. Its participants include all 
professionals involved in the case. The child (where 
appropriate) and the child’s parents/carers should be 
invited unless a specific reason for their exclusion is 
identified. Its aims are to pool all available information, 
outline a child protection plan, and identify the tasks to be 
carried out by different professionals. All professionals who 
are invited to child protection conferences should attend, 
and produce written reports in advance for the 
Chairperson, who will normally be the Child Care 
Manager/designate. The child protection conference will 
usually be followed by completion of a comprehensive 
assessment, and finalisation of the child protection plan. 
(iii) Child protection reviews, which are held at six monthly 
intervals where a child’s name is in the Child Protection 
Notification System, where (s)he is still residing with his or 
her parents/carers and where (s)he is still considered to be 
at risk. Child protection reviews should be attended by the 
core group of professionals involved with the case, and 
each should submit a written report in advance. The child 
(where appropriate) and the child’s parents/carers should 
be invited unless a specific reason for their exclusion is 
identified. The aims of a child protection review are to 
consider the child’s current situation, co-ordinate the views 
of participants, and amend the child protection plan. 
Inter-agency and Inter-professional Co-operation 
Co-operation between disciplines and agencies is essential throughout 
the lifetime of a child protection case. Commitment and flexibility in 
relation to carrying out the work specified in the child protection plan, 
together with willingness to exchange information promptly will be 
required from all professionals who are involved with the child. 
25 
 
Chapter Six 
Specially Vulnerable Children 
and Abuse Outside the Home 
Introduction 
Children in certain situations are especially vulnerable to abuse. These 
include children with disabilities and children who, for one reason or 
another are separated from parents or other family members and 
depend on others for their care and protection. The same categories 
of abuse — neglect, emotional abuse, physical abuse and sexual abuse 
— may be applicable, but may take a slightly different form, for example 
harsh disciplinary or behavioural regimes or inappropriate use of 
medication or physical restraints. 
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Children with Disabilities 
Children with disabilities can be more at risk of abuse because they 
may experience 
• sensory and communication difficulties 
• dependence on others for assistance including intimate care 
• limited understanding of sexuality or sexual behaviour 
• contact with numerous carers and helpers 
• fear of not being believed 
• perceived unreliability as witnesses. 
Children Out of Home 
Children who are without accommodation and children who have 
been placed by the health board in foster or residential care may be 
at special risk for the following reasons: 
(i) they may have previously been abused 
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(ii) they may be at risk from peers who have suffered abuse 
(iii) they may be dependent on a range of different persons for 
their care and feel powerless to take action if abused. 
Procedures exist for the protection of children in out of home care and 
these should be followed by all staff and carers. However, it is also 
important that children in care are fully aware of complaints systems, 
and have opportunities to make their problems known to others who 
are in a position to help them. Action to be taken in response to 
allegations of abuse against members of staff are outlined in Chapter 
Eight. 
Organised Abuse 
Organised abuse occurs rarely but presents particularly complex 
problems. Essentially, organised abuse occurs when either one person 
moves into an area or institution and systematically entraps children 
for abusive purposes (mainly sexually) or when two or more adults 
conspire to similarly abuse children, using inducements. It can occur 
in different settings, such as the family, extended family, community or 
institution. It is particularly associated with the following factors: 
(i) there may be numerous victims. Sometimes, help-lines and 
newspapers advertisements are necessary in order to 
contact victims; 
(ii) victims may be under particular pressure not to disclose 
because of feelings of shame and responsibility; 
(iii) some victims may have colluded with abusers to entrap 
other children and may have gone on to become abusers 
themselves. 
Any person who suspects the existence of organised abuse must 
contact the health board or An Garda Sı ´ocha´na without delay. The 
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investigation of organised abuse may require prolonged surveillance 
by An Garda Sı ´ocha´na, and information must be treated with particular 
sensitivity. 
Peer Abuse 
In some cases of child abuse, the alleged perpetrator will be a child. In 
these situations, the child protection procedures should be adhered to 
for both the victim and alleged abuser, that is, it should be considered 
a child protection issue for both children. 
Work must be done to ensure that perpetrators of abuse, even when 
they are children themselves, take responsibility for their behaviour and 
acknowledge that the behaviour is unacceptable. 
It is important that clarity exists in respect of which behaviours 
constitute peer abuse, particularly child sexual abuse. Consultation 
with the health board should help to clarify the nature of any sexual 
behaviour by children which gives rise to concern. 
Bullying 
Bullying can be defined as repeated verbal, psychological or physical 
aggression conducted by an individual or group against others. It is 
behaviour which is intentionally aggravating and intimidating, and 
occurs mainly in social environments such as schools, clubs and other 
organisations working with children. It includes behaviours such as 
teasing, taunting, threatening, hitting or extortion behaviour by one or 
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more children against a victim. While the more extreme forms of 
bullying would be regarded as physical or emotional abuse and are 
reportable to health board or An Garda Sı ´ocha´na, dealing with bullying 
behaviour is normally the responsibility of the school or organisation 
where it is taking place. Training for teachers and staff/volunteers in 
organisations working with children should include modules on raising 
awareness and developing techniques for dealing with bullying. 
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Chapter Seven 
Support Services to Children and 
Families 
Introduction 
Many of the children who come to the attention of the various services 
are living in difficult and stressful environments. Their families may be 
experiencing a variety of personal, social and health problems, and 
while children are not necessarily being abused in these situations, they 
may be at risk of future harm. 
Interventions to support families who are experiencing difficulties can 
greatly reduce the possibility of future risk or harm. Support may be 
given to families through the direct services of statutory and voluntary 
organisations, but also informally through extended families, friends, 
neighbourhoods, communities, parishes and other local networks. 
Dimensions of Family Support 
Family support may be offered at different levels 
(i) services specifically directed at children, aimed at 
increasing self confidence, self-esteem, social skills, 
enabling children to get over traumatic or damaging 
experiences or simply providing children with a break from 
a stressful environment. These services can range from 
clinical treatment, respite care (formal or informal) to 
provision of after school projects and involvement with 
local sport and recreation clubs and voluntary associations. 
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(ii) services to support families which are aimed at enhancing 
the skills of parents/carers by providing direct practical 
help, support and/or counselling. These can include respite 
care, direct financial help, and advice about housing, 
financial and welfare matters. 
Early intervention can prevent worsening of current difficulties for 
children and families. It can reduce future risk, help families to 
develop strategies for coping with stress, and prevent children from 
being separated from their parents/carers. 
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Chapter Eight 
Allegations of Abuse Against 
Employees and Volunteers 
Introduction 
Allegations of abuse may be made against employees (who for the 
purposes of these guidelines include paid staff, foster parents and 
unpaid volunteers). Employers may encompass disability organisations, 
schools, creches, or non-governmental organisations such as sports 
clubs. These guidelines are offered to assist managers in having due 
regard for the rights and interests of the child on the one hand, and 
those of the employee against whom the allegation is made on the 
other hand. 
General Procedures 
It is important to note that there are two procedures to be followed 
here: 
(i) the reporting procedure in respect of the child 
(ii) the procedure for dealing with the employee. 
In general it is recommended that the same person should not have 
responsibility for dealing with both the reporting issues and the 
employment issues. It is preferable to separate these issues and 
manage them independently. These procedures should be followed in 
the event of suspicion or disclosure of abuse against an employee. 
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Staff/volunteers may be subjected to erroneous or malicious 
allegations. Therefore any allegation of abuse should be dealt with 
sensitively and support provided for staff including counselling where 
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necessary. However, the primary goal is to protect the child while 
taking care to treat the employee fairly. 
Guidance on Reporting 
All organisations providing services to children must have clear 
written procedures on action to be taken when allegations of abuse 
against employees are received. Guidance should be provided for 
both children and employees on how to report suspected child abuse. 
The need for awareness and the requirement to report concerns should 
be reinforced through training and supervision. 
Employers should ensure that children and staff/volunteers are aware 
of internal line management reporting procedures. They should also be 
aware of the appropriate authorities to which they should report 
outside the organisation (i.e. the health board or An Garda Sı ´ocha´na) 
if they are inhibited for any reason from reporting the incident 
internally or where they are dissatisfied with the internal response. 
Employer’s Responsibility to Report to Statutory 
Authorities 
Where an employer becomes aware of an allegation of abuse by an 
employee the standard procedure for reporting allegations to the 
health board should be followed without delay (see Chapter Three). 
Health boards should have their own internal reporting procedures in 
place in regard to allegations made against their employees. 
Action taken in reporting an allegation of child abuse against an 
employee should be based on an opinion formed reasonably and in 
good faith. When an allegation is received it should be assessed 
promptly and carefully. It will be necessary to decide whether a formal 
report should be made to the health board; this decision should be 
based on reasonable grounds for concern as outlined in Chapter Two. 
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When an employer becomes aware of an allegation of abuse of a child 
or children by an employee during the execution of that employee’s 
duties, the employer should inform the employee of the following: 
(i) the fact that an allegation has been made against him/her; 
(ii) the nature of the allegation. 
The employee should be afforded an opportunity to respond. The 
employer should note the response and pass on this information when 
making the formal report to the health board. 
Organisations as well as individuals may avail of the immunity from 
civil liability provided in the Protections for Persons Reporting Child 
Abuse Act, 1998 provided they report ‘reasonably and in good faith’ 
to the appropriate authorities. Section 3(1) of the Act states: 
‘3(1) A person who, apart from this section, would be so liable 
shall not be liable in damages in respect of the communication, 
whether in writing or otherwise, by him or her to an appropriate 
person of his or her opinion that 
(a) a child has been or is being assaulted, ill-treated, 
neglected or sexually abused, or 
(b) a child’s health, development or welfare has been or is 
being avoidably impaired or neglected, 
unless it is proved that he or she has not acted reasonably and 
in good faith in forming that opinion and communicating it to the 
appropriate person.’ 
Procedures for Dealing with Employees and Employer’s 
Duty of Care to Children 
Employers have a dual responsibility in respect of both the child and 
the employee. All employers should have agreed procedures to 
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address situations where allegations of child abuse are made against 
an employee. When an allegation is made against an employee, the 
following steps should be taken: 
(i) Action should be guided by the agreed procedures, the 
applicable employment contract and the rules of natural 
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justice. 
(ii) The Chairperson (or equivalent head of organisation) 
should be informed as soon as possible. 
(iii) The first priority should be to ensure that no child is 
exposed to unnecessary risk. The employer should as a 
matter of urgency take any necessary protective measures. 
These measures should be proportionate to the level of 
risk and should not unreasonably penalise the employee, 
financially or otherwise, unless necessary to protect 
children. Where protective measures do penalise the 
employee, it is important that early consideration be given 
to the case. 
(iv) The follow up on an allegation of abuse against an 
employee should be made in consultation with the health 
board and An Garda Sı ´ocha´na. An immediate meeting 
should be arranged with these two agencies for this 
purpose. 
(v) After these consultation referred to above and when 
pursuing the question of the future position of the 
employee, the Chairperson (or equivalent head of 
organisation) should advise the person accused of the 
allegation and the agreed procedures should be followed. 
(vi) Employers should take care to ensure that actions taken by 
them do not undermine or frustrate any investigations 
being conducted by the health board or An Garda 
Sı ´ocha´na. It is strongly recommended that employers 
maintain a close liaison with these authorities to achieve 
this. 
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Guidance for Health Boards 
Health boards will regularly receive allegations of abuse against people 
who have contact with children in their workplace or in a sports or 
youth club. If the health board considers that children are, or may be, 
at risk from the alleged abuser, they should contact the institution or 
employer immediately. In this situation it is not necessary to notify the 
alleged abuser in advance of the allegations against him or her. 
Where a health board proposes to notify an employer or person-incharge 
of a club about an alleged abuser in their workplace, and where 
there is no immediate danger to children, the alleged abuser must be 
notified in advance of the allegations against him/her. The approach 
to an employer/person-in-charge in such cases may take place at any 
stage in the wider investigation and it may be practical that such an 
approach does not take place until any criminal or health board 
investigation has concluded. 
Health boards should put arrangements in place to provide feedback 
to employers/persons-in-charge in regard to the progress of a child 
abuse investigation involving an employee. Efforts should be made by 
health boards to investigate complaints against employees/volunteers 
promptly and to complete their assessment as quickly as possible 
bearing in mined the serious implications for the innocent 
employee/volunteer. Employers/persons-in-charge should be notified 
of the outcome of an investigation. The health board should pass on 
reports and records to the employer and to the employee/volunteer 
in question where appropriate. This will assist the employer/person-incharge 
in reaching a decision as to the action to be taken in the longer 
term concerning the employee/volunteer. 
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Chapter Nine 
Local Arrangements: Procedures 
and Training 
Local Procedures and Guidelines 
Statutory and voluntary/community organisations providing services 
for children should produce their own procedures, in line with these 
National Guidelines. The procedures should be appropriate to local 
circumstances. They should provide 
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(i) clear descriptions of responsibility at local level, both 
individual and corporate 
 
(ii) procedures for reporting child protection concerns and 
arrangements for inter-agency co-operation 
(iii) an outline of the key elements of assessment and 
investigation as operated by the health board and An 
Garda Sı ´ocha´na 
(iv) an outline of arrangements for training and support of staff 
(v) guidance on the involvement of families and children in 
child protection and welfare work 
Training 
Training in child protection and welfare must be provided in all 
organisations that offer services to children. The key elements of 
effective training are: 
(i) the inclusion of different disciplines and agencies 
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(ii) a focus on child protection and welfare legislation and 
policy along with national and local procedures 
(iii) dissemination of knowledge about child abuse, including 
physical and behavioural signs, effects and appropriate 
interventions 
(iv) A focus on inter-professional and inter-agency work along 
with the roles and responsibilities of individuals and 
organisations. 
(v) Dissemination of information about local services, contact 
addresses and methods of referral. 
As well as providing in-service training, organisations should encourage 
and facilitate employees/volunteers to participate in external training 
such as conferences, seminars and post-qualifying courses. 
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List of Health Board Addresses 
EASTERN HEALTH BOARD 
AREA CHILD CARE MANAGER 
Community Care Area Address Phone No. Fax No. 
Area 1 Tivoli Road 
Dun Laoghaire, Co Dublin 01-2843579 01-2808785 
Area 2 Vergemount Hall, Dublin 6 01-2698222 01-2830002 
Area 3 The Malting Business Pk 
54/55 Marrowbone Lane 
Dublin 8 01-4544826 01-4544827 
Area 4 Old County Road 
Crumlin, Dublin 12 01-4542511 01-4542122 
Area 5 The Lodge 
Cherry Orchard 
Ballyfermot, Dublin 10 01-6268101 01-6268281 
Area 6 Rathdown Road, Dublin 7 01-8680444 01-8821208 
Area 7 Aras Daibhin 
Jones’s Road, Dublin 3 01-8552000 01-8554136 
Area 8 Cromcastle Road 
Coolock, Dublin 5 01-8476122 01-8479944 
Area 9 O’Donegans 
4 New Road 
Newbridge Road, Naas 
Co Kildare 045-881974 045-881975 
Area 10 Glenside Road, Wicklow 0404-68400 0404-69044 
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MIDLAND HEALTH BOARD 
AREA CHILD CARE MANAGER 
Community Care Area Address Phone No. Fax No. 
Longford/ Health Centre 
Westmeath Mullingar 
Co Westmeath 044-40221 044-39170 
Laoise/Offaly Health Centre 
Tullamore 
Co Offaly 0506-41301 0506-21136 
MID-WESTERN HEALTH BOARD 
AREA CHILD CARE MANAGER 
Community Care Area Address Phone No. Fax No. 
Limerick Vocational Training Services 
Dooradoyle 
Limerick 061-482792 061-482471 
Clare Tobartaoiscain 
Ennis 065-23155 
Co Clare 065-23156 065-43952 
North Tipperary General Hospital 
Nenagh 
Co Tipperary 067-31491 067-41357 
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NORTH-EASTERN HEALTH BOARD 
AREA CHILD CARE MANAGER 
Community Care Area Address Phone No. Fax No. 
Cavan/ Health Care Unit 
Monaghan Monaghan 047-30400 047-84587 
Louth Community Care Office 
Dublin Rd 
Dundalk 
Co Louth 042-9332287 042-9333814 
Meath Family Resource Centre 
Commons Road 
Navan 
Co Meath 046-73178 046-73183 
NORTH-WESTERN HEALTH BOARD 
AREA CHILD CARE MANAGER 
Community Care Area Address Phone No. Fax No. 
Donegal Ballybofey 
Co Donegal 074-31391 074-31983 
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Sligo/ Markievicz House 
Leitrim Sligo 071-55177 071-55131 
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SOUTHERN HEALTH BOARD 
AREA CHILD CARE MANAGER 
Community Care Area Address Phone No. Fax No. 
South Lee Abbey Court House 
George’s Quay, Cork 021-923814 021-963822 
North Lee Abbeycourt House 
Georges Quay 
Cork 021-965511 021-963822 
North Cork Hibernian Way 
Bank Place 
Mallow, Co Cork 021-30200 021-42504 
West Cork Hibernian Buildings 
Main St 
Skibbereen, Cork 028-23141 028-23172 
Kerry 18 Denny St 
Tralee, Co Kerry 066-20300 066-81480 
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SOUTH-EASTERN HEALTH BOARD 
AREA CHILD CARE MANAGER 
Community Care Area Address Phone No. Fax No. 
Carlow/Kilkenny Community Care Centre 
James Green 
Kilkenny 056-52208 056-64172 
Waterford Community Care Centre 
Cork Road 
Waterford 051-842800 051-843688 
Wexford Community Care Centre 
Grogan’s Road 
ACC Building 
George’s St 053-65112 
Wexford 053-65113 053-23394 
South Tipperary Community Care Centre 
Western Rd 
Clonmel 
Co Tipperary 052-77000 052-25337 
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SOUTH-EASTERN HEALTH BOARD 
AREA SOCIAL WORK MANAGER 
Community Care Area Address Phone No. Fax No. 
Carlow/ Patrick St 
Kilkenny Kilkenny 056-52208 056-62741 
Waterford Community Care Centre 
Cork Road 
Waterford 051-842800 051-843688 
Wexford South Eastern Health Board 
Ely House 053-47718 
Wexford 053-47719 053-47706 
South Tipperary Community Care Centre 
Western Road 
Clonmel 
Co Tipperary 052-22011 052-25337 
WESTERN HEALTH BOARD 
AREA CHILD CARE MANAGER 
Community Care Area Address Phone No. Fax No. 
Galway Community Care Offices 
25 Newcastle Road 091-523122 
Galway ext. 6228 091-524231 
Mayo Co Clinic 
Castlebar 094-22333 
Co Mayo ext.2183 094-27106 
Roscommon HB Offices 
Lanesboro St 
Roscommon 0903-26732 0903-26732 
 111
48 
 
 
 
 
 
Appendix 2 
Suggested Template for a 
Standard Reporting Form 
for Reporting Child Protection 
and Welfare Concerns to a 
Health Board 
1. Date of Report: 
2. Name of person reporting: 
3. Address of person reporting: 
4. Relationship of reporting person with the child concerned 
5. Method of Report (telephone call, personal call to office): 
6. FAMILY DETAILS 
Details of child concerned 
Surname 
Forename 
D.O.B. 
Male/female 
Alias (known as) 
Address: 
Correspondence address (if different) 
Telephone number 
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7. State whether you consider your report to indicate (a) suspected 
or actual child abuse or (b) need for family support, giving reasons 
Physical Sexual Emotional 
Abuse Abuse Abuse Neglect 
Suspected o o o o 
Actual o o o o 
8. Details of other family members/household members 
NAME AGE RELATIONSHIP EMPLOYMENT/ LOCATION 
TO SCHOOL 
CHILD 
In cases of emergency, or outside health board hours, reports should be made to 
An Garda Sı ´ocha´na. 
9. Name of other professionals involved with child/ren and/or 
parents/carers. 
Public health nurse: 
School: 
General practitioner: 
Any other agency or professional involved (please describe the 
nature of any involvement): 
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10. REPORT DETAILS 
Describe, as fully as possible the nature of the problem or incident 
being reported, giving details of times and dates of individual 
incidents, the circumstances in which they occurred, any other 
persons who were present at the time, and their involvement: 
11. Has any explanation been offered by the child, and/or 
parents/carers, which would account for the current problem or 
incident? (Details) 
12. As far as possible, describe the state of the child/ren’s physical, 
mental and emotional well-being 
13. If child abuse is being alleged, who is believed to be responsible 
for causing it? 
Include (if known) 
Name: 
Address: 
Degree of contact with child: 
Degree of contact with other children: 
14. Describe (in detail) any risks to which the child/ren in this situation 
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are believed to be exposed 
15. How did this information come to your attention? 
16. What has prompted you to report your concern at this time? 
51 
17. What evidence of harm exists at present? 
18. Are there any factors in the child and/or parents/carers’ present 
situation, which may have relevance to the current concern? (for 
example, recent illness, bereavement, separation, addiction, 
mental health problem or other difficulty) 
19. Are there any factors in the child and/or parents/carers’ situation 
which could be considered protective or helpful (for example, 
extended family or community support). 
20. Has any action been taken in response to the current concern or 
incident/ (Details) 
21. Are the child’s parents/carers aware that this concern is being 
reported to the health board? 
22. Is there a need for urgent protective action at this point? 
23. Any other comments 
 
SIGNED 
 
DATE: 
52 
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APPENDIX 9 
  
PRISON/COMMUNITY TRANSFER OF INFORMATION FORM 
 
(Policy 26: Liaison and Transfer Arrangements Between Community and Prison Treatment Services) 
 
 
PRISON/COMMUNITY TRANSFER OF INFORMATION FORM 
 
This form must be faxed from the dispensing pharmacist in the community to the healthcare staff in the prison and 
vice versa as appropriate, before a new prescription is written or the next dose of methadone /medicines is 
administered. 
 
 
Client 
Name 
DOB Prison/Clinic Methadone 
dose (in 
words and 
figures) 
Date last 
dose 
dispensed 
Other 
medication 
Date last 
dispensed 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
            
 
Confirmed by: 
 
 
Name:     _______________       Signature: __________________________ 
                                                                      Pharmacist/RGN/RPN/MO/GP 
 
Date:       _____________ 
 
This form must be retained as per HSE/IPS policy. 
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APPENDIX 10 
 
HSE SERVICE PROVIDER (DTC/SATELLITE) CONTACT DETAILS 
  
(Policy 26: Liaison and Transfer Arrangements Between Community and Prison Treatment Services) 
  
 
HSE SERVICE PROVIDER (DTC/SATELLITE) CONTACT DETAILS 
  
 
 
Community Services Contact Details – Dublin Area 
 
 
Dublin 
Area 
GP  
Co-
ordinator 
Contact 
details 
Chief Pharmacist Contact details 
NAHB Dr Des 
Crowley 
087 
2198094 
Nihal Zayed 
2nd Floor 
PhibsboroTower 
Dublin 
 
087 2252860 
01 8820309/327 
 
nihal.zayed@mailc.hse.ie 
SWAHB Dr Margaret 
Bourke 
086 
8177112 
Denis O’Driscoll 
Bridge House 
Cherry Orchard 
Hospital 
Ballyfermot 
Dublin 10 
087 2904852 
 
 
 
denis.odriscoll@mailf.hse.ie
ECAHB Dr Cathal 
O’Sullivan 
087 
2937570 
Helen Johnston 
Centenary House 
Dun Laoghaire 
Co. Dublin 
086 8543733 
01 2803335 
 
helen.johnston@maild.hse.ie 
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METHADONE DISPENSING CLINICS 
 
Clinics East Coast Area of Dublin mid- Leinster. 
 
Drug 
Treatment 
Centre 
 
Opening 
Hours for 
pharmacy 
Fax Number Tel number E-mail of pharmacists 
Patrick Street, 
99 Patrick St. 
Dun Laoire 
Co. Dublin 
 
8.45- 12.30 & 
2.00- 2.30 
Weekdays only 
01 2841169 01 2301901 deirdre.hickey@maild.hse.ie 
Baggot Street, 
19 Haddington Road, 
Dublin 4. 
8.45- 11.30 
Weekdays & 
10.00- 11.30 
Weekends 
01 6603227 As fax, or 
01 6699500 
when pharmacy  
is closed 
rina.bacik@maild.hse.ie
mairead.tobin@maild.hse.ie 
Killarney Road, 
Drug Treatment 
Centre, 
Killarney road, 
Bray, Co. Wicklow. 
9.00- 11.45 
every day & 
2.00- 3.45 on 
weekdays only. 
01 2022897 012762918 john.kingston@maild.hse.ie 
 
Satellite Clinics where there is no pharmacy. 
Drug 
Treatment 
Centre 
 
Opening 
Hours for 
pharmacy 
Fax Number Tel number E-mail of pharmacists 
Fassaroe, 
Little Bray Family 
Resource Centre, 
Ard Chulann, 
Fassaroe, Bray, Co. 
Wicklow. 
Tues & 
Thursday 
5.00- 7.00 pm 
 Dr. Moloney 
 
Lincara Centre, 
Boghall Road, 
Bray, Co. Wicklow. 
Tues & 
Thursday 
7.30- 9.30 pm 
 Dr. Moloney 
Mounttown 
In Patrick St Clinic 
Mon & Wed 
2.00- 3.30 
 Dr Quinn 
Sallynoggin 
Health Centre, 
Lower Glenageary 
Road,Dun Laoire. 
Monday 8.00- 
9.30 pm & 
Wed, Thurs. 
5.30- 7.00 pm 
 Dr Savage 
Dundrum Health Centre, 
Dublin 14. 
 
Tues & 
Thursday 
6.00- 7.30 pm 
 Dr Mc Govern 
Loughlinstown Clinic, 
St Columcille’s Hospital, 
Loughlinstown, 
Co. Dublin. 
Tues & 
Thursday 
11.00- 1.00 
 Dr Ryan 
St. Cronan’s 
In Killarney Road Clinic 
Mon & Wed 
5.30- 7.00 
 Dr Quinn 
For contact details, which must 
not be given to clients, please 
phone: 
 
 
Chief pharmacist 
086 8543733 
helen.johnston@maild.hse.ie 
 
 
or GP co-ordinator 
0872 2937570 
cathal.osullivan @ maild.hse.ie 
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NORTHERN AREA HEALTH BOARD 
 
Clinic Opening Hours Phone No. Pharmacist Mobile No./Fax 
DISPENSING 
CLINICS 
    
City Clinic, 108 
Amiens St. 
Dublin 1 
 
 
 
 
City Clinic, 
109 Amiens St. 
Dublin 1 
Mon to Fri 9.00-
12.00 and 2.00-
3.30 
5.00-6.30pm 
Sat/Sun 9.30-
12. 
Mon-Fri 
9.00-12.00 and 
2.00-3.30 
Evening Prog. 
Mon-Fri 5.00-
6.30 
Sat/Sun 9.30-
12.00 
01-8555310 
01-8555311 
01-8555313 
 
 
 
 
As Above 
 
Siobhan Herron 
 
086-8634879 
01-8555314 
 
 
 
 
 
086-8848646 
087-6294479 
01-8555314 
 
 
Domville House, 
Ballymun Rd. 
Dublin 11 
Mon to Fri 9.00-
12.00 and 2.00-
3.30 
Mon to Fri 5.00-
6.30 
Sat/Sun 9.30-
12.00 
01-8620111 
01-8620298 
01-8620299 
Direct Lines: 
01-8579901/7 
01-8579901 
Sonya Sanchez 
Michael Barrett 
Danny Carroll 
Deirdre Devine 
 
01-8620297 
Mobile Bus, St. 
Marys Hospital, 
D.8 
Mon to Fri 9.15 - 
4.15  
Sat/Sun: 
 9.15-3.15  
087-2497420 
 
01-6207094 (St. 
Marys Hospital) 
Ismail Kajee 01-6207090 
The Mews, 224 
N.C.R., Dublin 7 
Mon to Fri 9.00-
12.00 
2.00 – 
3.30(Weds only) 
5 – 6.30 (Weds 
only) 
Sat/Sun 9.30-
11.30 
01-8383852 
01-8383794 
Direct Line: 
01-8823625 
Brid Powell 
Pauline Reilly 
01-8384830 
Wellmount 
Clinic, 
Wellmount 
Health Centre, 
Wellmount Pk, 
Finglas, D.11 
 
 
Mon to Fri 5.15 
– 6.30 
Sat/Sun 9.30-
10.30 
01-8346119 
Direct Line: 
01-8827780 
Paulina 
O’Hanlon 
 
01-8567702 
Darndale Clinic, 
Beldale View, 
Old Camp Lane, 
Darndale, D.17 
Mon to Fri 9.00-
12.00 and 2.00-
3.30 
Sat/Sun/Bank 
Hols 9.00-10.30 
01-8488951 Barry Flood 01-8488959 
Tolco,  
Cabra, D.11 
Mon –Fri: 
9 -12 
2 – 3.30 
5 – 6.30 
Sat/Sun 9.30 - 
11 
01-8301349 Pauline 
O’Hanlon 
01-8301349 
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Satellite Clinics 
 
Ballymun Health 
Centre, 
Ballymun, D.9 
Mon 5.30 – 7.00 01-8420011  01-8831289 
Barry Centre, 
Unit 3, Barry 
Shopping Ctr, 
Finglas West, 
D.11 
Mon/Wed/Thur 
9.30-12.45 
01-8643811 Richard 01-8643835 
Blanchardstown 
Mobile Clinic, 
JCM Hospital, 
D.15 
Mon/Tue/Wed 
2.00-5.30 
087-2497420 Ismail 01-6207090 
 
 
Bonnybrook c/o 
Bonnybrook 
Youth 
Resource, Glin 
Rd, D.17 
Wed/Fri 10.00-
11.30 
01-8489308  No Fax Machine 
Coolock Health 
Centre 
Cromcastle Rd, 
Coolock, D.5 
Tue 9.00-12.00    
Corduff Health 
Centre, Corduff, 
D.15 
Fri 2.00-5.00 01-8211131  01-8211136 
Donnycarney 
Drugs Project, 
Collins Ave 
East, D.5 
Mon 1.00-3.00 01-8328040  01-8512272 
Edenmore 
Health Centre, 
D.5 
Fri 8.00 – 10.00 01-8480666  01-8473903 
Kilbarrack 
Health Centre, 
Foxfield 
Crescent, D.5 
Tue/Thur/Fri 
2.00-5.00 
01-8391221  01-8399556 
Mulhuddart 
Clinic, 10 
Dromheath 
Ave., D.15 
 01-8208440  Fax same as 
phone number. 
Fax machine not 
working. 
Swords Health 
Centre, Bridge 
St, Co. Dublin 
Tue 5.00-7.00 01-8902200  01-8902121 
Thompson 
Centre, 53 
Mountjoy St., 
Dublin 1 
Mon 10.00-1.00 01-8601174   
Howth Health 
Centre, Co. 
Dublin 
Tue 5.00-7.00 01-8322984  01-8395717 
North Road, 
Finglas, D.11 
Wed 3.30-5.30    
Trinity Court, 
30/31 Pearse 
St, D.2 
Mon to Fri 9.30-
12.30 and 2.30-
4.30 
01-6488600 Pharmacist on 
duty 
01-6488700 
(main reception 
fax) 
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SOUTH WESTERN AREA HEALTH BOARD 
 
Clinic Opening Hours Phone No. Pharmacist Mobile No./Fax 
Mobile Bus. 
Tallaght Hosp. 
Grounds 
(As Belgard Rd.) 
10.00-12.00 
and 2.00-3.00 
01-4513745 
01-4513894 
Brian Cronin 086-8286680 
01-4513735 
Aisling Clinic, 
Ballyfermot 
Dublin 10 
9.00-12.00 
2.00-4.00 
5.00-7.00 
01-6206012 Gordon Ryan 
Ciara Stack 
01-6206011 
37 Castle St., 
Dublin 2 
Mon to Fri 9.00-
12.15 and 2.00-
4.00 
01-4767029 Blaithin Cotter 01-6778139 
Cork Street, D.8 Mon to Fri 
10.00-12.00 
Sat/Sun 10.00-
11.00 
01-4544933 
01-4544940 
Jo McDonagh 01-4544946 
Curlew Rd., 
Drimnagh, D.12 
Mon to Fri 9.30-
12.30 
01-4556422 Marie Dunne 01-4550645 
Dr. Steevens 
Clinic 
Dublin 8 
Mon to Fri 9.00-
12.00 and 2.00-
4.00 
Sat/Sun 11.00-
12.30 
01-6352530 Shaun Doyle 01-6352076 
Fortune House 
(Detox Ctr) 
Ballyfermot, 
D.10 
Mon to Fri 9.00-
12.00 and 2.00-
2.30 
01-6206036 Gordon Ryan 
Majella Stack 
01-6206031 
Inchicore Health 
Centre, Emmet 
Road, 
Dublin 8 
Mon to Fri 
12.30-1.30 and 
Sat/Sun 10.30-
11.30 
01-4531978  01-4544574 
Irish Town 
Health Ctr., 
Dublin 4 
 01-6608629  01-6683906 
Millbrook 
Lawns, St. 
Dominics S.C. 
Dublin 24 
Mon to Fri 
Starts at 5.30 
01-4525066   
 
 
The Lodge 
Old County Rd, 
Crumlin, D.12 
Mon to Fri 
10.00-12.00 and 
2.00-4.00 
01-4154817 Roweta Hussein 01-4154818 
JADD, 
Fortunestown 
Lane, 
Jobstown, 
Tallaght, D.24 
Mon to Fri 2.30-
4.30 
Sat/Sun 10.00 
11.00 
01-4630656 Pharmacist/ 
Nurse on duty 
01-4597639 
CASP, 
Ballyowen 
Meadows, 
Fonthill Rd, 
Clondalkin, 
D.22 
Mon to Fri 4.30-
6.00 
Sat/Sun 10.00-
11.00 
01-6166236  01-6166755 
Belgard rd, 
Tallaght 
Dublin 24 
As Mobile Bus, 
Tallaght 
01-4513894 Brian Cronin 01-4513735 
 
 
 
 
 
NATIONAL CONTACT DETAILS: 
 
 119
AREA Contact person: Contact details 
HSE North Western 
Area 
 
(Sligo, Leitrim, South 
Donegal and West 
Cavan) 
Ms. Trish Garland 
HSE West 
Addiction Service 
Charter House 
Old Market Street 
Sligo 
 
Donegal is covered by Moira Mills, 
Alcohol & Substance Advisory Service, 
Eunans Court, 
Letterkenny.  
Tel: (071) 9140409 
Fax: (071) 9140412 
 
 
 
 
 
Tel: (071) 9140409 
 
HSE North  
Eastern Area 
 
(Louth, Meath, 
Cavan, Monaghan) 
Ms. Lesley O’Sullivan 
Drug Services Facilitator 
HSE Dublin North East 
Primary, Community and Continuing 
Care 
St Brigids Complex, 
Kells Road, Ardee, 
Co. Louth 
 
Ms. Joanne O’Brien, 
Unit Liaison Pharmacist, 
HSE Dublin North East, 
Railway St, Navan, Co. Meath 
Tel: (041) 6850671 
 
 
 
 
 
 
 
 
Tel: (046) 90764351 
Tel: (087) 2704823 
HSE Southern Area 
 
(Cork and Kerry) 
Mr. Willie Collins, 
Co-ordinator Drugs & Alcohol Services, 
St. Finbar’s Hospital, 
Douglas Road, Cork. 
 
Dr. Declan O’Brien, 
Arbour House, St Finbar’s Hospital, 
Douglas Road, Co. Cork. 
 
Dr. Catherine Murphy, 
HSE Southern Area, Floor 2, 
Abbey Court House,  
George’s Quay, Cork. 
Tel: (021) 4966555 
 
 
 
 
Tel: (021) 4968933 
 
 
 
Tel: (021) 4965511 
HSE South Eastern 
Area 
 
(Wexford, Waterford, 
Kilkenny  
Carlow and Tipperary 
South Riding i.e. 
Tipperary Town, 
Cashel, Cahir and 
Carrick-on-Suir)   
Mr Tony Barden, 
Regional Drug Co-ordinator. 
 
Catherine Lawlor, 
Co-ordinator of Substance Misuse 
Carlow and Kilkenny. 
Tel: (051) 846720 
 
 
Tel: (056) 7784638 
HSE Midland Area 
 
Laoise, Offaly, 
Westmeath and 
Longford. 
Fran Byrne, 
Regional Administrator, 
Community Alcohol & Drug Service, 
St. Loman’s Hospital,  
Mullingar, Co. Westmeath 
Tel: Mob: (086) 3802612 
Or 
                (044) 84352 
HSE Western Area 
 
Mayo, Galway and 
Roscommon 
Ms. Fiona Walsh,  
Drugs Co-ordinator,  
64 Dominic Street, Galway 
Tel: (091) 561198 
HSE Mid Western 
Area 
 
Clare, Limerick and 
Tipperary North 
Riding i.e. Thurles 
Roscrea and Nenagh 
Mr. Rory Keane,  
A/Co-ordinator, Limerick Drug and 
Alcohol Service, Unit 4, 
Richmond Court, Mount Kenneth, Dock 
Road, Limerick. 
Tel: (061) 483572 
or 
Tel: (087) 2464393 
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APPENDIX 11 
 
IPS SURGERY CONTACT DETAILS 
 
(Policy 26: Liaison and Transfer Arrangements Between Community and Prison Treatment Services) 
 
 
 
Prison Phone Fax 
Mountjoy Medical Unit 01 8062915 01 8062915 
Mountjoy Main Surgery      01 8858953/8819/8967 01 8062859 
Dochas Centre 01 8858975 01 8062963 
Cloverhill Medical Unit 01 6034686/90 01 6304688 
Wheatfield Medical Unit 01 6209434/39 or  
01 6209480 
01 6209461 
St. Patrick’s Institution 01 8062905 01 8307705 
Midlands Prison 057 8672131 057 8672134 
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APPENDIX 12 
 
APPLICATION FOR A COMMUNITY TREATMENT PLACE 
 
(Policy 26: Liaison and Transfer Arrangements Between Community and Prison Treatment Services) 
 
 
 
APPLICATION FOR A COMMUNITY TREATMENT PLACE 
 
I wish to apply for a Community Drug Treatment Place for: 
 
Patients Name: _________________________________ 
 
Address: ________________________________________________ 
________________________________________________________ 
 
Date of Birth: ___________________________________ 
 
Prison: ________________________________________ 
 
Pris No.: _______________________________________ 
 
Expected Date of Release: ________________________ 
 
Prescribing Doctor: ______________________________ 
 
Medical Notes: __________________________________________ 
_______________________________________________________ 
_______________________________________________________ 
_______________________________________________________ 
_______________________________________________________ 
_______________________________________________________ 
_______________________________________________________ 
_______________________________________________________ 
_______________________________________________________ 
_______________________________________________________ 
_______________________________________________________ 
 
To be completed by Community Drug Treatment Service 
 
Patient ________________  
• Will have a treatment place in _________________ Centre/Clinic 
• Will not have a treatment place on the date of his/her release 
 
Signed: ____________________  Date: ___________________ 
 
 
 
 
 
 
 
APPENDIX 13 
 
CTL ENTRY/EXIT FORM 
(Policy 26: Liaison and Transfer Arrangements Between Community and Prison Treatment Services) 
CENTRAL PATIENT TREATMENT LIST – ENTRY FORM 
 
On receipt of completed form, the patient will be entered on the Central Patient Treatment List. This list may be checked by telephoning 01 677 1500. 
All information on this form should be filled in BLOCK LETTERS. 
THE FORM SHOULD BE FILLED IN FULL 
Treatment card cannot be processed without PATIENT SIGNATURE & PHOTOGRAPHS 
COMPLETED FORMS TO BE RETURNED TO F RAFFERTY AT TRINITY COURT 30/31 PEARSE STREET 
______________________________________________________________________________________________________ 
PATIENT DETAILS 
SURNAME:          ________________________________________________                       INSERT PHOTO             
 
FIRST NAME:     ________________________________________________                                   
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ADDRESS:           ________________________________________________ 
  
                               ________________________________________________ 
 
                                                   DAY                       MONTH                 YEAR    
 
DATE OF BIRTH: 
 
 
PATIENT GMS NO:                        
______________________________________________________________________________________________________ 
TREATMENT DETAILS 
 
          DAY                 MONTH              YEAR                                                                  DAY                 MONTH             
YEAR 
 
COMMENCEMENT DATE:                                                                            DAY DUE TO FINISH: 
 
(TICK WHERE APPROPRIATE) 
DETOXIFICATION:                                         MAINTENANCE:                                           STABILISATION:             
 
DISPENSING REQUIREMENTS:  __________________________________________________________________ 
 
                                                              __________________________________________________________________ 
 
______________________________________________________________________________________________________ 
 
DOCTOR/AGENCY NAME:      ______________________________________ 
 
ADDRESS:                                       ______________________________________ 
                                                                                                                                            STAMP MAY BE USED 
                                                         ______________________________________ 
 
TELEPHONE NO:                              __________________________________________ 
 
DOCTORS GMS NO: 
______________________________________________________________________________________________________ 
 
PHARMACY NAME:                  _______________________________________ 
 
ADDRESS:                                          ___________________________________________ 
                                                                                                                                                           STAMP MAY BE USED 
                                                              ___________________________________________ 
 
TELEPHONE NO:                             ___________________________________________ 
 
PHARMACY GMS NO:  
______________________________________________________________________________________________________ 
CENTRAL PATIENT TREATMENT LIST – EXIT FORM 
 
All information on this form should be filled in BLOCK LETTERS. 
THE FORM SHOULD BE FILLED OUT BY PRESCRIBING DOCTOR ONLY 
PLEASE RETURN COMPLETED FORMS TO THE CENTRAL PATIENT TREATMENT LIST, 30/31 PEARSE STREET, DUBLIN 2 
 
___________________________________________________________________________________________________________________________ 
PATIENT DETAILS 
SURNAME:                 ____________________________________________________ 
 
FIRST NAME:            ____________________________________________________ 
 
                                                    DAY                         MONTH                      YEAR 
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DATE OF BIRTH: 
 
TREATMENT CARD NUMBER:  PH   
___________________________________________________________________________________________________ 
EXIT DETAILS 
 
                                    DAY                           MONTH                    YEAR 
 
EXIT DATE:  
 
(TICK ONE BOX ONLY) 
TRANSFER TO OTHER GP/AGENCY 
 
TREATMENT SUCESSFULLY COMPLETED 
 
TREATMENT FAILURE 
 
DOUBLE SCRIPTING 
 
NO CONTACT FOR ONE MONTH 
 
BARRED 
 
R.I.P.                                                                                                             DATE R.I.P.:_________________ 
 
PRISON (ONE MONTH) 
 
HOSPITAL (ONE MONTH) 
 
 
OTHER: 
 
(PLEASESTATE:)____________________________________________________________________________________
________________________________________________________________________________________________________________________________________________________________________ 
 
DOCTOR/AGENCY NAME:   _________________________________________ 
 
ADDRESS:                                  _________________________________________ 
 
                                                           ______________________________________________      STAMP MAY BE USED    
 
SIGNATURE:                            __________________________________________ 
                                                                                                        (TICK APPROPRIATE BOX) 
 
PHARMACY NOTIFIED:                                        YES                          NO  
 
CARD RETRIEVED FROM PHARMACY:          YES                           NO 
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APPENDIX 14 
 
JOINT IPS/HSE ARRANGEMENTS FOR THE SUPPLY OF METHADONE TO PRISONERS ON 
CHRISTMAS/NEW YEAR TEMPORARY RELEASE 
 
 (Policy 26: Liaison and Transfer Arrangements Between Community and Prison Treatment Services) 
 
Information for all prison surgery staff: 
 
1. All patients on Methadone treatment will be assigned to a clinic, prior to release. 
 
2. The relevant sections of the Prison Release Form must be completed, for each patient, by healthcare staff. 
 
This states: 
y Patient details 
y Date of release 
y Date of return 
y Clinic/G.P. details 
y Dose of Methadone and confirmation of last dose given 
y Any other medication, if any, the patient has been prescribed. The clinics will dispense this medication to the 
patient, as long as they have same in stock. (They usually have most anti-depressants, hypnotics etc in 
stock). 
 
3. This form must then be faxed to the relevant clinic. 
 
4. Patients are NOT TO BE GIVEN their daily dose of Methadone in the surgery on the day of their release. 
 
5. A letter to confirm patient identification must then be prepared. This must be on headed prison paper, and 
should be in the format outlined i.e. include: 
y Patient photograph - this can be printed from PRIS, cut out and attached to the page. 
y This must then be signed across, in red pen, by a member of surgery staff. 
y Patient name, and assigned clinic details. 
y This letter is then given to the patient. This letter must be taken to the clinic, to confirm patient I.D. and will be 
retained by the clinic. 
 
6. All patients must attend their respective clinics on the day of release to have their Methadone dispensed 
by the pharmacist/nurse. Those patients attending clinics in SWAHB and ECAHB will also be required to see the 
doctor on the day of release. 
Methadone will be dispensed in the clinic on the day of release. 
 
7. On the last day of T.R., the dose of Methadone will be given in the clinic. Please ensure that all patients 
are aware of this, as they will not be dispensed Methadone on their return to prison. 
 
8. On the day of return, the relevant sections of the form will be completed by the Pharmacist/Nurse and this form 
will then be faxed back to the prison surgery. 
 
IPS Healthcare Directorate.                            Date: 13th December 2005 
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APPENDIX 15 
 
AUDIT REPORT OF UNPLANNED ARRIVAL AT COMMUNITY SERVICES 
 
(Policy 26: Liaison and Transfer Arrangements Between Community and Prison Treatment Services) 
 
Prison to Community Transition Arrangements for Prisoners on Methadone                    
Maintenance 
 
Incident Report 
 
Clinic Name:__________________________________ 
 
Address:      ___________________________________ 
 
                     ____________________________________ 
 
Telephone Number:   _________________________ 
 
E-Mail address:  __________________________ 
 
Contact person in Clinic:  _________________________ 
 
 
Client Name:   __________ 
 
 
Address:         ___________________ 
 
                          ________________________ 
 
Date of birth:   ___________________ 
 
Name of prison from which client released: 
 
Brief summary of the situation as faced by the clinic: 
 
 
 
 
 
 
 
 
Please email copy to Julian.Pugh@mailf.hse.ie, mob: 086 8299201, fax 01 6201601 
And email copy to Chief Pharmacist 
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APPENDIX 16 
 
METHADONE: DRUG INTERACTIONS 
 
 
 
Drug Effect Mechanism 
Alcohol Increased sedation, respiratory 
depression 
Additive CNS effect 
Benzodiazepines Enhanced sedative effect Additive CNS depression 
Tricylic 
Antidepressants 
Enhanced sedative effect Additive CNS depression 
Other opiates Enhanced sedative effect and 
respiratory depression 
Additive CNS depression 
Zopiclone(Zimovane, 
Zileze, Zopitan) 
Enhanced sedative effect Additive CNS depression 
Barbiturates (including 
Phenobarbitone) 
Reduced methadone levels, 
increased sedation 
Stimulation of hepatic 
enzymes involved in 
methadone metabolism 
by barbiturates 
Carbamazepine Reduced methadone levels Stimulation of hepatic 
enzymes involved in 
methadone metabolism 
by carbamazepine 
Phenytoin Reduced methadone levels Stimulation of hepatic 
enzymes involved in 
methadone metabolism, 
by phenytoin 
Urine acidifers Reduced methadone plasma  
levels 
Raised urinary excretion 
of methadone 
Cimetidine Possible increased methadone 
levels (few cases reported) 
Inhibition of hepatic 
enzymes by cimetidine 
Drug Effect Mechanism 
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Erythromycin Increased methadone levels 
expected 
Decreased methadone 
metabolism 
Fluconazole Raised methadone levels Decreased methadone 
metabolism 
Ketaconazole Raised methadone levels Decreased methadone 
metabolism 
Urine alkalanisers e.g. 
sodium bicarbonate 
Increased methadone levels Reduced urinary 
excretion of methadone 
Grapefruit juice Raised methadone levels Decreased methadone 
metabolism 
Buprenorphine Antagonist effect or enhanced 
sedative and respiratory 
depression 
Partial agonist of opiate 
receptors 
Cisapride May cause QT interval 
prolongation 
Increased risk factor for 
QT prolongation – 
monitor 
Cisapride, 
domperidone, 
metoclopramide 
May increase speed of 
methadone absorption, not the 
extent 
Possibly by reversing the 
delayed gastric emptying 
associated with opioids 
Fluoxetine 
? Other SSRI’s 
Raised methadone levels Decreased methadone 
metabolism 
Omeprazole Increased methadone levels 
possible 
Possible effect on 
methadone absorption 
from gut 
Nifedipine Increased nifedipine levels, no 
effect on methadone levels. 
Significance? 
Methadone increase 
metabolism of nifedipine 
Drug Effect Mechanism 
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Rifampicin Reduced methadone levels Rifampicin stimulates 
hepatic enzymes involved 
in methadone metabolism 
MAOI (Selegiline, 
Moclobemide) 
CNS excitation, delerium, 
hyperpyrexia, convulsions, 
hypotension or respiratory 
depression. Very severe 
interaction with Pethidine, 
evidence with methadone limited 
Unclear, avoid 
combination if possible 
Indinavir (Crixivan) Raised methadone levels Decreased methadone 
metabolism 
Ritonavir (Norvir) May reduce plasma methadone 
levels 
Effect on methadone 
metabolism 
Lopinavir with Ritonavir 
(Kaletra) 
May reduce plasma methadone 
levels 
  
Other protease 
inhibitors (Reyataz, 
Crixivan, Agenerase, 
Invirase) 
May raise or lower methadone 
levels 
Effect on methadone 
metabolism 
Nelfinavir (Viracept) May decrease methadone levels   
Zidovudine (Retrovir, 
Combivir) 
Raised levels of zidovudine, 
possible effect on methadone, 
may need to increase 
methadone dosage 
Unknown 
Nevirapine 
Decreased methadone levels Increased methadone 
metabolism 
 
 
Ref: Stockley’s Drug Interactions 2007 
        BNF 53, March 2007  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
